June 2013

Regulation of Lipid Homeostasis, Inflammatory Signalling and Atherosclerosis by the Peroxisome Proliferator-Activated Receptor Delta

Lazar A. Bojic
The University of Western Ontario

Supervisor
Dr. Murray Huff
The University of Western Ontario

Graduate Program in Biochemistry

A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of Philosophy

© Lazar A. Bojic 2013

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biochemistry Commons, Cardiovascular Diseases Commons, and the Molecular Biology Commons

Recommended Citation
https://ir.lib.uwo.ca/etd/1307

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact tadam@uwo.ca, wlswadmin@uwo.ca.
Regulation of Lipid Homeostasis, Inflammatory Signalling and Atherosclerosis by the Peroxisome Proliferator-Activated Receptor Delta

(Thesis format: Integrated-Article)

by

Lazar A. Bojic

Graduate Program in Department of Biochemistry

Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Lazar A. Bojic 2013
ABSTRACT

The peroxisome proliferator-activated receptor (PPAR) δ is a ligand-dependent transcription factor that has been implicated in metabolic and inflammatory regulation. The molecular and physiological mechanisms by which PPARδ activation regulates lipid metabolism, inflammatory signaling and protection from atherosclerosis in states of metabolic disturbance such as insulin resistance and dyslipidemia, were investigated in a series of in vitro and in vivo studies. In vitro experiments were performed in THP-1 human macrophages. These studies demonstrated that PPARδ activation inhibits atherogenic lipoprotein-induced lipid accumulation and the associated proinflammatory responses. Specifically, treatment of macrophages with the synthetic PPARδ agonists GW0742 or GW1516 attenuated triglyceride (TG) accumulation and cytokine expression induced by very low-density lipoprotein (VLDL). The primary mechanisms for these effects were increased fatty acid β-oxidation, decreased lipoprotein lipase (LPL) activity, reduced MAPK signaling and improved insulin signaling. With regard to cholesteryl ester (CE)-rich low-density lipoprotein (LDL), the PPARδ activators stimulated cholesterol efflux via ABCA1 to apoAI, resulting in the inhibition of native and modified LDL-induced CE accumulation. In vivo studies were conducted in high fat, high cholesterol (HFHC)-fed low-density lipoprotein receptor null (Ldlr−/−) mice. Following a 4-week induction phase of HFHC-feeding to stimulate early atherosclerotic lesion development, dietary supplementation with GW1516 for a subsequent 8-weeks prevented further plaque progression. This prevention was linked to inhibition of dyslipidemia, hyperinsulinemia, and glucose and insulin intolerance. Furthermore, GW1516 strongly attenuated aortic inflammation, insulin resistance and endoplasmic reticulum (ER)-stress, which likely contributed to inhibition of lesion progression.
Additional studies in the liver showed that PPARδ activation inhibits hepatic TG accumulation induced by HFHC-feeding. To further probe the mechanism for this effect, experiments were conducted in primary mouse hepatocytes isolated from wild-type (WT) or adenosine monophosphate-activated protein kinase (AMPK) β1−/− mice. These studies revealed that PPARδ activation in the liver stimulates fat oxidation due to upregulation of the PPARδ-target gene carnitine palmitoyl transferase (Cpt) 1a, which occurred independent of AMPK activation. Furthermore, GW1516 inhibited de novo lipogenesis, which was partially dependent on AMPK activation. The residual inhibitory effect on fatty acid synthesis was associated with correction of selective hepatic insulin resistance.

In summary, these studies provide significant insight and support for PPARδ activation as a therapeutic strategy to treat the dysregulation of lipid homeostasis, inflammatory signaling, metabolic disease, and their cardiovascular complications.

**Keywords:** PPARδ, macrophage foam cells, intervention, inflammation, atherosclerosis, insulin resistance, mouse model
To my late great-grandfather Lazar Pantelic.
If there is a heaven, I know you are still teaching there.
CO-AUTHORSHIP

The contribution of co-authors to chapters 2-5 of this thesis are acknowledged and outlined below.

Dr. Murray Huff, Ph.D, provided intellectual input and scientific expertise into the hypothesis, design and experimental details of the studies outlined in Chapters 2, 3, 4 and 5. Dr. Huff also reviewed and edited the manuscripts for Chapters 2-5. Dr. Robert Hegele, M.D. F.R.C.P, provided blood samples from patients in his clinic for isolation of very low-density lipoproteins and low-density lipoproteins used in Chapters 2 and 3. Dr. Hegele also provided intellectual input into the studies conducted in Chapters 2-5, and edited the manuscripts for Chapters 2 and 3. Dr. Robert Gros, Ph.D., provided intellectual input into the studies for Chapters 2-5. Dr. Gros also provided access to the Comprehensive Lab Animal Monitoring System and edited the manuscript for the studies described in Chapter 5. Cynthia Sawyez, B.Sc. (Hons), research technician, assisted with lipid mass experiments and oleate incorporation for Chapters 2-3, and performed tissue and plasma analyses for Chapters 4 and 5. Dawn Telford, B.Sc. (Hons), research technician, assisted with PCR analyses for Chapters 2 and 3, and assisted with animal studies, oleate incorporation assays, beta oxidation studies and fatty acid synthesis experiments for Chapters 4 and 5. Jane Edwards, B.Sc. (Hons), research technician, assisted with PCR and immunoblotting analyses for Chapters 2-5. Brian Sutherland, A.R.T., research technician, assisted with animal studies and tissue lipid analyses described in Chapters 4-5. Dr. Morgan Fullerton, Ph.D., post-doctoral fellow, provided intellectual input into the planning and execution of the studies and edited the manuscript for Chapter 5. Dr. Rebecca Ford, Ph.D., post-doctoral fellow, provided intellectual input into the planning and execution of the studies, and edited the manuscript for Chapter 5. Dr. Gregory Steinberg, Ph.D., provided intellectual input and
scientific expertise into the planning of the studies and edited the manuscript for
Chapter 5. Dr. Steinberg also provided access to AMPKβ1−/− mice for the primary
mouse hepatocyte experiments described in Chapter 5.
ACKNOWLEDGEMENTS

I would like to start by expressing my gratitude to my supervisor Dr. Murray Huff. Thank you for providing your expertise, support, and encouragement throughout the completion of my doctoral research. I truly appreciate the time and effort invested into the guidance and mentorship you have provided me during my time in the lab; science-related or otherwise. I thoroughly enjoyed my time here and I have taken away invaluable scientific and life lessons.

To my advisory committee members, Dr. Robert Gros and Dr. Robert Hegele, thank you for your many helpful discussions regarding my research, and for your encouragement and support throughout my training. Your doors were always open to me to discuss any problems or ideas, and I am sincerely grateful for everything you have done for me.

The work in this thesis was supported by grants from the Canadian Institutes of Health Research (FRN-8014) and Heart and Stroke Foundation of Canada (PRG-5967), as well as OGS and OGSST scholarships from the Ontario Graduate Scholarship Program.

To the Huff lab family, past and present, in alphabetical order: Amy, Brian, Cindy, Dawn, Erin, Jane, Josh, Julia, Nica, Sanjiv, Scott and several talented summer and undergraduate students. Thank you for everything. From technical expertise and assistance, to scientific planning and strategizing. From morning coffees to afternoon coffees; political debates to religious debates; smiles to frowns and a tear here and there. Thank you for making our lab such a great place to work and for your continuous encouragement and support during the mania and the pits. I could go on-and-on, and as you all know, I usually would. But for the sake of space, I'll stop there!

Mom, Dad, Mila, Grandpa, Pedja, Sandra, Simona, Stefanie and Sasha: to say that I couldn’t have done this without you guys is a vastly unbelievable understatement.
I am extremely blessed to have a wonderful family that provides endless love and support. Thank you.

To the loves of my life, Kathryn and Marley. Without you, none of this would have been at all possible. Thank you for your encouragement, support and unconditional love. I appreciate you more than I could ever put into words.

And last but certainly not least, I would like to thank my friends that made this experience one for the ages: Jake, Brad, Joe, Chris, Piya, Elnaz and Anthony. I still think that Federer is the greatest tennis player of all time, that cryopreservation will be on the cover of Science one day, that Jagerbombs never end well, that the Leafs will win the cup before we die, that if you get a good deal you should ‘take it ‘n go’, that Tebow’s game-winning pass in OT was a spectacle and that Usher is a better dancer than Michael Jackson. But we should probably get together for a beer or two on Friday afternoon to discuss these matters some more!
TABLE OF CONTENTS

Abstract and Key Words ii
Dedication iv
Co-Authorship v
Acknowledgments vii
Table of Contents ix
List of Figures xv
List of Tables xix
List of Appendices xx
List of Abbreviations xxi

Chapter 1 – Thesis topics review

1.1 General Introduction 1
1.2 Dyslipidemia and Cardiovascular Disease
   General Introduction 2
   1.2.1 Atherosclerosis 5
   1.2.2 Cholesterol-Rich Macrophage Foam Cells 9
   1.2.3 Inflammation and Apoptosis in Cholesterol-Rich Foam Cells 13
   1.2.4 Triglyceride-Rich Macrophage Foam Cells 15
   1.2.5 Inflammation in Triglyceride-Rich Foam Cells 18
   1.2.6 Atherosclerotic Lesion Progression 19
1.3 Lipoprotein Metabolism 25
   1.3.1 Lipoproteins 25
   1.3.2 Exogenous Lipoprotein Metabolism 27
   1.3.3 Endogenous Lipoprotein Metabolism 28
1.4 Regulation of Fatty Acid and Cholesterol Metabolism 32
Chapter 2 - Activation of PPARδ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein.

2.1 Introduction 94
2.2 Materials and Methods 96
  2.2.1 Lipoproteins 96
  2.2.2 Cell Culture 96
  2.2.3 Luciferase Reporter Assays 97
  2.2.4 Cellular Lipid Mass 98
  2.2.5 Enzyme-linked Immunosorbent Assay 98
  2.2.6 Quantitative Real-Time PCR Gene Abundance Analysis 98
  2.2.7 LPL Activity, TG Synthesis, FA β-oxidation and FA Uptake 99
  2.2.8 Immunoblot Analysis and Densitometry 100
  2.2.9 Statistical Analyses 101
2.3 Results 101
2.4 Discussion 135
2.5 References 142

Chapter 3 - Activation of PPARδ inhibits human macrophage foam cell formation induced by native and modified low-density lipoprotein

3.1 Introduction 148
3.2 Materials and Methods 152
  3.2.1 Lipoproteins 152
  3.2.2 Cell Culture 152
  3.2.3 Cellular Lipid Mass 152
Chapter 4 - PPARδ agonist GW1516 attenuates diet-induced atherosclerosis and associated aortic inflammation in Ldlr−/− mice

4.1 Introduction

4.2 Materials and Methods

4.2.1 Animals and Diets

4.2.2 Plasma Lipid, Blood Glucose and Plasma Insulin Determinations

4.2.3 Glucose Tolerance and Insulin Tolerance

4.2.4 Tissue Histology and Immunohistochemistry

4.2.5 Immunoblotting and Densitometry

4.2.6 Quantitative Real-Time PCR Gene Abundance Analysis

4.2.7 Statistical Analyses

4.3 Results

4.4 Discussion

4.5 References
Chapter 5 - PPARδ-specific activation in liver attenuates triglyceride accumulation via enhanced fatty acid oxidation, reduced fatty acid synthesis and improved insulin sensitivity

5.1 Introduction 221
5.2 Materials and Methods 225
  5.2.1 Animals and Diets 225
  5.2.2 Activation of AMPK in vivo 225
  5.2.3 Energy Expenditure 226
  5.2.4 Primary Mouse Hepatocyte Isolation, Lipogenesis and Fatty Acid Oxidation 226
  5.2.5 Plasma, Blood and Tissue Analyses 227
  5.2.6 Immunoblotting and Densitometry 227
  5.2.7 Quantitative Real-Time PCR Gene Abundance Analysis 228
  5.2.8 Statistical Analyses 228
5.3 Results 229
5.4 Discussion 248
5.5 References 252

Chapter 6 - Discussion

6.1 Summary of Findings 257
6.2 Conclusions and Future Directions 265
  6.2.1 Chapter 2 Conclusions 265
  6.2.2 Chapter 2 Future Directions 267
  6.2.3 Chapter 3 Conclusions 269
  6.2.4 Chapter 3 Future Directions 271
  6.2.5 Chapter 4 Conclusions 273
  6.2.6 Chapter 4 Future Directions 274
6.2.7 Chapter 5 Conclusions 277
6.2.8 Chapter 5 Future Directions 279
6.3 Overall Thesis Conclusion 281
6.4 References 284

Curriculum Vitae 294
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Composition of the arterial wall</td>
<td>7</td>
</tr>
<tr>
<td>1.2</td>
<td>Cholesterol homeostasis in macrophages</td>
<td>11</td>
</tr>
<tr>
<td>1.3</td>
<td>VLDL-induced foam cell formation</td>
<td>17</td>
</tr>
<tr>
<td>1.4</td>
<td>VLDL-induced MAPK signaling in macrophage foam cells</td>
<td>21</td>
</tr>
<tr>
<td>1.5</td>
<td>Atherosclerotic lesion progression</td>
<td>23</td>
</tr>
<tr>
<td>1.6</td>
<td>Endogenous and exogenous lipoprotein metabolism</td>
<td>30</td>
</tr>
<tr>
<td>1.7</td>
<td>Regulation of the sterol regulatory element binding proteins</td>
<td>35</td>
</tr>
<tr>
<td>1.8</td>
<td>The carnitine palmitoyl-transferase system</td>
<td>42</td>
</tr>
<tr>
<td>1.9</td>
<td>Regulation of fatty acid synthesis and oxidation by AMPK</td>
<td>46</td>
</tr>
<tr>
<td>1.10</td>
<td>Insulin signaling</td>
<td>50</td>
</tr>
<tr>
<td>1.11</td>
<td>Selective versus pure insulin resistance</td>
<td>55</td>
</tr>
<tr>
<td>1.12</td>
<td>Consequences of PPARδ activation and PPARδ deletion</td>
<td>64</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>PPARδ-specific activation attenuates VLDL-induced triacylglycerol mass accumulation</td>
<td>103</td>
</tr>
<tr>
<td>2.2</td>
<td>GW0742 and GW501516 are PPARδ-specific agonists</td>
<td>106</td>
</tr>
<tr>
<td>2.3</td>
<td>PPARδ activation regulates triglyceride metabolism</td>
<td>108</td>
</tr>
<tr>
<td>2.4</td>
<td>Effect of PPARδ activation on FFA re-esterification mechanisms</td>
<td>111</td>
</tr>
<tr>
<td>2.5</td>
<td>PPARδ agonists attenuate VLDL-stimulated expression of AP-1 associated inflammatory cytokines</td>
<td>113</td>
</tr>
<tr>
<td>2.6</td>
<td>PPARδ activation does not affect basal cytokine expression in THP-1 human macrophages</td>
<td>115</td>
</tr>
</tbody>
</table>
2.7 The effect of PPARδ agonists on media IL-1β protein; the effect of VLDL on TNFα or IL-6 expression and the VLDL-induced inflammatory response in the presence of an inhibitor of NFκB

2.8 Prevention of VLDL-induced TG accumulation and cytokine expression are independent effects of PPARδ activation

2.9 Free fatty acids are the primary effectors of the VLDL-induced inflammatory response in human macrophages

2.10 MAPK signaling in THP-1 human macrophages in response to VLDL

2.11 Effects of inhibitors on cell signalling cascades

2.12 VLDL induces human macrophage inflammation via AKT/FoxO1 signaling

2.13 PPARδ activation normalizes VLDL-stimulated inflammatory signaling

2.14 Inhibition of β-oxidation had no effect on the ability of PPARδ activation to correct VLDL-induced inflammatory signaling

2.15 Effects of PPARδ agonists on expression of ILK and PDK1

3.1 PPARδ activation attenuates LDL-induced cholesteryl ester mass accumulation

3.2 Effect of PPARδ activation on uptake and FFA re-esterification into cholesteryl ester
3.3 PPARδ activation enhances ABCA1 and ABCG1 mRNA and protein, leading to increased cholesterol efflux

3.4 PPARδ agonists and ACAT inhibitors do not further affect the oxLDL-mediated reduction in proinflammatory cytokine expression

3.5 oxLDL dose-dependently reduces proinflammatory cytokine expression which is associated with a dose-dependent increase in LXR, PPARγ and PPARδ target genes

4.1 GW1516 regresses diet-induced dyslipidemia

4.2 GW1516-treatment attenuates rate of body weight gain and epididymal fat mass

4.3 GW1516 improves diet-induced dysregulation of metabolic indices

4.4 GW1516 attenuates HFHC-induced atherosclerosis

4.5 GW1516 attenuates lipid accumulation, M1 macrophage markers and induces a shift towards M2 macrophage markers in full length aortae

4.6 GW1516 corrects aberrant MAPK and NF-κB signaling in full-length aortae of HFHC-fed mice

4.7 GW1516 corrects aberrant insulin signaling, the UPR and ER-stress in aortae of HFHC-fed mice

4.8 GW1516 activates aortic PPARδ but not PPARα or PPARγ

4.9 GW1516 stimulates aortic expression of regulators of G-protein coupled receptor signaling Rgs4 and Rgs5
5.1 GW1516 attenuates diet-induced hepatic steatosis, in part, via increased fatty acid oxidation

5.2 GW1516 increases AMPK and ACC phosphorylation, which is not required for fatty acid oxidation

5.3 GW1516 activates hepatic AMPK in vivo, yet stimulates carbohydrate utilization

5.4 GW1516 inhibits hepatic fatty acid synthesis as a consequence of AMPK activation and correction of selective hepatic insulin resistance

5.5 GW1516 corrects the gluconeogenic branch of insulin signalling during selective hepatic insulin resistance which improves fasting hyperglycemia

5.6 GW1516 attenuates hepatic inflammation and ER-stress

6.1 PPARδ activation inhibits macrophage foam cell formation and the inflammatory response

6.2 Thesis Summary
## LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Lipoprotein Classification</td>
<td>26</td>
</tr>
<tr>
<td>1.2</td>
<td>Animal Diets</td>
<td>71</td>
</tr>
<tr>
<td>Appendix</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>7.1</td>
<td>Copyright permission (Chapter 1)</td>
<td>291</td>
</tr>
<tr>
<td>7.2</td>
<td>Copyright permission (Chapter 2)</td>
<td>292</td>
</tr>
<tr>
<td>7.3</td>
<td>Ethics Approval – Animal Research</td>
<td>293</td>
</tr>
</tbody>
</table>
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCA1</td>
<td>ATP binding cassette transporter A1</td>
</tr>
<tr>
<td>ABCG1</td>
<td>ATP binding cassette transporter G1</td>
</tr>
<tr>
<td>ACAT</td>
<td>acyl CoA:cholesterol acyltransferase</td>
</tr>
<tr>
<td>ACC</td>
<td>acetyl-coenzyme A carboxylase</td>
</tr>
<tr>
<td>ACOX</td>
<td>acyl-coenzyme A oxidase</td>
</tr>
<tr>
<td>ADFP</td>
<td>adipocytes differentiation related protein</td>
</tr>
<tr>
<td>AMPK</td>
<td>adenosine monophosphate-activated protein kinase</td>
</tr>
<tr>
<td>ANGPTL4</td>
<td>angiopoietin-like 4</td>
</tr>
<tr>
<td>ANOVA</td>
<td>analysis of variance</td>
</tr>
<tr>
<td>AP-1</td>
<td>activated protein-1</td>
</tr>
<tr>
<td>apoB</td>
<td>apolipoprotein B</td>
</tr>
<tr>
<td>apoC</td>
<td>apolipoprotein C</td>
</tr>
<tr>
<td>apoE</td>
<td>apolipoprotein E</td>
</tr>
<tr>
<td>Arg</td>
<td>arginase</td>
</tr>
<tr>
<td>ASO</td>
<td>antisense oligonucleotides</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>BCL-6</td>
<td>B-cell lymphoma 6</td>
</tr>
<tr>
<td>CCL</td>
<td>chemokine ligand</td>
</tr>
<tr>
<td>CD</td>
<td>cluster of differentiation</td>
</tr>
<tr>
<td>CD36</td>
<td>scavenger receptor class B, member 3</td>
</tr>
<tr>
<td>CE</td>
<td>cholesteryl ester</td>
</tr>
<tr>
<td>CETP</td>
<td>cholesteryl ester transfer protein</td>
</tr>
<tr>
<td>CPT1α</td>
<td>carnitine palmitoyltransferase-1 alpha</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DGAT</td>
<td>diacylglycerol acyltransferase</td>
</tr>
<tr>
<td>Acronym</td>
<td>Definition</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>DHCR24</td>
<td>24-dehydrocholesterol reductase</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethylsulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>dpm</td>
<td>disintegrations per minute</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme linked immunosorbent assay</td>
</tr>
<tr>
<td>ERK</td>
<td>extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>FA</td>
<td>fatty acid</td>
</tr>
<tr>
<td>FABP</td>
<td>fatty acid binding protein</td>
</tr>
<tr>
<td>FAF-BSA</td>
<td>fatty acid free- bovine serum albumin</td>
</tr>
<tr>
<td>FAS</td>
<td>fatty acid synthase</td>
</tr>
<tr>
<td>FC</td>
<td>free cholesterol</td>
</tr>
<tr>
<td>FFA</td>
<td>free fatty acid</td>
</tr>
<tr>
<td>FH</td>
<td>familial hypercholesterolemia</td>
</tr>
<tr>
<td>FoxO</td>
<td>forkhead box O</td>
</tr>
<tr>
<td>FPLC</td>
<td>fast performance liquid chromatography</td>
</tr>
<tr>
<td>G-6-Pase</td>
<td>glucose-6-phosphatase</td>
</tr>
<tr>
<td>GAPDH</td>
<td>glyceraldehyde-3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GK</td>
<td>glucokinase</td>
</tr>
<tr>
<td>GLUT</td>
<td>glucose transporter</td>
</tr>
<tr>
<td>GRB2</td>
<td>growth factor receptor binding protein</td>
</tr>
<tr>
<td>GTT</td>
<td>glucose tolerance test</td>
</tr>
<tr>
<td>HDL</td>
<td>high density lipoprotein</td>
</tr>
<tr>
<td>HFHC</td>
<td>high-fat high cholesterol</td>
</tr>
<tr>
<td>HL</td>
<td>hepatic lipase</td>
</tr>
<tr>
<td>HMG-CoA</td>
<td>3-hydroxy-3-methylglutaryl coenzyme A</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>homeostasis model assessment of insulin resistance</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ICAM</td>
<td>intracellular adhesion molecule</td>
</tr>
<tr>
<td>IDL</td>
<td>intermediate density lipoprotein</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>INSIG</td>
<td>insulin signaling protein</td>
</tr>
<tr>
<td>iNos</td>
<td>inducible nitric oxide synthase</td>
</tr>
<tr>
<td>i.p.</td>
<td>intraperitoneal</td>
</tr>
<tr>
<td>IR</td>
<td>insulin receptor</td>
</tr>
<tr>
<td>IRS</td>
<td>insulin receptor substrate</td>
</tr>
<tr>
<td>ITT</td>
<td>insulin tolerance test</td>
</tr>
<tr>
<td>JNK</td>
<td>c-Jun N-terminal kinase</td>
</tr>
<tr>
<td>LCAT</td>
<td>lecithin-cholesterol acyltransferase</td>
</tr>
<tr>
<td>LCM</td>
<td>laser capture microdissection</td>
</tr>
<tr>
<td>LDL</td>
<td>low density lipoprotein</td>
</tr>
<tr>
<td>LDLR</td>
<td>low-density lipoprotein receptor</td>
</tr>
<tr>
<td>LPDS</td>
<td>lipoprotein deficient serum</td>
</tr>
<tr>
<td>LPL</td>
<td>lipoprotein lipase</td>
</tr>
<tr>
<td>LPS</td>
<td>lipopolysaccharide</td>
</tr>
<tr>
<td>LXR</td>
<td>liver X receptor</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen activated protein kinase</td>
</tr>
<tr>
<td>MCP</td>
<td>macrophage chemoattractant protein</td>
</tr>
<tr>
<td>MEK</td>
<td>mitogen activated protein kinase kinase</td>
</tr>
<tr>
<td>MGAT</td>
<td>monoacylglycerol acyltransferase</td>
</tr>
<tr>
<td>MIP</td>
<td>macrophage inflammatory protein</td>
</tr>
<tr>
<td>mTORC</td>
<td>mammalian target of rapamycin complex</td>
</tr>
<tr>
<td>MTP</td>
<td>microsomal triglyceride transfer protein</td>
</tr>
<tr>
<td>NEFA</td>
<td>non-esterified fatty acid</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Nfκb</td>
<td>nuclear factor kappa B</td>
</tr>
<tr>
<td>NS</td>
<td>not significant</td>
</tr>
<tr>
<td>OA</td>
<td>oleic acid</td>
</tr>
<tr>
<td>oxLDL</td>
<td>oxidized low-density lipoprotein</td>
</tr>
<tr>
<td>PCSK9</td>
<td>proprotein convertase subtilisin/kexin type 9</td>
</tr>
<tr>
<td>PDK</td>
<td>pyruvate dehydrogenase kinase</td>
</tr>
<tr>
<td>PEPCK</td>
<td>phosphoenolpyruvate carboxykinase</td>
</tr>
<tr>
<td>PGC1α</td>
<td>peroxisome proliferator activated receptor gamma coactivator1α</td>
</tr>
<tr>
<td>PI3-K</td>
<td>phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>PL</td>
<td>phospholipid</td>
</tr>
<tr>
<td>PPAR</td>
<td>peroxisome proliferator activated receptor</td>
</tr>
<tr>
<td>PPRE</td>
<td>peroxisome proliferator response element</td>
</tr>
<tr>
<td>RGS</td>
<td>regulators of G-protein coupled receptor signaling</td>
</tr>
<tr>
<td>qRT-PCR</td>
<td>quantitative real-time reverse transcriptase polymerase chain reaction</td>
</tr>
<tr>
<td>SCAP</td>
<td>SREBP cleavage activating protein</td>
</tr>
<tr>
<td>SEM</td>
<td>standard error of the mean</td>
</tr>
<tr>
<td>SMC</td>
<td>smooth muscle cell</td>
</tr>
<tr>
<td>SOCS</td>
<td>suppressor of cytokine signaling</td>
</tr>
<tr>
<td>SREBP</td>
<td>sterol response element binding protein</td>
</tr>
<tr>
<td>TC</td>
<td>total cholesterol</td>
</tr>
<tr>
<td>TG</td>
<td>triacylglycerol</td>
</tr>
<tr>
<td>TLC</td>
<td>thin layer chromatography</td>
</tr>
<tr>
<td>TLR</td>
<td>toll like receptor</td>
</tr>
<tr>
<td>TNF</td>
<td>tumour necrosis factor</td>
</tr>
<tr>
<td>UPR</td>
<td>unfolded protein response</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>VLDL</td>
<td>very low density lipoprotein</td>
</tr>
<tr>
<td>VSMC</td>
<td>vascular smooth muscle cell</td>
</tr>
</tbody>
</table>
1.1 GENERAL INTRODUCTION

Cardiovascular disease (CVD) represents the leading cause of death in the industrialized world, and will likely soon achieve this status worldwide (Lloyd-Jones et al., 2010). The underlying cause of most cardiovascular events is atherosclerosis, a decades-long chronic inflammatory disease of large and medium sized arteries, ultimately resulting in the formation of complex lesions known as plaques (Glass and Witztum, 2001, Moore and Tabas, 2011). Unstable plaques are prone to rupture, resulting in the formation of thrombi that can subsequently induce the acute clinical manifestations of myocardial infarction or stroke (Libby et al., 2011). Major risk factors for the development of atherosclerosis include age, hypertension, smoking, obesity, diabetes and increased plasma concentrations of cholesterol and triglycerides (TG) (Libby et al., 2011). Despite the success of pharmacological treatment of many of these risk factors, the prevalence of CVD in all groups of Canadians has continued to rise (Lee et al., 2009). The class of drugs known as statins effectively lower plasma cholesterol levels and CVD (Cannon et al., 2004). However, significant residual risk remains, possibly due to the fact that statins do not improve other cardiometabolic risk factors such as high plasma TG, obesity and diabetes. Consequently, novel therapeutic strategies to alleviate these unmet medical needs are highly sought-after.

This thesis focuses on defining the mechanism of action and therapeutic potential of peroxisome proliferator-activated receptor (PPAR) δ activation in the regulation of lipid metabolism, inflammatory signaling and protection from

* a version of the PPARδ section of this chapter is published: Bojic and Huff (2013) Curr Opin Lipidol 24(2), 171-177.
atherosclerosis in states of metabolic disturbance such as insulin resistance and dyslipidemia.

1.2 DYSLIPIDEMIA AND CARDIOVASCULAR DISEASE

Cholesterol is an essential precursor in the synthesis of all steroid hormones, bile acids and the myelin sheath that surrounds axons (Goldstein and Brown, 2009). Furthermore, cholesterol is a major component of all cellular membranes, providing barrier functions between microenvironments and modulating membrane fluidity (Goldstein and Brown, 2009). Cells acquire cholesterol from a number of sources including de novo cholesterol synthesis, as well as uptake of cholesteryl ester (CE)-rich apoB100 containing lipoproteins, namely low-density lipoprotein (LDL) in the periphery, and CE-rich high-density lipoprotein (HDL) in the liver.

Since 1913 when Anitschkow and Chalatow first experimentally demonstrated the link between plasma cholesterol and atherosclerosis (Chatalow, 1983), clinical studies have clearly shown that a 2-fold increase in plasma cholesterol is associated with a 6-fold increase in CVD risk (Neaton and Wentworth, 1992). The fact that the cholesterol biosynthetic pathway was a regulated process that could be manipulated to modulate plasma cholesterol was well established in the 1950s and 1960s, which launched the search for cholesterol synthesis inhibitors (Vance and Van den Bosch, 2000). Three-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, the rate-limiting step in the production of cholesterol, which subsequently became the major target for the treatment of hypercholesterolemia using the class of drugs called statins (Tobert, 2003). Although compactin (mevastatin), isolated from Penicillium citrinum, was the first potent inhibitor of HMG-CoA reductase reported by Akiro Endo in 1976 (Endo et al., 1976), the first statin to be approved for use in the clinical arena was lovastatin, discovered by Alberts and colleagues at Merck Research Laboratories (Alberts et al., 1980). Since these early
studies, statins have become the standard of care in reducing plasma LDL-cholesterol (LDL-C) in a variety of patient populations, yielding primary and secondary prevention against CVD (Mills et al., 2008). Despite the overwhelming evidence from large randomized controlled trials demonstrating the success of statins in reducing morbidity and mortality in high risk CVD patients, about 50-75% of cardiovascular events are not prevented with these drugs (Mazzone et al., 2008). In addition to high plasma LDL-C, atherogenic dyslipidemia is now characterized by increased plasma TG-rich very low-density lipoprotein (VLDL) and low plasma HDL, neither of which are appreciably affected by statin treatment (Musunuru, 2010). Therefore, additional therapeutic strategies are required to complement existing medical therapies in CVD risk management.

Fasting hypertriglyceridemia is strongly associated with elevated rates of atherosclerotic CVD, particularly in patients with type 2 diabetes (Talayero and Sacks, 2011). The extent of atherosclerosis in this patient population is positively correlated with plasma concentrations of TG-rich lipoproteins, namely VLDL as well as intermediate density lipoprotein (IDL), also known as VLDL-remnants (Reyes-Soffer et al., 2013). Importantly, individuals with type 2 diabetes are at significantly higher risk for developing CVD, even if LDL-C has been reduced to the therapeutic goal (Talayero and Sacks, 2011). Since each of VLDL, IDL and LDL harbors one apoB100 molecule, measuring total apoB reflects the total number of potentially atherogenic particles in plasma and is therefore a stronger predictor of CVD risk than simply measuring LDL-C (Walldius and Jungner, 2006). As such, targeting apoB100 specifically represents an attractive therapeutic target in the treatment of dyslipidemia. Antisense oligonucleotides (ASO) against apoB100 successfully reverse diet-induced dyslipidemia in mice without affecting intestinal lipid absorption or accumulation, and without causing hepatic steatosis (Crooke et al., 2005, Mullick et al., 2011). Furthermore, apoB100 ASOs profoundly inhibit the
development of murine atherosclerosis (Mullick et al., 2011). Preliminary trials in humans have shown that apoB100 ASOs are generally well-tolerated, and effectively lower all plasma apoB100-containing lipoproteins (Lippi and Favaloro, 2011). Future trials are required to determine whether apoB ASOs will reach the clinical arena. Nevertheless, reducing plasma apoB100 may confer protection from development of CVD.

Raising plasma HDL-cholesterol (HDL-C) has been given considerable attention as a potential therapeutic strategy based on a substantial body of evidence suggesting the cardioprotective capacity of these lipoproteins. HDL is responsible for reverse cholesterol transport, the process by which cholesterol is drawn from peripheral tissues, and is transported to the liver for biliary excretion (Rader et al., 2009). Furthermore, epidemiological evidence reproducibly shows an inverse correlation between plasma HDL-C levels and CVD (Nicholls et al., 2012). As a result, this has led to the development of the HDL hypothesis: interventions to raise HDL-C will confer reduced CVD risk (Rader and Tall, 2012). However, recent human trials have suggested that simply raising total HDL-C levels may not be the appropriate goal. Torcetrapib, the first generation cholesteryl ester transfer protein (CETP) inhibitor, successfully raised plasma HDL-C levels yet cardiovascular events and all cause mortality were significantly higher in the treatment arm of the phase III clinical trial (Barter and Rye, 2012). The increased mortality in torcetrapib-treated individuals was attributed to off-target effects of the drug (Barter and Rye, 2012), prompting further evaluation of CETP inhibition as therapeutic approach to treating CVD. The next major phase III clinical trial involving a CETP inhibitor (dalcetrapib-OUTCOMES) was conducted by Roche and was halted early due to interim analyses demonstrating that the drug was not providing reduced CVD risk, despite significantly raising HDL-C (Schwartz et al., 2012). These results suggest that the HDL-C hypothesis may require replacement by the ‘HDL flux hypothesis’, in which interventions to raise HDL reverse cholesterol transport capacity and HDL turnover may
confer protection from CVD (Rader and Tall, 2012). Although the application of this hypothesis is in its infancy, interventions that increase reverse cholesterol transport and not simply bulk HDL-C are in development (Nicholls et al., 2012).

In summary, therapeutic interventions that lower LDL-C beyond statin monotherapy, decrease plasma apoB100 concentrations, decrease plasma triglycerides or increase the capacity of HDL to promote reverse cholesterol transport may prove to be effective in reducing CVD.

1.2.1 Atherosclerosis

Atherogenesis begins with the entry and retention of apoB-containing lipoproteins within the arterial intima of susceptible regions of large and medium sized arteries (Tabas et al., 2007). Subsequent to lipoprotein retention, a series of biological and maladaptive immune responses ensue (Tabas et al., 2010). Complex interactions between the endothelium, vascular smooth muscle cells and immune cells such as macrophages, drive plaque progression through a non-resolving expansion of the arterial intima which protrudes into the arterial lumen (Moore and Tabas, 2011). Although this protrusion can eventually lead to tissue ischemia, the predominant acute clinical events are myocardial infarction or stroke caused by rupture of unstable plaques generating thrombi that can occlude local or distal arteries (Libby et al., 2011).

An artery consists of three morphologically distinct layers: the intima, media and adventitia (Figure 1.1). The intima is the innermost layer, which is defined by an endothelial cell monolayer on the luminal side, the internal elastic lamina on peripheral side and extracellular matrix collagen and proteoglycans in between (Lusis, 2000). Endothelial cells of the intima regulate vascular tone via the production of vasoactive mediators (Sudano et al., 2006). The medial layer consists of vascular smooth muscle cells that participate in the regulation of vascular tone as well as the synthesis and secretion of elastin, collagen and sulfated glycosaminoglycans. The intimal side of the
Figure 1.1: Composition of the arterial wall.

Arteries contain three distinct layers: (1) the intima which is defined by an endothelial cell monolayer on the luminal side that protects the subendothelial intima from entry of atherogenic lipoproteins, (2) the media which consists of vascular smooth muscle cells that participate in the regulation of vascular tone as well as the synthesis and secretion of elastin, collagen and sulfated glycosaminoglycans and (3) the adventitia which is comprised of connective tissue with sporadic fibroblasts, smooth muscle cells and progenitor cells.
Adapted from illustrations by Christine Rudewich for the Robarts Research Institute
arterial media is defined by the internal elastic lamina, while the adventitial side is defined by the external elastic lamina (Lusis, 2000). Finally, the adventitia, the outermost arterial layer, is comprised of connective tissue with sporadic fibroblasts, smooth muscle cells and progenitor cells.

Normally the endothelial monolayer provides a protective barrier between the arterial lumen and the subendothelial intima (Libby et al., 2011). However, in curvatures and bifurcations of the arterial tree, blood flow is disturbed, characterized by retrograde and oscillatory shear stress which promotes a proinflammatory endothelial cell phenotype (Cybulsky and Jongstra-Bilen, 2010). In turn, these regions of the endothelial monolayer exhibit increased adhesiveness and permeability to atherogenic lipoproteins. Upon entry into the intima, apoB100 interacts with extracellular matrix glycosaminoglycans resulting in lipoprotein trapping which in turn leads to oxidative and hydrolytic modification of apoB by secretory phospholipase A2 and secretory sphingomyelinase, both of which are produced by macrophages (Moore and Tabas, 2011). In response to retention and modification of apoB, the proinflammatory phenotype of endothelial cells is extended to the upregulation of adhesion molecules such as P-selectin, intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), which collectively promote the endocytosis of monocytes into the subendothelial space (Moore and Tabas, 2011).

Once resident in the intima, monocytes give rise to a heterogeneous population of cells that regulate immune responses (Becker et al., 2012). Monocyte-derived dendritic cells internalize, process and present antigens (such as lipid or modified apoB fragments) to T-cells, potentiating immune cell recruitment (Becker et al., 2012). Monocyte-derived macrophages engulf lipoprotein-derived lipids in attempt to clear the atherogenic substrate, and are hence considered atheroprotective in early lesions (Moore and Tabas, 2011). However, overwhelming accumulation of apoB100-containing
lipoproteins in the intima renders macrophage lipid uptake and efflux mechanisms dysregulated, which generates lipid-laden macrophage foam cells (Libby et al., 2011). The accumulation of foam cells coupled with the inflammatory response contributed by both dendritic cells and macrophages defines the unresolving nature of a growing atheroma (Libby et al., 2011).

1.2.2 CHOLESTEROL-RICH MACROPHAGE FOAM CELLS

Macrophage cholesterol homeostasis is regulated by uptake, storage and efflux (Figure 1.2). The development of CE-rich lipoprotein-induced “macrophage foam cells” - a histological term that reflects the microscopic appearance of lipid-laden macrophages - is initiated by the ingestion and processing of LDL in both its native and modified forms (Libby et al., 2011). Native LDL uptake occurs via the LDL receptor (LDLR), which undergoes negative feedback regulation under high intracellular sterol concentrations (Goldstein and Brown, 2009). Although this pathway certainly contributes to foam cell development (Goldstein and Brown, 2009), the predominant LDL uptake pathway by macrophages in lesions is that of modified LDL via the scavenger receptors cluster of differentiation (CD) 36 and scavenger receptor A I/II (SRAI/II). Upon entry into the intima, LDL particles undergo oxidative modification rendering them high-affinity scavenger receptor ligands (Moore and Freeman, 2006). Unlike the native LDLR, scavenger receptors do not undergo negative feedback regulation in response to intracellular sterol accumulation (Moore and Freeman, 2006). Consequently, macrophage uptake of modified LDL particles in lesions can persist indefinitely, and is only limited by substrate availability and cell viability.

Once internalized, lipoprotein derived cholesteryl esters are hydrolyzed in the late endosomes to free cholesterol and fatty acids (Maxfield and Tabas, 2005). Through mechanisms that are poorly understood, the late endosomal protein Niemann Pick C1 (NPC1) traffics late endosomal free cholesterol to the endoplasmic reticulum (ER),
Figure 1.2: Cholesterol homeostasis in macrophages.

The LDL receptor (LDLR) mediates the uptake of native LDL particles through receptor-mediated endocytosis. Modified LDL, namely oxLDL is also taken up via receptor mediated endocytosis by the scavenger receptors CD36 and SRAI/II. Upon internalization, CE is hydrolyzed in the late endosomes/early lysosomes into free cholesterol and transferred to the endoplasmic reticulum for processing. The two major pathways for this free cholesterol are: (1) efflux via the cholesterol efflux transporters ABCA1 (to apoAl) and ABCG1 (to HDL₃), and (2) re-esterification by ACAT into cholesteryl ester for storage in cytoplasmic lipid droplets.
where acyl-CoA:cholesterol acyltransferase (ACAT) re-esterifies free cholesterol to cholesteryl fatty acid esters for storage in cytoplasmic lipid droplets (Brown et al., 1980, Ikonen, 2008). Lipid droplet CE is a defining feature of LDL-induced macrophage foam cells in atherosclerotic plaques. However, it has been suggested that as lesions progress, ACAT activity diminishes (Rong et al., 2013). As proof-of-concept, the ablation of macrophage ACAT1 in hypercholesterolemic mouse models of atherosclerosis results in increased atherosclerotic lesion area (Accad et al., 2000, Fazio et al., 2001). Subsequent studies demonstrated that the increase in atherosclerosis in ACAT-deficient settings is due to enrichment of free cholesterol in ER membranes, which initiates the ER-stress response and promotes a proinflammatory, apoptosis-susceptible macrophage (Li et al., 2005, Seimon et al., 2009). As a result, hyperlipidemia coupled to diminishing ACAT activity in advanced plaques contributes to the potentiation of plaque progression. Under these circumstances, it is critical that the rate of cholesterol efflux maintains intracellular free cholesterol content below inflammatory and cytotoxic levels.

Normally free cholesterol released from the late endosomal pathway, as well as free cholesterol mobilized from cytoplasmic lipid droplets, can traffic to the plasma membrane via the Golgi-to-membrane vesicular pathway to become accessible for cholesterol efflux out of the cell (Tall et al., 2008). The removal of plasma membrane cholesterol from macrophages is the predominant pathway for cholesterol mobilization from plaques during atherosclerosis regression (Fisher et al., 2012), and occurs via ATP-binding cassette (ABC) A1- and ABCG1-mediated free cholesterol transport to apolipoprotein A1 (apoA1) and HDL respectively (Tall et al., 2008). HDL particles are also recognized by the scavenger receptor, class B type I (SR-BI) in the periphery as well as the liver (Trigatti et al., 2003). Increasing the cholesterol efflux pathway has very clear cardioprotective effects (Fisher et al., 2012). Intravenous injection of apoAl into hypercholesterolemic rabbits successfully delayed lesion progression, and intravenous
Infusion of a recombinant form of apoAI induced significant regression of atherosclerosis in apoE deficient mice (Miyazaki et al., 1995, Shah et al., 2001). Conversely, as predicted, combined deletion of ABCA1 and ABCG1 in macrophages significantly increases lesion development in mice (Yvan-Charvet et al., 2007). Interestingly, ABCG1 deletion alone is atheroprotective due to compensatory upregulation of ABCA1 (Tarling et al., 2010).

In summary, dynamic regulation of cholesterol uptake, storage and efflux requires a fine balance in plaque macrophages, and ultimately dictates the fate of atherosclerotic lesions.

1.2.3 INFLAMMATION AND APOPTOSIS IN CHOLESTEROL-RICH FOAM CELLS

As alluded to in sections 1.1 and 1.2.1, a major characteristic of atherosclerosis is chronic low-grade inflammation. Although it has recently been challenged (Spann et al., 2012), the generally accepted paradigm is that cholesterol-treated macrophages exhibit a proinflammatory phenotype (Moore and Tabas, 2011). Specifically, oxidized LDL (oxLDL) has been reported to stimulate proinflammatory cytokine expression through CD36 in concert with the pattern recognition toll-like receptors (TLR) (Moore and Tabas, 2011). The assembly of CD36-TLR complexes leads to the activation of nuclear factor kappa B (Nfκb) signal transduction to simulate expression of inflammatory mediators (Stewart et al., 2010). In macrophages isolated from CD36 deficient patients, oxLDL fails to stimulate cytokine expression (Janabi et al., 2000), and loss of this scavenger receptor protects mice against diet-induced atherosclerosis and aortic inflammation (Febbraio et al., 2000, Manning-Tobin et al., 2009). Furthermore, specific deletion of TLR4 or TLR6 abrogates oxLDL-induced inflammatory responses in vitro (Stewart et al., 2010), while TLR1, TLR2 and TLR6 deletion attenuates atherogenesis in a variety of atherosclerosis mouse models (Curtiss et al., 2012, Mullick et al., 2005).
In addition to lipoprotein-mediated cell-surface stimulation of inflammatory signal transduction, intracellular cholesterol accumulation can also lead to macrophage inflammation. In particular, free cholesterol loading stimulates an ER-stress pathway known as the unfolded protein response (UPR), which serves as a repair pathway during times of ER perturbation (Martinet et al., 2012, Tabas and Ron, 2011). However, prolonged ER-stress leads to the induction of a specific branch of the UPR involving C/EBP homologous protein (CHOP), which in turn stimulates Nfκb signaling, and eventually apoptosis and secondary necrosis. These latter consequences of free cholesterol-induced ER-stress are central features of advanced atherosclerotic lesions that are vulnerable to rupture (Li et al., 2005, Thorp et al., 2009). Increased ER-stress markers have been visualized in plaques isolated from hypercholesterolemic mice (Zhou et al., 2005). Furthermore, Chop/apoE double knockout mice background exhibit substantially smaller atherosclerotic lesions than Chop+/+;apoE−/− mice (Thorp et al., 2009). Moreover, the global deletion of Chop reduced plaque macrophage apoptosis and necrosis, thus resulting in more stable atherosclerotic lesions (Thorp et al., 2009). Subsequently it was shown that macrophage-specific deletion of Chop also reduced plaque vulnerability (Tsukano et al., 2010). Importantly, free cholesterol loaded macrophages with ER-stress-induced inflammation and apoptosis are significant contributors to the accelerated atherosclerosis progression observed in the insulin resistant state (Tabas et al., 2010).

Despite the overwhelming evidence that cholesterol-treated and cholesterol-loaded macrophages are proinflammatory the data are not consistent across all experimental settings. THP-1 human monocytes that are differentiated into macrophages and treated with LDL that has been mildly or extensively oxidized displayed reduced expression of a panel of proinflammatory cytokines (Qiu et al., 2007). In a subsequent study, addition of the TLR2/TLR4 ligand lipopolysaccharide (LPS)
stimulated an Nfκb-mediated inflammatory response in primary human monocytes, which was completely inhibited by the addition of oxLDL (Kannan et al., 2012). Recently, Spann et al. demonstrated that cholesterol loading of mouse peritoneal macrophages results in downregulation of cholesterol biosynthesis, which consequently increases intracellular concentrations of a very specific oxysterol, desmosterol. Importantly, desmosterol is a potent activator of the liver X receptor (LXR), a nuclear hormone receptor that is known to mediate anti-inflammatory processes (Spann et al., 2012). Collectively, these studies suggest that understanding macrophage inflammatory responses in the context of hypercholesterolemia requires further study. This controversy will be further elaborated on in Chapter 3 of this thesis.

1.2.4 TRIGLYCERIDE-RICH MACROPHAGE FOAM CELLS

The canonical atherogenic lipoprotein is CE-rich LDL. However, elevated plasma TG-rich VLDL is now regarded as a significant contributor to the development of cardiovascular disease, particularly in the context of insulin resistance and type 2 diabetes (Talayero and Sacks, 2011). Although a causal relationship between TGs and atherosclerosis has been difficult to establish (Goldberg et al., 2011), TG-rich apoB-containing lipoproteins have been localized in plaques isolated from humans as well as animal models of disease (Proctor and Mamo, 1998, Rapp et al., 1994), justifying further investigation of the impact of these lipoproteins on macrophage foam cell formation.

It is well established that VLDL readily stimulates TG accumulation in macrophages (Figure 1.3), which is initiated by cell-surface bound lipoprotein lipase (LPL) hydrolyzing the TG-rich core of VLDL particles (Bates et al., 1984, Huff et al., 1991). The liberated fatty acids (FAs) are subsequently taken up by cells either via passive diffusion or via protein-mediated uptake by the FA translocase (FAT)/CD36. Upon internalization, FA binding proteins transport FAs to the outer mitochondrial membrane for activation to fatty acyl-CoAs by acyl-CoA synthetases (Yen et al., 2008).
Figure 1.3: VLDL-induced foam cell formation.

The interaction between VLDL and cell-surface bound lipoprotein lipase (LPL) results in the hydrolysis of the VLDL TG-rich core to free fatty acids (FFAs). These FFAs are internalized either via passive diffusion or protein-mediated uptake by the fatty acid translocase (FAT) CD36. Upon internalization, FFAs are either re-esterified into TG by the DGAT enzymes for storage in cytoplasmic lipid droplets, or transported into the mitochondria by CPT1α for fatty acid β-oxidation. Excessive fatty acid uptake without sufficient β-oxidation results in the development of TG-rich macrophage foam cells.
This activation step is a requirement for further FA trafficking within the cell. For example, the acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes catalyze the re-esterification of FAs into triacylglycerol for storage in cytoplasmic lipid droplets, and use activated fatty acyl-CoAs as the acyl donors (Yen et al., 2008). Although the exact process by which TG is deposited into lipid droplets is not fully understood, it is believed that the DGAT enzymes synthesize TGs mainly at the lipid bilayer of the ER (Walther and Farese, 2012). Nevertheless, macrophage exposure to VLDL stimulates foam cell formation due to substantial accumulation of cytoplasmic TG. It is therefore important that the process of FA β-oxidation maintains TG homeostasis to prevent excessive accumulation of lipid-laden macrophages in the arterial intima. Fatty acid oxidation will be discussed in detail in section 1.4.4.

1.2.5 INFLAMMATION IN TRIGLYCERIDE-RICH FOAM CELLS

Although TG-rich macrophages are by definition foam cells, the induction of inflammatory responses does not occur in response to TG accumulation per se. Rather, the stimulation of macrophage inflammation and cytotoxicity is thought to occur as a consequence of VLDL-derived free fatty acid (FFA) exposure to cells. Inhibition of LPL resulted in complete abrogation of the VLDL-stimulated inflammatory response in mouse peritoneal macrophages (Saraswathi and Hasty, 2006). Additionally, peritoneal macrophages and bone marrow-derived macrophages isolated from Dgat1 transgenic mice fed a high fat diet accumulate a significant amount of TG, but were protected from an inflammatory response (Koliwad et al., 2010), which further demonstrates that FFAs are responsible for an inflamed macrophage phenotype rather than TGs themselves. A number of groups independently suggested that FFAs activate TLR-dependent signaling to generate macrophage inflammation and lipotoxicity (Lee et al., 2004a, Shi et al., 2006). However, this claim has more recently been cast in doubt by other studies (Anderson et al., 2012, Erridge and Samani, 2009).
VLDL-derived FAs elicit macrophage inflammatory responses, at least in part due to stimulation of MAPK signaling. The MAP kinases extracellular signal-related kinase (ERK)1/2 and p38 cooperatively regulate the activated protein (AP)-1 transcription factor (Figure 1.4), which is known to participate in the induction of a host of proinflammatory cytokines (Eferl and Wagner, 2003). VLDL not only stimulates ERK1/2 activation (Saraswathi and Hasty, 2006), but it also potentiates LPS-induced cytokine expression (Stollenwerk et al., 2005), attributable to the simultaneous activation of parallel pathways by each stimulus. In addition to inducing MAPK signaling, VLDL-derived FAs can also promote an insulin-resistant macrophage phenotype, which can potentiate the inflammatory response (Su et al., 2009). The impact of macrophage insulin resistance on inflammation, apoptosis and atherosclerosis will be further discussed in section 1.5.3.2 of this thesis. Interestingly, in contrast to free cholesterol-induced macrophage inflammation, FFA-induced cytokine expression does not require Nfkbeta activation (Erridge and Samani, 2009).

The induction of macrophage foam cell formation and the inflammatory response by VLDL, as well as the ability of peroxisome proliferator-activated receptor (PPAR)-δ activation to attenuate these effects is the topic of Chapter 2 of this thesis (Bojic et al., 2012).

1.2.6 Atherosclerotic Lesion Progression

The stages of atherosclerosis are numerically classified based on histological features at each stage of the disease (Stary, 2000). Initial lesions, classified as Type I (Stary et al., 1994), are characterized by thickening of the arterial intima due to the accumulation of lipoproteins and increased cellularity (Figure 1.5), with development of isolated groups of macrophage foam cells. In many cases, Type I lesions can be detected during infancy (Stary et al., 1994). As foam cell accumulation persists to the point of gross microscopic detection, the lesion becomes classified as Type II, also
Figure 1.4: VLDL-induced MAPK signaling in macrophage foam cells.

VLDL-derived FAs stimulate the phosphorylation of the MAP kinases extracellular signal-related kinase (ERK)1/2 and p38 via mechanisms that remain to be elucidated. Phosphorylated ERK1/2 and p38 cooperatively stimulate the activation of the activated protein (AP)-1 transcription factor. Activated AP-1 translocates into the nucleus where it binds to AP-1 response elements (AP-1RE) within promoter regions of proinflammatory cytokine genes.
Figure 1.5: Atherosclerotic Lesion Progression.

Endothelial dysfunction and build up of arterial lipids and lipoproteins stimulate the recruitment of macrophages to the site of vascular insult. Macrophages of the arterial intima scavenge lipoprotein-derived lipids, resulting in foam cell formation. Excessive macrophage foam cell accumulation results in the development of a lipid core associated with proinflammatory immune responses. To stabilize the expanding lipid core, smooth muscle cells are stimulated by inflammatory effectors from the lesion to proliferate into the plaque and deposit extracellular matrix proteins such as collagen. This results in the formation of a fibrous plaque. Consequences of unresolved atherogenesis include vessel occlusion, rupture and thrombosis, all of which can induce an acute cardiovascular event such as myocardial infarction or stroke.
Adapted from illustration an illustration by Grahams Child
referred to as a fatty streak. At this stage, smooth muscle cells indigenous to the lesion location can also take up lipid resulting in a smooth muscle cell-foam cell phenotype (Stary et al., 1994). The bridge between Type II lesions and advanced plaques are Type III intermediate lesions, for which the major histological feature is microscopically visible extracellular pools of lipid, namely cholesterol crystals (Stary et al., 1994). This is most likely due to the onset of ER-stress-induced apoptosis of macrophage foam cells as a consequence of unresolved inflammation in the plaque, coupled to defective clearance of dead cells and debris by phagocytic immune cells (Moore and Tabas, 2011). Despite monocyte recruitment persisting at all stages of lesion development in efforts to clear the atherogenic substrates and debris (Swirski et al., 2006), the presence of extracellular cholesterol crystals and debris disrupts and displaces extracellular matrix within the lesion. Consequently, the classification extends to Type IV lesions, or atheromas, which are characterized by the presence of a defined lipid core causing severe intimal disorganization (Stary et al., 1995). Secondary necrosis is also a major feature of Type IV lesions as a result of continued ER-stress-induced apoptosis as discussed in section 1.2.3. It is important to note that Type I to III lesions are clinically silent, and it is at the Type IV lesion stage that blood flow may begin to be significantly disrupted and lead to compromised arterial function (Stary, 2000). Intimal and newly recruited medial smooth muscle cells increase the presence of fibrotic tissue in the plaque, which consists of elastin, collagen, proteoglycans and glycoproteins that forms a fibrous cap as an effort to stabilize the necrotic lipid core. The presence of this cap is the prominent new feature that defines the progression to Type V lesions (Stary et al., 1995). Despite increased fibrous cap formation, local immune cells produce matrix-metalloproteinases that degrade the deposited extracellular matrix, which eventually leads to fibrous cap thinning (Weber et al., 2008). The resultant lesions are prone to neovascularization, which increases leakage, hemorrhage, and rupture (Weber et al., 2008). All of these processes
contribute to the contact of plaque debris with the circulation, triggering coagulation and thrombus formation, thereby increasing likelihood of arterial occlusion leading to myocardial infarction or stroke. Therefore, whether lesion progression, stabilization or regression occurs is determined by the complex interactions between the physical and environmental factors within the lesion.

1.3 LIPOPROTEIN METABOLISM

Whole body lipid homeostasis is maintained through a balance between exogenous uptake and endogenous synthesis of fatty acids and cholesterol, as well as the trafficking of these lipids in macromolecular complexes called lipoproteins.

1.3.1 LIPOPROTEINS

All lipoproteins are spherical, soluble lipid carriers comprised of a hydrophobic TG and CE rich core encased by a hydrophilic monolayer of phospholipids, free cholesterol and apolipoproteins (Hegele, 2009). The classification of lipoproteins is based on their density, lipid composition and apolipoprotein association (Table 1.1). In addition to providing structural support to lipoprotein complexes, apolipoproteins also determine the interaction of lipoproteins with cell surface receptors as well as their rate of catabolism.

The largest lipoproteins are chylomicrons which are formed in the intestine and transport dietary TGs on an apoB48 backbone, with trace amounts of dietary cholesterol. Very low-density lipoproteins (VLDL), secreted by hepatocytes, carry endogenous TG with modest amounts of endogenous as well as exogenous CE on an apoB100-backbone, and are associated with apoEs and apoCs. The catabolism of VLDL results in VLDL-remnant lipoproteins called intermediate density lipoproteins (IDL), which transport roughly equal partitions of TG and CE. Further catabolism of IDL followed by a series of
TABLE 1-1 Lipoprotein Classification

<table>
<thead>
<tr>
<th>Lipoprotein Class</th>
<th>Percent Composition</th>
<th>Site of Origin</th>
<th>Associated Apolipoproteins</th>
<th>Primary Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chylomicrons</td>
<td>84% TG, 8% PL, 6% CE, 2% protein</td>
<td>Intestine</td>
<td>Al, AII, AIV, B48, CII, CI, CIII, E</td>
<td>Delivery of dietary TG</td>
</tr>
<tr>
<td>Very Low Density Lipoproteins (VLDL)</td>
<td>58% TG, 20% PL, 15% CE, 9% protein</td>
<td>Liver</td>
<td>B100, C1, CII, CIII, E</td>
<td>Delivery of endogenous TG</td>
</tr>
<tr>
<td>Intermediate Density Lipoproteins (IDL)</td>
<td>29% TG, 26% PL, 34% CE, 11% protein</td>
<td>VLDL catabolism</td>
<td>B100, CI, CII, CIII, E</td>
<td>Delivery of endogenous TG and CE</td>
</tr>
<tr>
<td>Low Density Lipoproteins (LDL)</td>
<td>8% TG, 22% PL, 50% CE, 20% protein</td>
<td>VLDL catabolism</td>
<td>B100</td>
<td>Delivery of cholesterol</td>
</tr>
<tr>
<td>High Density Lipoproteins (HDL)</td>
<td>8% TG, 30% PL, 29% CE, 33% protein</td>
<td>Peripheral lipidation of liver and intestine secreted apoAI</td>
<td>Al, All</td>
<td>Reverse cholesterol transport from periphery to liver</td>
</tr>
</tbody>
</table>

Adapted from (Wasan et al., 2008). Nat Rev Drug Discov, 1, 84-99.
modifications and lipid exchanges with various lipoproteins, results in the formation of CE-rich LDL particles (Hegele, 2009).

Cholesteryl Ester is also transported by HDL, the smallest lipoprotein type. The protein backbone of HDL particles is apoAI, which is predominantly secreted from the liver and initially lipidated by hepatic ABCA1 (Timmins et al., 2005). This lipidation results in the formation of nascent HDL which enters the plasma and undergoes a series of enzymatic lipid transfer modifications to form mature HDL (Sorci-Thomas and Thomas, 2012). Cholesterol is effluxed to HDL as free cholesterol and is re-esterified into the hydrophobic core of the particles by HDL-associated lecithin-cholesterol acyltransferase (LCAT). Once HDL becomes CE-enriched, it can be remodeled by cholesteryl ester transfer protein (CETP) in plasma which facilitates the movement of CE from HDL to VLDL in exchange for TG. In turn, HDL particles become better substrates for hepatic lipase (HL). Mature HDL particles serve as carriers of cholesterol from the periphery to the liver, where cholesterol is converted to bile acids for subsequent excretion (Repa and Mangelsdorf, 2000).

1.3.2 EXOGENOUS LIPOPROTEIN METABOLISM

Absorption of dietary lipids occurs in the jejunal portion of the small intestine. Cholesterol is absorbed via protein-mediated uptake by the transporter Niemann-Pick C1-like1 (NPC1L1) on the brush-border membrane of the intestinal lumen (Huff et al., 2006), whereas dietary TG requires hydrolysis by pancreatic lipase before it can be taken up by soluble passive diffusion. Upon internalization into intestinal enterocytes, fatty acids are sequentially re-esterified into TG by the MGAT and DGAT enzymes. It is dietary TG, rather than cholesterol, which determines the rate of formation of the exogenously derived TG-rich chylomicron particles (Karpe, 2002). The apoB48 backbone of chylomicrons is derived from editing of full-length APOB mRNA by the apoB mRNA editing enzyme (APOBEC1), which deaminates cytidine 6666 of the APOB
transcript to a uridine (Rosenberg et al., 2011). This results in a change at position 2153 of the apoB protein from glutamine to a stop codon, yielding a translated protein that is the N-terminal 48% of the 550kDa polypeptide apoB100 chain (Chen et al., 1987). In humans, APOBEC1 is expressed exclusively in the intestine, whereas mice express this enzyme in both intestine and liver. ApoB48 is cotranslationally lipidated with TG, CE and phospholipids by microsomal triglyceride transfer protein (MTP) within the ER of intestinal enterocytes prior to secretion into the lymphatic system as a chylomicron (Figure 1.6).

Chylomicrons, upon entry into the lymphatics and into plasma, become associated with apoEs and apoCs, both of which are required for the metabolism of chylomicron particles. Specifically, apoCII is required for the activation of TG hydrolysis by LPL, an enzyme which is secreted by parenchymal cells of muscle and adipose tissue, and is anchored to capillary endothelial cells by heparin sulfate proteoglycans. Chylomicron-derived FFAs and glycerols are taken up predominantly by adipose tissue and re-esterified into TGs for storage. The resultant chylomicron remnant particles are efficiently taken up by the liver through LDLR- and LDL receptor related protein (LRP)-mediated uptake by recognition of apoE (Blasiole et al., 2007), concluding the exogenous lipid metabolism pathway.

1.3.3 ENDOGENOUS LIPOPROTEIN METABOLISM

The endogenous lipoprotein pathway begins with the recycling of TG and cholesterol from chylomicron remnants in the liver, intersecting with the hepatic de novo synthesis of these lipids. Approximately 80% of circulating cholesterol is produced by the body, mostly in hepatocytes, making the liver the primary regulator of whole body cholesterol and lipid homeostasis (Hegele, 2009).

Synthesis of both cholesterol and TG begins with the formation of acetyl-CoA derived from the metabolism of glucose or fatty acids. The 32-step cholesterol
Figure 1.6: Endogenous and Exogenous Lipoprotein Metabolism.

Dietary triglycerides and cholesterol are packaged onto apoB48 within the intestinal enterocytes. The resultant chylomicron particles are secreted into the lymphatics, which subsequently enter the blood stream. Lipoprotein lipase (LPL) hydrolyzes triglycerides (TGs) which allows uptake of free fatty acids (FFAs) into peripheral tissues. The remnant cholesteryl ester (CE)-rich particle is taken up by the liver through LDL receptor (LDLR)- and LDLR related protein (LRP)-mediated endocytosis. Dietary and newly synthesized lipids are packaged onto apoB100, which is secreted by the liver as VLDL. These particles also undergo hydrolysis by LPL. The CE-rich VLDL-remnant particles (IDL), and IDL modified to LDL particles, can be taken up by the liver or peripheral tissues through the LDLR. The reverse cholesterol transport pathway involves the removal of cholesterol from peripheral tissues via efflux to HDL. This lipoprotein particle is efficiently cleared by SR-BI in the liver, where cholesterol is converted to bile acids for excretion in bile.
biosynthetic pathway is initiated by the condensation of two acetyl-CoA molecules to produce acetoacetyl-CoA, which is the substrate for HMG-CoA-synthase in the formation of HMG-CoA. Subsequently, HMG-CoA-reductase, the rate-limiting enzyme in the cascade and target of statins, catalyzes the generation of mevalonate, which through a series of condensation reactions yields squalene. The cyclization of squalene produces lanosterol, which is converted to cholesterol through a further 19-step process with the final reaction being the conversion of desmosterol to cholesterol by dehydrocholesterol reductase (DHCR) 24.

Fatty acid synthesis is initiated by the carboxylation of acetyl-CoA by acetyl-CoA carboxylase (ACC) to malonyl-CoA, which is subsequently elongated to palmitic acid by fatty acid synthase (FAS). Fatty acids can then be further elongated and/or monounsaturated prior to subsequent esterification into TG by the MGAT and DGAT enzymes in the ER.

The availability of both cholesterol and TG is required for the formation of VLDL particles. The apoB100 backbone of VLDL is cotranslationally lipidated by MTP exclusively in the liver prior to its secretion into the bloodstream. Within capillary beds of target tissues such as adipose and muscle, endothelial cell LPL hydrolyzes the TG-rich VLDL core liberating FFAs and glycerol which are taken up via soluble passive diffusion or CD36-mediated uptake. Re-esterification into TGs in adipose or fatty acid oxidation in muscle ensues. Following LPL-mediated hydrolysis of VLDL particles, VLDL-remnants or IDLs are formed, which can be taken up by recognition of apoE by the LDLR or the LRP following HL modification (Hu et al., 2008). Alternatively, IDL can become further enriched in CE from HDL via CETP, and can be further modified by HL, consequently resulting in the formation small sense CE-rich LDL particles. In humans, IDL modification leading to LDL formation is the predominant pathway.
The final lipoprotein in the endogenous pathway is CE-rich LDL, which is mainly taken up receptor-mediated endocytosis. The LDLR is expressed ubiquitously, recognizes apoB100 and mediates the principal mechanism of LDL uptake. It accounts for approximately one third of LDL uptake by extrahepatic tissues. However, the liver is the primary site of LDLR expression and therefore regulates most of the clearance of circulating LDL particles.

1.4 REGULATION OF FATTY ACID AND CHOLESTEROL METABOLISM

1.4.1 STEROL REGULATORY ELEMENT BINDING PROTEINS

The sterol regulatory element binding proteins (SREBPs) are the master transcriptional regulators of lipid homeostasis (Horton et al., 2002). The three isoforms of the SREBP family are encoded by two genes; SREBP1, which generates the SREBP-1α and SREBP-1c isoforms through the use of different promoters to produce alternate forms of exon 1, and SREBP2 (Horton et al., 2002). The three members of the SREBP family have distinct but overlapping transcriptional programs. SREBP-1c is expressed predominantly in hepatocytes, where it directly activates the expression of genes involved in fatty acid synthesis and elongation in response to increases in plasma insulin levels. SREBP-1α and SREBP-2 are expressed ubiquitously where they regulate genes involved in cholesterol homeostasis in response to intracellular sterol concentrations (Shao and Espenshade, 2012).

All three SREBPs contain three basic domains: (i) an N-terminal basic helix-loop-helix (bHLH) leucine zipper DNA binding motif for binding to sterol response elements (SREs) within promoter regions of their target genes, (ii) two hydrophobic transmembrane domains separated by a short loop that projects into the lumen of the ER and (iii) a regulatory C-terminal domain that interacts with the SREBP cleavage activating protein (SCAP) (Horton et al., 2002). The SREBPs are synthesized as inactive precursors, retained in the ER due to their interaction with SCAP through the MELADL
peptide sequence (Sun et al., 2005). Under conditions of high intracellular sterols, SCAP also interacts with the insulin induced genes (INSIG) 1/2; ER-anchor proteins that retain the SCAP/SREBP complex in the ER. When sterols are depleted, SCAP undergoes a conformational change resulting in the dissociation from INSIG, which allows access of COPII vesicles containing a Sar-1/Sec23/Sec24 complex to SCAP/SREBP. In turn, the SCAP/SREBP complex is trafficked to the Golgi for processing to active transcription factors (Sun et al., 2005). Depletion of hepatic SCAP results in the complete absence of processing of all three SREBPs, concomitant with normalization of lipogenesis and hypertriglyceridemia (Moon et al., 2012), demonstrating a lack of redundancy for SCAP-mediated SREBP transport to the Golgi. Once the SCAP/SREBP complex reaches the Golgi, SREBPs undergo sequential cleavage by the Site 1 and Site 2 proteases (Shao and Espenshade, 2012). The Site 1 protease is a serine protease that cleaves the ER-luminal loop separating the SREBP transmembrane domains. Subsequently, the Site 2 zinc metalloproteinase releases the N-terminal bHLH leucine zipper fragment, allowing for its translocation into the nucleus where it binds to SREs within target gene promoters (Figure 1.7) (Shao and Espenshade, 2012). SREBP-1a and SREBP-2 activate transcription of genes involved in cholesterol uptake and cholesterol synthesis such as LDLR and HMG-CoA reductase, to restore sterol balance (Shao and Espenshade, 2012). SREBP-1c on the other hand, stimulates the expression of genes involved in fatty acid synthesis and elongation, including ACC, FAS and stearoyl-CoA desaturase (SCD) (Moon et al., 2012).

In addition to SCAP, the INSIGs provide another layer of trafficking regulation to the SREBPs, owing to a convergent feedback loop (Goldstein et al., 2006). The two INSIG isoforms (INSIG-1 and INSIG-2) are protein products of separate genes and are differentially regulated. INSIG-1 transcription is activated by SREBP-1c in a feed forward mechanism to regulate the amount of cholesterol being restored. INSIG-2 produces two
Figure 1.7: Regulation of the Sterol Regulatory Element Binding Proteins.

The sterol regulatory element binding proteins (SREBP) reside in the endoplasmic reticulum (ER) membrane as inactive precursors. During periods of high intracellular sterol, SREBPs interact with SREBP cleavage activating protein (SCAP), which in turn interacts with Insig to retain SREBPs within the ER membrane. Upon depletion of intracellular sterol, or insulin-mediated degradation of Insig, the dissociation of SCAP from Insig results in the trafficking of the SCAP-SREBP complex to the Golgi where sequential processing by Site 1 (S1P) and Site 2 proteases (S2P) releases the active nuclear SREBP transcription factor. SREBP transcription factors translocate into the nucleus and bind to sterol regulatory elements (SREs) within promoter regions of genes required for lipogenesis.
Adapted from (Shao and Espenshade, 2012). *Cell Metab*, 16, 414-9.
transcripts that encode the same protein, but are differentially regulated. INSIG-2a is a liver-specific isoform whereas INSIG-2b is ubiquitously expressed, yet has very low liver expression (Goldstein et al., 2006). Evidence that the INSIGs are required for the regulation of lipid homeostasis in liver was provided by Engelking and colleagues, when they simultaneously disrupted hepatic INSIG-1 and -2 (Engelking et al., 2005). The resultant phenotype was profound hepatic steatosis on a chow diet as a result of hyperactive SREBP-mediated lipogenesis, demonstrating that the INSIG proteins are essential for SREBP feedback regulation (Engelking et al., 2005).

The INSIGs are also regulated by plasma insulin, which sets the stage for reciprocal regulation during fasting and feeding cycles (Goldstein et al., 2006). As mentioned above, SREBP-1c is activated in response to increases in circulating insulin. During the fasted state, plasma insulin is low. In turn, SREBP-1c is inactive meaning that INSIG-1 expression is low. However, INSIG-2a levels are high, which contributes to SREBP-1c retention in the ER during the fasted state. As plasma insulin rises during feeding, INSIG-2a is rapidly degraded by Akt-dependent mechanisms allowing for SREBP-1c processing and translocation into the nucleus (Yecies et al., 2011). As a result, INSIG-1 levels increase owing to convergent feedback regulation, resulting in the prevention of SREBP-1c hyperactivity. In mice overexpressing hepatic Insig1, normal fasting/re-feeding regulation of INSIG-2 ensues, yet the livers of these animals are resistant to acute lipogenesis in the fed state (Engelking et al., 2004). This suggests that insulin-mediated suppression of INSIG-2 is required for insulin-induced SREBP-1c lipogenesis during feeding. In states of insulin resistance, hyperinsulinemia persists during fasting, resulting in the chronic downregulation of INSIG-2, which in part contributes to the hyperactivity of SREBP-1c-mediated lipogenesis (Yecies et al., 2011).
1.4.2 DE NOVO LIPOGENESIS

Lipolysis of adipose tissue TG is the major contributor of FAs to VLDL-TG during periods of fasting (Zechner et al., 2012), while de novo lipogenesis is a minor contributor (Barrows and Parks, 2006). However during feeding, adipose tissue lipolysis is suppressed whereas hepatic de novo lipogenesis is simultaneously increased by insulin. Consequently, a major contributor to the pool of FAs for VLDL-TG in the fed state is de novo lipogenesis.

The synthesis of FAs begins with the carboxylation of acetyl-CoA to malonyl-CoA by ACC. Subsequently, malonyl-CoA provides two carbon units to FAS for the synthesis of 16 and 18 carbon saturated fatty acids. The resultant fatty acids require activation by long chain acyl-CoAs synthetase to fatty acyl-CoA before they can become substrates for subsequent processing or partitioning (Walther and Farese, 2012). Fatty acyl-CoAs are stearoyl CoA-desaturase (SCD) substrates for desaturation and subsequent esterification to cholesterol in the production of cholesteryl esters. Additionally, activated fatty acids are also used by CPT1α and DGAT for entrance into the mitochondria for fatty acid oxidation and for re-esterification of fatty acids into TGs, respectively (Walther and Farese, 2012).

The generation of TG is the major mechanism for metabolic fuel storage in living organisms (Yen et al., 2008). Two convergent pathways contribute to TG production, both of which utilize fatty acyl-CoAs as acyl donors. The canonical glycerol phosphate pathway occurs in most tissues and begins with the acylation of glycerol-3-phosphate by acyl-CoA:glycerol-3-phosphate acytransferase to yield lysophosphatidic acid. Subsequently, lysophosphatidic acid is further acylated and dephosphorylated to produce diacylglycerol (DG) (Liu et al., 2012). In the monoacylglycerol pathway, which occurs mainly in the intestine, liver and adipose tissue, fatty acyl-CoAs are esterified to the 2-position of monoacylglycerol by acyl-CoA:monoglycerol acyltransferase (MGAT) to
produce DG (Liu et al., 2012). In the final step of TG synthesis, fatty acyl-CoAs are esterified to the 3-position of the resultant DG from either pathway by the DGAT enzymes (Liu et al., 2012). Newly synthesized TGs from both pathways are then transferred to cytoplasmic lipid droplets for storage via mechanisms that are not completely understood (Walther and Farese, 2012), or become incorporated into apoB-containing lipoproteins via MTP in the liver and intestine for secretion.

The esterification of fatty acyl-CoAs onto DG occurs via sequential reactions in the ER by the resident DGAT enzymes DGAT1 and DGAT2. Despite having similar function, the two DGAT isoforms differ in gene family as well as protein sequence, with DGAT1 encoding a polypeptide chain approximately 35% longer than DGAT2 (Liu et al., 2012). Nevertheless, DGAT1 is ubiquitously expressed but is most abundant in the small intestine and adipose tissue and is least abundant in the liver. Gene knockout studies revealed that Dgat1−/− mice are resistant to diet-induced dyslipidemia, obesity and insulin resistance (Smith et al., 2000), whereas Dgat2−/− mice die soon after birth due to lipopenia (Stone et al., 2004). Together these studies suggest that DGAT2 is responsible for the majority of TG synthesis required for survival.

Interestingly, overexpression of Dgat1 specifically in white adipose tissue results in protection from diet-induced insulin resistance despite increased adiposity (Chen et al., 2002). Furthermore, overexpression of either form of DGAT in the liver results in a similar phenomenon. Dgat1 or Dgat2 liver-transgenic mice develop profound hepatic steatosis in the complete absence of insulin resistance. In addition, these mice do not accumulate any appreciable fat in skeletal muscle or adipose tissue and surprisingly display substantially reduced plasma triglycerides (Monetti et al., 2007). As discussed in section 1.2.5, macrophages isolated from Dgat1 transgenic mice display significant TG accumulation without an overt inflammatory phenotype (Koliwad et al., 2010). Collectively these studies suggest that the efficient synthesis of TG by DGAT1 results in
the partitioning of fat into cytoplasmic lipid droplets which protects cells from FA
overload, lipotoxicity and lipoprotein overproduction thus conferring protection from
metabolic disturbance (Monetti et al., 2007).

1.4.3 CHOLESTEROL ESTERIFICATION

The ACAT enzymes are another group within the superfamily of membrane
bound acyltransferases. ACAT1 and ACAT2 utilize fatty acyl-CoA donors and
cholesterol as substrates in the esterification of cholesterol to generate CE for storage in
cytoplasmic lipid droplets and lipoprotein secretion. The two isoforms are encoded by
different genes and also differ in their tissue distribution. ACAT1 is ubiquitously
expressed, whereas ACAT2 is found exclusively in the small intestine and liver.
Knockout of Acat1 results in normal cholesterol absorption as well as normal intestinal,
hepatic and plasma lipids due to the compensation of cholesterol esterification by
ACAT2. The most significant change in Acat1−/− mice compared to their wild-type
counterparts was virtually undetectable CE in the adrenal cortex and in isolated
peritoneal macrophages (Meiner et al., 1996). In contrast, Acat2−/− mice cannot
synthesize CE within the intestine and as a result, have reduced capacity to absorb
cholesterol from the diet. Additionally, these mice cannot synthesize CE in the liver and
therefore do not become hypercholesterolemic when fed a high-fat high-cholesterol diet
(Buhman et al., 2000).

The different physiological roles of the ACAT isoforms become more readily
apparent when examining atherosclerosis. Breeding Acat1−/− mice to either
atherosclerosis susceptible apoE−/− or Ldlr−/− background does not protect from
atherosclerosis (Accad et al., 2000). In fact, lesion complexity is exacerbated compared
to Acat1 WT on either background. In addition, bone marrow transplantation from Acat1−/
−/− mice to these atherogenesis models also worsens atherosclerosis lesion pathology
(Fazio et al., 2001). As discussed in section 1.2.2, this is likely due to FC-induced ER-
stress, apoptosis and secondary necrosis as a result of the inability of macrophages to sequester cholesterol as metabolically inert CE. Subsequently, Acat2−/− mice were bred to both Ldlr−/− and apoE−/− mice. In contrast to the Acat1−/− crosses, Acat2 deficiency protects against atherosclerosis (Lee et al., 2004b, Willner et al., 2003), probably owing to the lack of hypercholesterolemia in these animals as outlined above (Buhman et al., 2000). Finally, tissue-specific targeting of Acat2 attenuates atherogenic dyslipidemia (Zhang et al., 2012). Collectively, these studies demonstrate that pharmacological inhibition of ACAT2 would likely be beneficial for treatment of atherosclerosis.

1.4.4 FATTY ACID OXIDATION

A critical process in maintaining lipid homeostasis and generating ATP is the oxidation of fatty acids. In hepatocytes, stimulation of fat oxidation also limits TG availability for VLDL assembly and secretion, in turn contributing to reduced plasma TG levels. In the muscle and heart, fatty acid oxidation is vital for the generation of ATP required for contractility. In macrophages, activation of fat oxidation is crucial to maintaining intracellular TG in balance with uptake and storage, which can contribute to reduced foam cell formation.

The rate-limiting step in the oxidation of fatty acids is CPT1-mediated entry into the mitochondria (Figure 1.8) (Bonnefont et al., 2004). CPT1 is an outer mitochondrial membrane enzyme that uses activated fatty acyl-CoA donors in the production of acylcarnitine. Subsequently, acylcarnitine can freely translocate across the outer and inner mitochondrial membranes. Upon entry into the mitochondrial matrix, CPT2, which is localized on the inner mitochondrial membrane, catalyzes the reformation of fatty acyl-CoA, and liberates carnitine for subsequent CPT1-mediated reactions (Bonnefont et al., 2004). Fatty acyl-CoA processing via four enzymatic steps ensues in the mitochondrial matrix to generate acetyl-CoA groups that can enter the Kreb’s cycle to be oxidized for
**Figure 1.8: The carnitine palmitoyl-transferase system.**

Carnitine palmitoyl-transferase (CPT) 1 is located on the outer mitochondrial membrane, and uses activated fatty acyl-CoA donors in the production of acylcarnitine. The production of this intermediate allows for fatty acyl-carnitine to freely translocate across the outer and inner mitochondrial membranes. Upon entry into the mitochondrial matrix, CPT2, which is localized on the inner mitochondrial membrane, catalyzes the reformation of fatty acyl-CoA, and liberates carnitine for subsequent CPT1-mediated reactions. Fatty acyl-CoA processing via four enzymatic steps ensues in the mitochondrial matrix to generate acetyl-CoA groups which enter the Kreb’s cycle to be oxidized for the production of ATP, CO$_2$ and water.
the production of ATP, CO₂ and water. In most tissues, CPT1α is the predominant isoform that regulates fat oxidation. However, a CPT1β isoform also exists, which is mainly expressed in the skeletal muscle, adipose tissue and heart (Bonnefont et al., 2004).

Regulation of fat oxidation occurs via multiple mechanisms. CPT1 is regulated at a transcriptional level by a series of complex transcription factors including PPARγ-coactivator 1 α (PGC1α), PPARα and PPARδ. Additionally, CPT1 is also allosterically regulated by malonyl-CoA (Rasmussen et al., 2002). During periods of feeding, malonyl-CoA levels are high due to increased flux through the ACC de novo lipogenesis pathway as outlined above. Conversely, during periods of fasting, malonyl-CoA levels drop due to decreased ACC activity, alleviating the impediment on CPT1-mediated fatty acid oxidation (O’Neill et al., 2013). Animal models in which malonyl-CoA levels are manipulated can vastly alter metabolic phenotypes. Liver-specific deletion of fatty acid synthase results in substantially increased hepatic malonyl-CoA content, reduced CPT1α-mediated oxidation and as a result, hepatic steatosis (Chakravarthy et al., 2005). On the other hand, hepatic overexpression of malonyl-CoA decarboxylase (which degrades malonyl-CoA to acetyl-CoA) resulted in depletion of hepatic malonyl CoA. Consequently, fat oxidation was increased, and dyslipidemia and insulin resistance were normalized (An et al., 2004). Collectively, these studies highlight the importance of fatty acid β-oxidation in whole body lipid homeostasis, and suggest that therapeutic interventions to increase fat oxidation may confer protection from metabolic disease.

1.4.4.1 FATTY ACID OXIDATION – PPAR REGULATION

The PPARs are a class of ligand-dependant transcription factors that regulate whole body lipid homeostasis (Harmon et al., 2011). Two members of this family, namely PPARα and PPAR δ, stimulate transcriptional programs that initiate fat oxidative machinery. In the liver, the major PPAR isoform is PPARα, which binds to PPAR
response elements (PPREs) within promoters of specific genes as an obligate heterodimer with the retinoid X receptor (RXR) (Harmon et al., 2011). This heterodimerization and initiation of transcription occurs in response to activation by endogenous ligands such as FAs and FA metabolites, or by synthetic ligands such as fibrates (Mandard et al., 2004). The canonical PPARα target is acyl-CoA oxidase (ACO), which stimulates peroxisomal oxidation of long chain FAs (Mandard et al., 2004). This stimulation of hepatic fatty acid oxidation is likely the key component in the ability of fibrates, synthetic ligands for PPARα, to effectively lower plasma TG levels. Fibrates are the current standard of care in the treatment of hypertriglyceridemia in dyslipidemic patients with insulin resistance (Reyes-Soffer et al., 2013).

In addition to PPARα, the other PPAR isoform that can stimulate fat utilization is PPARδ (Wang et al., 2003). In fact, CPT1α is a known PPARδ target gene (Lee et al., 2006a). The ability of PPARδ activation to regulate fatty acid oxidation and consequently prevent macrophage foam cell formation and hepatic steatosis is a significant component of the data in chapters 2 and 5 of this thesis. A more detailed discussion of PPARδ-regulated processes and functions will be presented in section 1.7.

1.4.5 AMPK – THE PIVOTAL REGULATOR OF FAT OXIDATION AND LIPOGENESIS

The adenosine monophosphate-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase that controls cellular and whole body energy metabolism (O’Neill et al., 2013). The heterotrimeric protein consists of an α-catalytic subunit, as well as β- and γ-regulatory subunits both of which are required for the catalytic activity of the α-subunit (O’Neill et al., 2013). Hepatocytes isolated from mice lacking the β1-subunit display significantly reduced AMPK activity (Dzamko et al., 2010). As an energy-sensing protein kinase, AMPK operates as a fulcrum between anabolic and catabolic processes in response to changes in cellular AMP and ATP levels (Figure 1.9). During periods of low energy such as fasting, increases in cellular
Figure 1.9: Regulation of FA synthesis and oxidation by AMPK activation.

AMPK operates as a fulcrum between anabolic and catabolic processes in response to changes in adenylate charge. During periods of low energy, increased cellular AMP binds to the γ-subunit of AMPK, inducing a conformational change in the heterotrimer that unmasks α-catalytic subunit to upstream kinases. The two major AMPK-activating kinases are liver kinase B1 (LKB1) and calcium/calmodulin-dependent protein kinase kinase (CaMKK), both of which phosphorylate AMPK on Thr172 within the α-catalytic subunit. LKB is an AMP-sensitive kinase. Activated AMPK stimulates the phosphorylation of SREBP-1c which inhibits SREBP-1c processing and reduces expression of genes required for fatty acid synthesis. Concomitantly, AMPK phosphorylates ACC, which inhibits ACC function thereby inhibiting the production of malonyl CoA. This limits substrate availability for fatty acid synthesis. Reduced malonyl-CoA also results in the derepression of CPT1α, thus increasing fatty acid oxidation.
ADP and AMP results in the binding of either of these nucleotides to the γ-subunit of AMPK, inducing a conformational change in the heterotrimer that unmasks the activation loop of the α-catalytic subunit to upstream kinases (O’Neill et al., 2013). The two major AMPK-activating kinases are liver kinase B1 (LKB1) and calcium/calmodulin-dependent protein kinase kinase (CaMKK), both of which phosphorylate AMPK on Thr172 within the α-catalytic subunit. In addition, ADP and AMP suppress AMPK inactivation by preventing the dephosphorylation of phospho-Thr172 by protein phosphatases PP2A and PP2C (Oakhill et al., 2011, Sanders et al., 2007). Activated AMPK inhibits anabolic processes (such as lipogenesis) and stimulates catabolic processes (such as fatty acid oxidation) to simultaneously conserve and produce energy. Once cellular energy has been restored, or feeding has occurred thus providing energy excess due to the stimulation glycolysis and fatty acid oxidation by dietary glucose and TG, respectively, AMP levels are depleted and ATP levels are increased. Accordingly, PP2A and PP2C reduce AMPK activity, catabolic processes cease and anabolic processes ensue (O’Neill et al., 2013).

Amongst the myriad of AMPK targets is ACC, which is thought to be the major contributor to the pivotal regulation of lipogenesis and oxidation (O’Neill et al., 2013). ACC exists in two isoforms, ACC1 and ACC2, which are phosphorylated by AMPK on Ser79 and Ser221, respectively (O’Neill et al., 2013). Phosphorylation of these ACC sites by AMPK results in the inactivation of ACC thus reducing malonyl-CoA production. In turn, substrate availability for FAS is limited, thereby downregulating lipogenesis to conserve energy. Additionally, low malonyl-CoA alleviates allosteric inhibition of CPT1α and therefore stimulates fat oxidation. Given the ability of activated AMPK to favorably regulate metabolic processes and so collectively reduce cellular fat deposition, pharmacological modulators of AMPK represent a promising therapeutic strategy to regulate of lipid imbalances observed in cardiometabolic disease (Pinkosky et al., 2013).
1.5 INSULIN SIGNALING

Insulin is a peptide hormone that is produced, processed and secreted by the β-cells of the pancreas in response to feeding, and is central to regulating the metabolism of carbohydrate, protein and lipids. Insulin responsive tissues such as muscle, adipose and liver among others, express plasma membrane bound insulin receptors which transduce the insulin signal. Binding of insulin to the extracellular ligand-binding domain rapidly stimulates the intrinsic activity of the receptor tyrosine kinase, resulting in autophosphorylation of tyrosine residues in the intracellular subunit domains (Kido et al., 2001). This autophosphorylation event causes the recruitment of insulin receptor substrate (IRS) proteins to the cytoplasmic tail of the insulin receptor that serve as docking proteins between the membrane-bound receptor and its intracellular effectors. One major downstream target of the insulin signal is phosphoinositide 3 (PI3)-kinase, which signals the phosphorylation and activation of protein kinase B/Akt (Kido et al., 2001). Under normal physiology, the downstream consequences of acute insulin-stimulated Akt activation include suppression of hepatic glucose production and promotion of de novo lipogenesis.

1.5.1 INSULIN-REGULATED HEPATIC GLUCOSE METABOLISM

Dietary glucose stimulates the release of insulin from the pancreas, which induces a feedback loop to suppress hepatic gluconeogenesis to maintain normal (low) blood glucose levels (Brown and Goldstein, 2008). Molecularly, insulin inhibits hepatic glucose production by stimulating the phosphorylation of forkhead box O1 (FoxO1) through the action of Akt (Figure 1.10). Phosphorylated FoxO1 is excluded from the nucleus, which effectively downregulates the transcription of genes involved in gluconeogenesis, most prominently glucose 6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PEPCK) (Matsumoto et al., 2006). Mice overexpressing constitutively active hepatic FoxO1 exhibit hyperglycemia and
**Figure 1.10: Insulin signaling.**

Insulin signalling via the insulin receptor results in enhanced IRS/PI3K signalling, leading to Akt phosphorylation. In turn Akt phosphorylates its downstream effector substrates mTORC1 and FoxO1. Akt-induced phosphorylation of mTORC1 renders the protein active, resulting in increased SREBP-1c-mediated fatty acid synthesis. In contrast, Akt-mediated phosphorylation of FoxO1 results in the inhibition of FoxO1 translocation into the nucleus. This suppresses *PEPCK* expression and consequently inhibits gluconeogenesis.
hyperinsulinemia, whereas RNAi knockdown of FoxO1 reverses these metabolic abnormalities (Kamagate et al., 2008).

1.5.2 INSULIN-REGULATED HEPATIC LIPID METABOLISM

Another major effect of insulin signaling in the liver is stimulation of de novo lipogenesis by activation of SREBP-1c. Mice lacking hepatic insulin receptors have severely diminished expression of the SREBPs and their targets (Biddinger et al., 2008), suggesting that hepatic insulin signaling is required for the stimulation of lipogenesis in the fed state. The molecular basis for insulin-stimulated SREBP activity occurs through dual actions of Akt in the insulin signaling cascade. As outlined in section 1.4.1, Akt can directly target INSIG2a for degradation via mechanisms that are not completely understood, thereby allowing for SREBP processing and translocation into the nucleus (Yecies et al., 2011). On the other hand, activated Akt stimulates the phosphorylation of the mammalian target of rapamycin complex (mTORC) 1 (Figure 1.10), which is known to enhance the transcription of SREBP-1c and its targets (Li et al., 2010, Yecies et al., 2011). Despite the insulin-mediated increase in hepatic de novo lipogenesis, insulin signaling also acutely suppresses hepatic VLDL secretion. The Akt-mediated phosphorylation and nuclear exclusion of FoxO1 reduces MTP expression (Kamagate et al., 2008), thus inhibiting cotranslational lipidation of apoB100. Additionally, insulin activates the MAPK\textsuperscript{erk} pathway, which also regulates MTP expression and reduces lipid availability for VLDL secretion (Allister et al., 2005).

1.5.3 INSULIN RESISTANCE

The metabolic syndrome is defined as a cluster of abnormalities including increased waist circumference, hypertension, low plasma HDL, high fasting blood glucose and high plasma TG, which collectively puts individuals at risk for the development of premature cardiovascular disease (Eckel et al., 2010). Insulin resistance is considered central to the pathophysiology of the metabolic syndrome and is clinically
defined as the inability of insulin to maintain glucose homeostasis (Haas and Biddinger, 2009). In response to elevated blood glucose levels during fasting in the insulin resistant state, the pancreas responds by increasing insulin secretion to compensate for the lack of sensitivity in peripheral tissues, thus maintaining glycemic control (Eckel et al., 2010). Eventually the pancreas cannot provide sufficient insulin, blood glucose increases, and the diabetic state ensues. Therefore, insulin resistance has been causally linked to the development of type 2 diabetes (Eckel et al., 2010).

Although the clinical definition of insulin resistance is useful, it fails to address other processes that are a result of insulin resistance. Insulin resistance is most prominently manifest in three organs: adipose, muscle and liver (Li et al., 2010). In the adipose tissue, failure of insulin to suppress TG lipolysis increases FA release and contributes to elevated plasma FFAs as well as the hepatic pool of FA available for TG re-synthesis and VLDL assembly and secretion. In muscle, the inability of insulin to stimulate glucose transporter (GLUT) 4 translocation to the plasma membrane, reduces insulin-mediated glucose uptake and contributes to fasting hyperglycemia. In the liver, however, an interesting paradox occurs where the lipogenic SREBP-1c branch of insulin signaling remains sensitive, whereas the gluconeogenic FoxO1 branch becomes resistant.

1.5.3.1 INSULIN RESISTANCE IN THE LIVER

As alluded to above, hepatic insulin resistance cannot simply be defined as the failure of insulin to propagate signal transduction through the insulin receptor. Impaired insulin receptor signaling has been observed in a variety of settings (Nyomba et al., 1990, Nyomba et al., 1991, Ozcan et al., 2004), and likely contributes to insulin resistance at certain stages of disease progression. However, in mice with hepatic insulin receptor ablation (termed pure insulin resistance), hyperinsulinemia and hyperglycemia still develop, yet in the complete absence of hepatic steatosis and
hypertriglyceridemia due to reduced SREBP-1c activity (Biddinger et al., 2008). Hence, the diabetic triad of hyperinsulinemia, hyperglycemia and hypertriglyceridemia breaks down in pure insulin resistance. This resulted in the hypothesis that normal insulin signaling must occur in the liver to at least some particular point (Brown and Goldstein, 2008). After this hypothesized point, the insulin signal should bifurcate to generate insulin resistant and insulin sensitive branches of the pathway (termed selective insulin resistance) (Figure 1.11). This dual action of insulin is a major contributor to the hypertriglyceridemia and hyperglycemia observed in the insulin resistant state.

Inhibition of PI-3K and Akt kinase activity in primary rat hepatocytes revealed that these were common mediators of the gluconeogenic and lipogenic branches of the insulin signal (Li et al., 2010). However, mTORC1 inhibition abolished insulin-induced SREBP-1c expression, but had no effect on insulin-mediated suppression of PEPCK (Li et al., 2010), demonstrating that the bifurcation point of the insulin signal is Akt. Hence, fasting hyperinsulinemia during insulin resistance chronically drives de novo lipogenesis, but fails to suppress gluconeogenesis due to the inability of Akt to phosphorylate and inactivate FoxO1. Furthermore, active FoxO1 results in constitutive activation of MTP expression, and together with increased lipogenesis contributes to increased apoB100 secretion (Biddinger et al., 2008, Kamagate et al., 2008).

The bifurcation of the insulin signaling cascade begs the questions of how and why Akt phosphorylates and activates mTORC1 but fails to phosphorylate and inactivate FoxO1. Recently, it has been demonstrated that a particular cytosolic calcium sensing kinase, calcium-calmodulin dependent kinase II gamma (CaMKIIγ), stimulates the phosphorylation of FoxO1 on non-Akt sites, thereby promoting FoxO1 entry into the nucleus to stimulate hepatic glucose production (Ozcan et al., 2012). Importantly, activity of CaMKIIγ was significantly increased in obese ob/ob mice as well as wild type mice fed a high-fat diet for 20-weeks. Adenoviral knockdown of CaMKIIγ in either of these settings
Figure 1.11: Selective versus pure insulin resistance.

Selective hepatic insulin resistance – Under hyperinsulinemic/insulin resistant conditions, the elevated plasma insulin results in chronic phosphorylation of the cascade to Akt. Paradoxically, the ability of Akt to phosphorylate mTORC1 remains sensitive, whereas Akt-mediated phosphorylation of FoxO1 becomes resistant. In turn, mTORC1-driven SREBP-1c-mediated lipogenesis is significantly increased, whereas FoxO1-processes remain activated rather than inhibited as in normal insulin signalling. Consequently, PEPCK-mediated gluconeogenesis ensues. The combined physiological effects of selective hepatic insulin resistance are: hyperinsulinemia, hypertriglyceridemia and hyperglycemia (the so-called diabetic triad) as well as hepatic TG accumulation.

Pure hepatic insulin resistance – With liver-specific deletion of the insulin receptor, the diabetic triad breaks down. Although these animals develop hyperinsulinemia, the liver cannot respond to the plasma insulin. As a result, mTORC1 remains inactive, whereas the lack of impediment on FoxO1 renders it chronically active. The physiological consequences in this scenario are: hyperinsulinemia and hyperglycemia, with normal plasma and hepatic TG.
diminished hepatic gluconeogenic gene expression, decreased fasting glycemia and improved insulin sensitivity (Ozcan et al., 2012). Given that ER-stress is known to accompany insulin resistance in the liver (Ozcan et al., 2004), and that ER-stress can dramatically increase cytosolic calcium levels (Fu et al., 2012), it is plausible that the CaMKIIγ-specific phosphorylation of FoxO1 is significantly induced during hepatic insulin resistance and prevents insulin-mediated phosphorylation and suppression of FoxO1 activity. However, this hypothesis has yet to be explored.

1.5.3.2 INSULIN RESISTANCE IN THE VASCULATURE

In addition to promoting atherogenic risk factors, namely dyslipidemia, insulin resistance may also drive atherosclerosis directly at the level of the artery wall (Tabas et al., 2010). Bone marrow transplantation from insulin receptor knockout mice (Insr−/−) into Ldlr+/− recipients substantially increased atherosclerotic lesion formation, specifically due to ER-stress induced apoptosis and necrotic core formation (Han et al., 2006). Furthermore, crossing Akt1−/− mice onto the apoE−/− background yields profound coronary atherosclerosis, attributable to increased inflammation in the vessel wall (Fernandez-Hernando et al., 2007). In macrophages deficient for the insulin receptor, FC-induced ER-stress and apoptosis involves increased nuclear FoxO1 translocation and activity (Senokuchi et al., 2008). Consistent with this, FoxO1 is known to stimulate the transcription of at least one proatherogenic inflammatory cytokine in macrophages (Su et al., 2009), and FoxO1 ablation in vascular endothelial cells attenuates atherosclerosis development (Tsuchiya et al., 2012). All of these studies use proof-of-concept genetic ablation of insulin signaling strategies and consequently fail to address whether a selective insulin resistant phenotype may be occurring in the vessel wall during diet-induced atherogenesis.

A recent study demonstrated that macrophages isolated from Insr−/− or ob/ob mice displayed a significant reduction in expression and activity of the sarcoplasmic
endoplasmic reticulum calcium ATPase, which led to reduced flux of cytosolic calcium back into the ER and as a result, increased ER-stress-induced apoptosis (Liang et al., 2012). This study suggests that a similar mechanism of insulin resistance may occur in the liver as well as in the vasculature. Thus, therapeutic agents that correct selective hepatic insulin resistance may also alleviate vascular insulin resistance, and reduce atherosclerosis through either of these mechanisms.

1.6 TYPE 2 DIABETES

As insulin resistance persists, the pancreas responds by continuously increasing insulin secretion in an attempt to maintain glycemic control. However, maintenance of blood glucose homeostasis does not occur indefinitely, as pancreatic β-cells cannot undergo hyperplasia *ad infinitum* to keep up with the insulin resistant state of the periphery (Prudente et al., 2009). Consequently, the full type 2 diabetic state ensues, putting patients at up to four-fold higher risk of developing CVD than non-diabetic subjects (Fox et al., 2007, Fox et al., 2004). The proatherogenicity of type 2 diabetes has been thought to be multi-factorial, as hyperlipidemia, hyperglycemia, hyperinsulinemia and increased oxidative stress and inflammation combine to accelerate atherogenesis (Ginsberg, 2000).

Despite considerable data demonstrating a positive correlation between diabetes and development of cardiovascular disease, delineating the relative contribution of each process outlined above to cardiovascular risk has proven difficult. Elevated plasma TG remains an independent risk factor for CVD development (Musunuru, 2010), and residual CVD risk left behind by statin monotherapy is at least 50% (Mazzone et al., 2008). The ACCORD Lipid trial tested whether LDL-C lowering statin therapy in combination with TG-lowering fibrate therapy further reduced CVD risk. There was no significant reduction observed in patients receiving combination therapy compared to those receiving statin alone (Ginsberg et al., 2010). With respect to hyperglycemia,
intensive long-term glucose lowering has not proven successful in reducing cardiovascular events (Gerstein et al., 2011). Finally, the conjecture that hyperinsulinemia is atherogenic is also controversial, as this would imply that insulin is a proatherogenic molecule. If this were the case, then insulin therapy would be a poor choice for patients with insulin resistance or type 2 diabetes (Ginsberg, 2000). However, results from the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated a nearly statistically significant \((P=0.052)\) effect of insulin and sulfonylurea treatment in reducing cardiovascular events (Group, 1998), and insulin glargine treatment for 6 years had a neutral effect on cardiovascular outcomes (Gerstein et al., 2012). Although assessment of long-term CVD prevention with insulin secretagogues such as GLP-1 analogues and DPP4 inhibitors has not been completed, the data accumulated thus far suggests that CVD risk is not worsened and might be reduced, due at least in part to TG-lowering (Anagnostis et al., 2011, DeFronzo et al., 2008). Interestingly, the GLP-1 analogue exenatide reverses FC-induced ER-stress and apoptosis in macrophages (Liang et al., 2012). Collectively, these studies suggest that patients with type 2 diabetes should be treated to the current standard of care for hyperglycemia and hyperlipidemia, until new clinical trials further our understanding of how to manage CVD risk in patients with type 2 diabetes.

### 1.7 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS

The peroxisome proliferator-activated receptor (PPAR) \(\delta\) has emerged as an important regulator of lipid homeostasis and inflammatory signaling. Recent \textit{in vitro}, \textit{in vivo} and human clinical studies have highlighted a role for PPAR\(\delta\) activation in prevention and treatment of insulin resistance and atherosclerosis.

#### 1.7.1 PPAR OVERVIEW

The PPARs are a class of ligand-dependant transcription factors within the nuclear receptor superfamily. The three isoforms \((\text{PPAR}\alpha, \text{PPAR}\gamma \text{ and PPAR}\delta)\) are
encoded by three separate genes, which exhibit overlapping but largely distinct patterns of tissue distribution and function (Chawla et al., 1994, Kliewer et al., 1994). PPARs follow the basic modular structure common to most nuclear receptors (Harmon et al., 2011). Six exons encode four distinct domains which regulate PPAR function (Fournier et al., 2007). Exon 1 encodes the N-terminal activating function (AF)-1 domain which is a ligand-independent modulation domain amenable to post-translational modifications (Fournier et al., 2007). Exons 2 and 3 encode the zinc-finger DNA binding domain of PPARs, which bind to the PPAR response element (PPRE) direct repeat sequence AGGTCAnAGGTCA within promoter regions of PPAR-target genes (Fournier et al., 2007). The hinge region, which is thought to participate in the nuclear translocation signal, is encoded by exon 4 (Fournier et al., 2007). The carboxy-terminal AF-2 domain, encoded by exons 5 and 6, contains the ligand binding domain and co-factor dimerization domains (Fournier et al., 2007). Additionally, the AF-2 domain includes the RXR-heterodimerization interface (Fournier et al., 2007).

In an unliganded state, the PPAR-RXR heterodimer is bound to the PPRE by co-repressors such as the nuclear co-repressor (NCoR) or the silencing mediator of retinoid and thyroid hormone receptor (SMRT), which are part of the histone deacetylase (HDAC) complex. Deacetylated histones keep chromatin tightly wound, thereby repressing gene expression. Consequently, in the absence of ligand, PPARs exert active repression of their target genes (Harmon et al., 2011). However, the binding of ligand induces a PPAR conformational change that results in the dissociation of co-repressor complexes from the PPAR-RXR heterodimer. This conformational change in PPARs results in a so-called “PPAR LxxLL charge clamp” in the AF-2 domain, which stimulates the recruitment of LxxLL-containing co-activator complexes, such as the nuclear co-activator (NCoA) and the steroid receptor co-activator (SRC). NCoA and SRC are part of the histone acetyl transferase (HAT) complex (Harmon et al., 2011), which modifies
chromatin structure thereby allowing for gene transcription to ensue (Fournier et al., 2007). Hence, ligand-dependent activation of PPARs results in active gene transcription.

In addition to active repression and ligand-dependent activation, regulation of PPAR target genes can occur as a result of post-translational modification of the AF-1 domain. One such example is the phosphorylation of the AF-1 domain of PPARγ by cyclin-dependent kinase (CDK) 5 (Choi et al., 2010). Consequently, PPARγ target genes are further actively repressed as a result of stronger association of the receptor with corepressor complexes which exert greater HDAC activity (Choi et al., 2010). Ligand-binding in the AF-2 domain of PPARγ inhibits CDK5-mediated phosphorylation of PPARγ, which is one mechanism by which thiazolidinediones exert their anti-diabetic action (Choi et al., 2010). Additionally, inhibition of CDK5 results in the de-repression of PPARγ target genes as a result of this ligand-independent modification of the AF-1 domain (Choi et al., 2011). Although this discovery has led to the search for novel approaches of modulating PPAR activity by manipulating the co-regulator complexes associated with PPARs, this field is still in its infancy and requires further study.

PPARs most prominently differ in their ligand binding pockets as well as the tissues in which they are expressed. However, these receptors have a large compliment of target genes, which can create difficulties in establishing PPAR-specific effects (Harmon et al., 2011). Nevertheless, PPARα is predominantly expressed in hepatocytes, where activation of this isoform stimulates the catabolism of fatty acids while suppressing inflammatory responses (Mandard et al., 2004). Fibrates are synthetic ligands for PPARα which are currently used as therapeutic agents in the treatment of hypertriglyceridemia. PPARγ is expressed primarily in adipocytes where it functions as an essential regulator of adipose tissue inflammation, fat storage and differentiation (Barak et al., 1999, Rosen et al., 1999, Tontonoz et al., 1994). In addition, PPARγ activation increases expression of adiponectin, an adipokine that enhances insulin
sensitivity (Yamauchi et al., 2001). PPARγ is the target of thiazolidinediones, used clinically in the treatment of type 2 diabetes. In contrast to the more restricted tissue distribution of PPARα and PPARγ, PPARδ is ubiquitously expressed with particularly high abundance in muscle tissue and macrophages (Vosper et al., 2001, Wang et al., 2004). Although PPARδ activation has yet to achieve clinical application, recent advancements have reduced the gap between preclinical studies and clinical use.

1.7.2 PPARδ IN MACROPHAGES

Macrophage exposure to VLDL or VLDL-derived fatty acids readily stimulates foam cell formation (Whitman et al., 1999), the inflammatory response and ER-stress induced apoptosis, independent of lipopolysaccharide (Anderson et al., 2012, Saraswathi and Hasty, 2006). Induction of the inflammatory response was independent of toll-like receptors 4 or 2 (Anderson et al., 2012). Paradoxically, VLDL-derived fatty acids also activate macrophage PPARδ resulting in up-regulation of genes involved in fatty acid catabolism, including CPT1α (Chawla et al., 2003, Lee et al., 2006a). Thus, from an evolutionary standpoint, PPARδ serves as a fatty acid sensor in cells of the vasculature to prevent arterial lipid accumulation under normolipidemic conditions. However, in the context of hypertriglyceridemia, if PPARδ-regulated lipid homeostasis induced by fatty acids were sufficient to clear the incoming atherogenic substrate, atherosclerosis would not ensue. The requirement for potent synthetic agonists of PPARδ to reduce VLDL-induced macrophage lipid deposition has not been examined.

PPARδ also regulates the macrophage inflammatory response, in part, through the repressor protein B-cell lymphoma 6 (BCL-6) (Lee et al., 2003). In the absence of ligand, PPARδ is bound to BCL-6, thereby repressing its function. Consequently, proinflammatory cytokine expression is elevated. Ligand activation induces a conformational change in PPARδ resulting in dissociation of BCL-6 from the PPARδ corepressor complex and subsequent transrepression of proinflammatory mediators
(Figure 1.12). This phenomenon has also been documented in PPARδ knockout cells and cells expressing dominant negative PPARδ, suggesting that defective PPARδ, the absence of PPARδ, or ligand-activation of PPARδ render similar anti-inflammatory effects, due to the lack of BCL-6 sequestration (Figure 1.12) (Barish et al., 2008, Lee et al., 2003, Takata et al., 2008). Thus, in addition to protection from lipid overload, activation of PPARδ by fatty acids also serves to protect macrophages from lipotoxic proinflammatory responses under normolipidemic conditions. However, as discussed in sections 1.2.5 and 1.5.3.2, VLDL and VLDL-derived fatty acids mediate proinflammatory cytokine expression through MAPK activation (Anderson et al., 2012, Saraswathi and Hasty, 2006), and insulin resistant macrophages display enhanced proinflammatory cytokine expression due to dysregulated Akt/forkhead box protein O1 (FoxO1) signaling (Su et al., 2009). The impact of PPARδ activation on VLDL-induced macrophage inflammatory responses remains to be established.

Clinically relevant plaques are prone to rupture and exhibit lipid rich necrotic cores as a result of inflammation and ER-stress-induced apoptosis (Moore and Tabas, 2011). Defective macrophage apoptosis is central to necrotic core formation and is therefore a major component of the progression of complex lesions to clinically relevant lesions (Tabas, 2010). Phagocytosis of apoptotic cells results in the engulfment of large amounts of lipids, including FAs, into the macrophage (Erwig and Henson, 2008), which in turn activates PPARδ expression (Mukundan et al., 2009). Bone marrow derived macrophages (BMDMs) from Pparδ−/− mice displayed significantly reduced phagocytosis of apoptotic cells (Mukundan et al., 2009), concomitant with a significant reduction in the expression of opsonins, molecules that regulate enhanced recognition and phagocytosis of apoptotic cells (Erwig and Henson, 2008, Lauber et al., 2004). In wild-type BMDMs, the PPARδ agonist GW0742 stimulated the expression of opsonins and enhanced clearance of apoptotic cells which was entirely PPARδ-dependent.
**Figure 1.12: Consequences of PPARδ activation and PPARδ deletion:**

**PPARδ Activation** - PPARδ binding sites within promoter regions of its target genes are known as PPAR response elements (PPREs). In an unliganded state, the PPARδ-retinoid X receptor (RXR) obligate heterodimer is bound to corepressor complexes, which inhibits basal transcription of PPARδ target genes. Ligand activation results in a conformational change in the receptor leading to dissociation of the corepressor complexes and subsequent recruitment of coactivator complexes to the PPARδ-RXR heterodimer. As a result, PPARδ-responsive genes are transcriptionally activated. Part of the PPARδ corepressor complex is the BCL-6 protein, which acts as an inflammatory repressor protein in response to ligand activation of PPARδ. The ligand-induced conformational change in PPARδ results in the dissociation of BCL-6 from the PPARδ corepressor complex. Subsequently, BCL-6 corepressor complexes are recruited to promoter regions of inflammatory cytokine genes, leading to the inhibition of proinflammatory mediator expression.

**PPARδ Deletion** – Genetic ablation of PPARδ mimics the liganded state of the receptor, as the presence PPARδ is required for the corepressor complex to maintain basal target gene expression suppressed. Moreover, PPARδ is required for BCL-6 sequestration. Hence, when PPARδ is eliminated, cytokine expression is suppressed by BCL-6, and PPARδ-target genes are derepressed.
(Mukundan et al., 2009). These studies uniquely demonstrate that PPARδ activation in macrophages orchestrates efficient clearance of dying cells by induction of opsonin expression and represents a therapeutically relevant mechanism. Collectively, studies in cultured macrophages suggest that PPARδ activation may serve as a guardian of the vascular insult, and thus impact atherogenesis.

1.7.3 PPARδ ACTIVATION AND THE PROTECTION FROM DIET-INDUCED ATHEROSCLEROSIS

The in vivo role of PPARδ on atherosclerosis has proven elusive, due, in part, to the unique transcriptional regulation of proinflammatory processes (when associated) and anti-inflammatory processes (when dissociated) by the PPARδ:BCL-6 complex. Lee et al. demonstrated that transplantation of Pparδ−/− bone marrow into Ldlr−/− recipient mice resulted in significant atheroprotection (Lee et al., 2003). As discussed above, these studies revealed that deletion of Pparδ mimicked the liganded state of the receptor, and suggested that ligand-activation may be atheroprotective. However, in subsequent studies involving prevention protocols, administration of synthetic PPARδ agonists produced conflicting reports. The first two reports PPARδ activation in vivo utilized the GW0742 compound, and only showed an effect at megadoses at which this ligand is no longer PPARδ-specific (Li et al., 2004) (Graham et al., 2005). A subsequent study showed that lower PPARδ-specific doses of GW0742 reduced lesions and aortic expression of inflammatory cytokines in the angiotensin II–induced mouse model of atherosclerosis (Takata et al., 2008). It is important to note that angiotensin II significantly increases PPARδ expression, resulting in increased BCL-6 sequestration and enhanced inflammation (Takata et al., 2008). The next generation PPARδ agonist, GW1516, at PPARδ-specific doses, prevented atherosclerosis in apoE−/− mice fed a high-fat diet, concomitant with reduced aortic inflammatory cytokine expression (Barish et al.,
However, lesion complexity and morphometry were not examined. Nevertheless, the prevention protocols used to date have not examined the ability of PPARδ activation to attenuate or to induce regression pre-established lesions. Furthermore, insulin resistance within arterial macrophages is known to enhance lesion development. The impact of PPARδ activation on arterial wall insulin sensitivity remains to be determined.

1.7.4 PPARδ ACTIVATION IN HEPATOCYTES

Hyperinsulinemia results in amplified stimulation of mTORC1, which consequently drives the master transcriptional regulator of lipogenesis, sterol regulatory element binding protein (SREBP)-1c (Haas et al., 2012, Horton et al., 2002, Yecies et al., 2011). In turn, SREBP-1c activates the lipogenic transcriptional program, which includes genes such as fatty acid synthase (Fasn), acetyl-CoA carboxylase (Acc) and stearoyl-CoA desaturase (Scd) (Horton et al., 2002). In db/db mice GW1516 treatment increased hepatic expression of Fasn, Acc and Scd2 leading to a modest increase in hepatic triglyceride (Lee et al., 2006b). In Ldlr<sup>−/−</sup> mice, adenoviral PPARδ (adPPARδ) gene delivery stimulated the expression of Fasn, Acc1, Acc2, Srebf1c and Pgc1b, and increased liver triglyceride content (Liu et al., 2011). In contrast, HepG2 cells treated with GW0742 displayed a marked reduction in TG accumulation, due to reduced processing of nuclear SREBP-1, which resulted in attenuated expression of Fasn and Scd1 (Qin et al., 2008). GW0742 increased expression of insulin-induced gene (Insig)-1, an SREBP-1 endoplasmic reticulum (ER) retention protein which contains a PPAR response element within its promoter. These results were reproduced in livers of db/db mice injected with adPPARδ (Qin et al., 2008). The spectrum of results observed in these studies can be explained by different mouse models, diets, selection of drugs used, or gene delivery versus drug strategies of increasing PPARδ activity. However, that PPARδ activation increases hepatic steatosis is counterintuitive, given the overwhelming data demonstrating that PPARδ activation improves whole-body insulin
sensitivity and lipid homeostasis, and stimulates fatty acid oxidation in a variety of cell
types and tissues (Lee et al., 2006b, Tanaka et al., 2003, Wang et al., 2003). Therefore,
additional studies are required to reconcile the ability of PPARδ activation to regulate
resistant hepatic steatosis linked to insulin resistance.

Liver inflammation has been implicated as a major contributor to hepatic insulin
resistance (Gregor and Hotamisligil, 2011, Hummasti and Hotamisligil, 2010). PPARδ
activation in HepG2 cells attenuates interleukin (IL)-6-induced inflammation and insulin
resistance. These effects were mediated via PPARδ inhibition of IL-6-induced signal
transducer and activator of transcription (STAT)-3, resulting in restoration of normal
insulin signaling (Serrano-Marco et al., 2011). Importantly, livers of Pparδ/-/- mice
displayed significantly elevated phospho-STAT-3, suggesting that PPARδ regulates
STAT-3 in vivo, contributing to improved insulin resistance (Serrano-Marco et al., 2011).
Kupffer cell-specific deletion of Pparδ in mice resulted in impaired hepatic Akt
phosphorylation coupled with increased hepatic inflammation (Odegaard et al., 2008).
Together, these studies demonstrate that activation of hepatic PPARδ attenuates
inflammation and contributes to improved hepatic insulin sensitivity. Further
experimentation is required to determine whether selective PPARδ agonists reduce
hepatic inflammation in vivo.

1.7.5 PPARδ AGONISTS IN HUMANS

The available in vitro and in vivo data prompted the examination of selective
PPARδ agonists in human clinical trials for the treatment of metabolic dysregulation,
including dyslipidemia. In healthy volunteers, GW1516 (2.5 mg or 10 mg/day for 2
weeks) reduced plasma TG concentrations, enhanced post-prandial TG clearance and
increased plasma HDL-cholesterol (Sprecher et al., 2007). In moderately obese men,
GW1516 (10 mg/day for 2 weeks) stimulated moderate weight loss, reduced plasma TG,
NEFA, total cholesterol and LDL cholesterol. Hepatic fat content was reduced in the
GW1516-treated cohort. Fasting plasma insulin and fasting blood glucose levels were decreased and insulin sensitivity improved as calculated by the homeostasis model assessment of insulin resistance (HOMA-IR). No adverse effects were observed (Riserus et al., 2008). Recently, a large multi-dose study of GW1516 (2.5, 5.0 and 10 mg/day for 12 weeks) in subjects with low HDL-C revealed significant increases in HDL-C and apo A-I with concomitant reductions in plasma FFA, apoB, VLDL, IDL and large LDL particles, all of which demonstrate a transition toward a less atherogenic lipoprotein profile (Olson et al., 2012). In dyslipidemic men with central obesity, a recent randomized double-blind, crossover trial of 6-week intervention periods with placebo or GW1516 (2.5mg/day), lipoprotein kinetic studies provided mechanistic insight into the anti-dyslipidemic properties of GW1516 (Ooi et al., 2011). Decreased plasma TG, NEFA, apoB-100 and apoB-48 concentrations were observed. GW1516 decreased VLDL apoB concentrations due to an enhanced fractional catabolic rate, which was related to a significantly lower production rate of apo C-III. GW1516 increased plasma HDL-cholesterol, concomitant with increased apo A-II production and reduced CETP activity (Ooi et al., 2011).

Recent back-to-back randomized, double-blind, placebo-controlled, parallel group studies involving a novel PPARδ agonist (MBX-8025) administered as monotherapy or in combination with atorvastatin, examined the ability of PPARδ agonists to improve dyslipidemia in overweight patients (Bays et al., 2011, Choi et al., 2012). In the first study, MBX-8025 alone or in combination with atorvastatin significantly reduced plasma concentrations of apoB100 and LDL-cholesterol. However, the combination did not significantly reduce either of these parameters beyond that of atorvastatin alone. In contrast to atorvastatin monotherapy, MBX-8025 alone or in combination with atorvastatin significantly reduced plasma TGs and NEFAs, and increased HDL-C (Bays et al., 2011). In addition, MBX-8025 reduced HOMA-IR, the
number of patients meeting diagnostic criteria for the metabolic syndrome, VLDL particle number, the preponderance of small and very small LDL particles and increased LDL peak diameter (Bays et al., 2011, Choi et al., 2012). MBX-8025 was well tolerated, with no major adverse effects (Bays et al., 2011, Choi et al., 2012). Collectively, these human trials demonstrate that PPARδ agonists exert favourable effects on CVD risk factors that are not improved by statin monotherapy. Whether PPARδ agonists reduce the residual CVD risk beyond statin treatment requires longer-term outcome and safety studies.

1.8 MODELS TO BE USED

1.8.1 CELL CULTURE

THP-1 cells are a monocytic cell line initially derived from the blood of a one-year-old boy with acute monocytic leukemia (Tsuchiya et al., 1980). Treatment of THP-1 monocytes with phorbol esters such as phorbol 12,13-dibutyrate, results in their differentiation into macrophage-like cells, which exhibit many characteristics of native, mature macrophages (Auwerx, 1991). Although the extent to which differentiated THP-1 cells mimic vascular wall macrophages is not fully understood, these cells have been used extensively as a model to gain insight into macrophage foam cell formation and function (Qin, 2012). Treatment of THP-1 cells with a phorbol ester results in the upregulation of scavenger receptors (Johnson et al., 2003), which makes THP-1 macrophages a reasonable model to recapitulate macrophage behavior during atherogenesis. One caveat to these cells is that phorbol ester treatment results in the downregulation of LDLR expression (Johnson et al., 2003), which results in reduced uptake of native LDL compared to modified LDL. However, high doses of LDL (100-200μg/mL) will stimulate CE uptake and foam cell formation (Banka et al., 1991), which still makes THP-1 macrophages a fundamentally good model to study foam cell formation in response to native LDL in the context of hypercholesterolemia. In the context of hypertriglyceridemia, THP-1 macrophages synthesize and secrete LPL (Qin,
2012), and can therefore readily take up VLDL-derived fatty acids resulting in foam cell formation. These cells were used extensively for the studies described in Chapters 2 and 3.

1.8.2 Ldlr⁻/⁻ MICE

Deletion of the Ldlr in C57Bl/6J disrupts normal murine lipoprotein metabolism, resulting in elevated plasma cholesterol, particularly in the LDL fraction as a result of defective LDL clearance (Ishibashi et al., 1993). Furthermore, these animals develop increased cholesterol in both VLDL and IDL when fed a high-fat diet (Getz and Reardon, 2006). Ldlr⁻/⁻ mice fed a high-fat, cholesterol containing (HFHC) diet for 12 weeks recapitulate many features of the metabolic syndrome such as dyslipidemia, hyperinsulinemia, insulin resistance and hepatic steatosis (Assini et al., 2013). Furthermore, these animals develop atherosclerotic lesions that are relatively advanced, exhibiting significant lipid accumulation, increased macrophage and smooth muscle cell infiltration and enhanced collagen deposition (Assini et al., 2013). Ldlr⁻/⁻ mice were extensively used for the studies described in Chapters 4 and 5.

1.8.3 ANIMAL DIETS

1.8.3.1 CHOW DIET

Laboratory chow was used as a control diet which provided a reference for metabolic indices altered by feeding the HFHC diet. The chow diet contains complex carbohydrates and 14% calories as fat (4% by weight). The caloric value of the chow diet is 3.0 kcal/g (Table 1-2). The chow diet was fed ad libitum to mice in studies described in Chapters 4 and 5.
TABLE 1-2 Animal Diets

<table>
<thead>
<tr>
<th>Formula</th>
<th>Traditional Chow Diet (TD 8604)</th>
<th>High-fat, high cholesterol (HFHC) diet (TD09268)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>195 g/kg</td>
<td></td>
</tr>
<tr>
<td>DI-Methionine</td>
<td>*See represented ingredients, exact amounts not specified</td>
<td>3 g/kg</td>
</tr>
<tr>
<td>Sucrose</td>
<td>341.46 g/kg</td>
<td></td>
</tr>
<tr>
<td>Corn starch</td>
<td>150.75 g/kg</td>
<td></td>
</tr>
<tr>
<td>Corn Oil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anhydrous Milkfat</td>
<td>160 g/kg</td>
<td></td>
</tr>
<tr>
<td>Lard, (Pork)</td>
<td>50 g/kg</td>
<td></td>
</tr>
<tr>
<td>Cellulose</td>
<td>35.13 g/kg</td>
<td></td>
</tr>
<tr>
<td>Mineral Mix</td>
<td>50 g/kg</td>
<td></td>
</tr>
<tr>
<td>Zinc Carbonate</td>
<td>0.04 g/kg</td>
<td></td>
</tr>
<tr>
<td>Vitamin Mix</td>
<td>10 g/kg</td>
<td></td>
</tr>
<tr>
<td>Choline Bitartrate</td>
<td>3 g/kg</td>
<td></td>
</tr>
<tr>
<td>Ethoxyquin</td>
<td>0.02 g/kg</td>
<td></td>
</tr>
</tbody>
</table>

Macronutrients

<table>
<thead>
<tr>
<th>% by weight (% of calories)</th>
<th>Traditional Chow Diet (TD 8604)</th>
<th>High-fat, high cholesterol (HFHC) diet (TD09268)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein</td>
<td>24.3 (32)</td>
<td>17.3 (15.2)</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>40.2 (54)</td>
<td>48.7 (42.8)</td>
</tr>
<tr>
<td>Fat</td>
<td>4.7 (14)</td>
<td>21.2 (42)</td>
</tr>
<tr>
<td>Kcal/g</td>
<td>3.0</td>
<td>4.5</td>
</tr>
<tr>
<td>Cholesterol (wt%)</td>
<td>0.005%</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

*Represented Ingredients: Dehulled soybean meal, wheat middlings, flaked corn, ground corn, fish meal, soybean oil, brewers dried yeast, cane molasses, dried whey, dicalcium phosphate, calcium carbonate, iodized salt, choline, chloride, magnesium oxide, Vitamin A acetate, Vitamin D3, Vitamin E, niacin, pyridoxine hydrochloride, menadione, sodium bisulfite, Vitamin B 12, manganous oxide, ferrous sulfate copper sulfate, zinc oxide, calcium iodate cobalt carbonate, chromium, potassium sulfate, kaolin
1.8.3.2 WESTERN DIET WITH ADDED CHOLESTEROL (HFHC DIET)

The western diet commonly used to induce metabolic abnormalities and atherosclerosis is composed of 42% calories as fat (21.2% by weight). Of the total fat, saturated fatty acids comprise 58% by weight, monounsaturated fatty acids 36% and polyunsaturated fatty acids 5%. This diet contains 0.05% cholesterol (by weight), derived from milkfat and lard (Harlan Teklad, TD96125). The addition of 0.15% cholesterol (for a total of 0.2%) modifies the western diet to the HFHC diet (Harlan Teklad, TD09268). Diets with the same or similar amounts of dietary cholesterol are known to increase macrophage inflammation and exacerbate the development of dyslipidemia, insulin resistance, hepatic steatosis and atherosclerosis (Subramanian et al., 2011, Subramanian et al., 2008). The carbohydrate component is 42.8% of calories (48.7% by weight) and is derived from sucrose, while the protein source is casein (15.2% of calories, 17.3% by weight). This diet does not contain any cholate. The caloric value of the HFHC diet is 4.5 kcal/g (Table 1-2). The HFHC diet was fed ad libitum to mice in studies described in Chapters 4 and 5.

1.9 SCOPE OF THESIS AND HYPOTHESES

Dyslipidemia and insulin resistance are major risk factors for the development of premature atherosclerosis. Specifically, elevated plasma TG-rich VLDL can readily induce macrophage foam cell formation, and insulin resistance is becoming increasingly accepted to accelerate foam cell formation. Therapeutic strategies that improve insulin sensitivity, the atherogenic lipid profile of the insulin resistant state and have direct effects on cells of the vessel wall to reduce macrophage foam cell formation and atherosclerosis, remain sparse. Therefore, identification and characterization of the novel therapeutic strategies that correct the metabolic consequences of insulin resistance are becoming increasingly important.
The studies in this thesis were undertaken to understand the physiological and molecular mechanisms involved in the attenuation of macrophage foam cell formation, the inflammatory response, atherosclerosis and metabolic dysregulation by activation of PPARδ. We first examine the ability of synthetic PPARδ ligands (GW0742 and GW501516) to specifically activate PPARδ and attenuate VLDL-induced macrophage foam cell formation. We investigated both the lipid lowering and anti-inflammatory capabilities of PPARδ-specific activation in this setting, and determined the mechanism by which the GW compounds lower macrophage TG accumulation and prevent VLDL-induced proinflammatory cytokine expression. We next examined the ability of these compounds to attenuate CE-rich lipoprotein-induced foam cell formation. To determine if our in vitro results translated in vivo, we subsequently determined whether intervention to a high-fat high-cholesterol diet with GW501516 was able to either prevent progression, or induce regression of pre-established atherosclerotic lesions. Additionally, we studied whether GW501516 was capable of correcting pre-established metabolic dysregulation, including hepatic steatosis, and sought to define the mechanisms involved. Therefore, Chapters 2 to 5 of this thesis address the following hypotheses:

1. PPARδ-specific activation in macrophages attenuates TG accumulation and the inflammatory response, induced by VLDL (Chapter 2).

2. PPARδ-specific activation in macrophages attenuates CE accumulation and the inflammatory response, induced by native and modified forms of LDL (Chapter 3).

3. PPARδ-specific activation in vivo attenuates progression of diet-induced atherosclerosis, aortic inflammation and aortic insulin resistance in Ldlr^{-/} mice (Chapter 4).
4. Hepatic PPARδ-specific activation attenuates steatosis via increased fatty acid oxidation, reduced *de novo* lipogenesis and improves insulin sensitivity in *Ldlr*−/− mice (Chapter 5).
1.10 REFERENCES


Qin, Z. (2012). The Use of Thp-1 Cells as a Model for Mimicking the Function and Regulation of Monocytes and Macrophages in the Vasculature. Atherosclerosis 221, 2-11.


Rong, J.X., Blachford, C., Feig, J.E., Bander, I., Mayne, J., Kusunoki, J., Miller, C.,
Davis, M., Wilson, M., Dehn, S., et al. (2013). Acat Inhibition Reduces the Progression of
Preexisting, Advanced Atherosclerotic Mouse Lesions without Plaque or Systemic
Toxicity. Arterioscler Thromb Vasc Biol 33, 4-12.

Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman,
Adipose Tissue in Vivo and in Vitro. Mol Cell 4, 611-617.

(2011). Transcriptome-Wide Sequencing Reveals Numerous Apobec1 Mrna-Editing

Investigating the Mechanism for Amp Activation of the Amp-Activated Protein Kinase

Saraswathi, V., and Hasty, A.H. (2006). The Role of Lipolysis in Mediating the
Proinflammatory Effects of Very Low Density Lipoproteins in Mouse Peritoneal

Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J.,

Seimon, T.A., Wang, Y., Han, S., Senokuchi, T., Schrijvers, D.M., Kuriakose, G., Tall,
Apoptosis and Plaque Necrosis in Advanced Atherosclerotic Lesions in Mice. J Clin
Invest 119, 886-898.

Senokuchi, T., Liang, C.P., Seimon, T.A., Han, S., Matsumoto, M., Banks, A.S., Paik,
(Foxos) Promote Apoptosis of Insulin-Resistant Macrophages During Cholesterol-
Induced Endoplasmic Reticulum Stress. Diabetes 57, 2967-2976.

Serrano-Marko, L., Barroso, E., El Kochairi, I., Palomer, X., Michalik, L., Wahl, W., and
Beta/Delta Agonist Gw501516 Inhibits Il-6-Induced Signal Transducer and Activator of
Transcription 3 (Stat3) Activation and Insulin Resistance in Human Liver Cells. Diabetologia
55, 743-751.

Shah, P.K., Yano, J., Reyes, O., Chyu, K.Y., Kaul, S., Bisgaier, C.L., Drake, S., and
Cercek, B. (2001). High-Dose Recombinant Apolipoprotein a-I(Milano) Mobilizes Tissue
Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in
Apolipoprotein E-Deficient Mice. Potential Implications for Acute Plaque Stabilization.
Circulation 103, 3047-3050.


Chapter 2*

Activation of PPARδ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein

2.1 INTRODUCTION

Excessive lipid accumulation within macrophages of the arterial intima drives the synthesis and secretion of proinflammatory mediators, potentiating atherogenesis (Hansson, 2005). Canonically, elevated plasma low density lipoprotein (LDL) is considered a major lipoprotein contributing to accelerated atherogenesis. However, epidemiological evidence strongly suggests that hypertriglyceridemia also increases the risk of premature atherosclerosis, especially in the context of metabolic syndrome and type 2 diabetes (Nordestgaard et al., 2007, Reaven, 2005). Plasma triacylglycerol (TG)-carrying very low density lipoprotein (VLDL) has been localized within atherosclerotic lesions from human patients and animal models (Proctor and Mamo, 1998, Rapp et al., 1994), providing rationale for examining the mechanisms by which these lipoproteins induce the development of macrophage foam cells. VLDL readily induces macrophage lipid accumulation (Evans et al., 1993, Whitman et al., 1999, Whitman et al., 1998), which in turn stimulates the synthesis of cytokines such as IL-1β and MIP-1α (Saraswathi and Hasty, 2006, Stollenwerk et al., 2005a, Stollenwerk et al., 2005b). The mechanisms regulating these lipid-induced macrophage inflammatory responses have not been fully characterized.

In mouse macrophages, VLDL-induced expression of Mip-1α requires fatty acid liberation by lipoprotein lipase (LPL) and is dependent on the activation of ERK1/2 (Saraswathi and Hasty, 2006). Furthermore, VLDL potentiates LPS-stimulated macrophage IL-1β secretion via activation of the transcription factor AP-1 (Stollenwerk et

*a version of this chapter is published Bojic et al. (2012) ATVB 32(12), 2919-28.
al., 2005a). which is known to be regulated by MAP kinases ERK1/2 and p38 (Eferl and Wagner, 2003). The involvement of p38, which is thought to act cooperatively with ERK1/2 in AP-1 associated inflammatory responses (Eferl and Wagner, 2003), has not been established (Saraswathi and Hasty, 2006). In addition, macrophage insulin resistance may potentiate the inflammatory response. Macrophage-specific deletion of the insulin receptor in Ldlr/- mice significantly increased atherosclerosis (Han et al., 2006), an effect attributed to impaired macrophage Akt/FoxO1 signaling (Han et al., 2006). Insulin-resistant macrophages with cholesterol-induced ER-stress display impaired Akt phosphorylation, increased nuclear FoxO1 activity and enhanced apoptosis (Senokuchi et al., 2008). Furthermore, IL-1β is a FoxO1 target gene in macrophages with insulin resistance (Su et al., 2009). Collectively, these studies highlight the importance of examining the role of AKT/FoxO1 signaling in the VLDL-induced inflammatory response.

The peroxisome proliferator-activated receptors (PPARs) are important regulators of metabolic and inflammatory signaling (Lee et al., 2003b). The three known isoforms, namely PPARα, PPARγ and PPARδ, each exhibit distinct tissue distribution and PPAR-specific regulation of gene transcription (Lee et al., 2003b). In contrast to PPARα and PPARγ, expression of PPARδ is ubiquitous, with high levels in macrophages (Vosper et al., 2001), where its biological role is unclear. Macrophage PPARδ is activated by VLDL-derived fatty acids (Chawla et al., 2003, Lee et al., 2006), and conflicting reports have demonstrated that synthetic ligands promote either lipid accumulation (Vosper et al., 2001), or fatty acid catabolism (Chawla et al., 2003, Lee et al., 2006). Consequently, the net effect of PPARδ activation on VLDL-induced TG accumulation is unknown. The anti-inflammatory properties of PPARδ activation have been linked to the liberation of BCL-6 from unliganded PPARδ (Lee et al., 2003a), which inhibits expression of AP-1-inducible cytokines by localizing to AP-1 response elements and recruiting co-repressors to these promoter regions (Vasanwala et al., 2002).
Additionally, in adipocytes and cardiomyocytes, PPARδ agonists inhibit LPS-induced NFκB regulated cytokine expression (Ding et al., 2006, Rodriguez-Calvo et al., 2008). The mechanism(s) underlying VLDL-induced cytokine expression in macrophages, in the absence of LPS, and the impact of PPARδ activation have not been elucidated.

In the present study, we report that synthetic ligand activation of PPARδ attenuates VLDL-stimulated TG accumulation by activating a transcriptional program resulting in attenuation of LPL activity, increased fatty acid uptake and enhanced β-oxidation. VLDL stimulates the expression of proinflammatory cytokines IL-1β, MIP-1α, and ICAM-1 via both ERK1/2- and AKT/FoxO1-dependent signaling mechanisms. Furthermore, macrophage treatment with synthetic PPARδ ligands inhibits proinflammatory cytokine expression, by inhibiting VLDL-stimulated ERK1/2 activation and reversing VLDL-mediated inhibition of AKT/FoxO1 phosphorylation.

2.2 MATERIALS AND METHODS

2.2.1 LIPOPROTEINS

Subjects were recruited from the Lipid Clinic at the London Health Sciences Center University Campus (London, Ontario, Canada). The University of Western Ontario Health Science Standing Committee on Human Research approved the studies (IRB reference #15685). VLDL (Sf 20 to 400) was isolated from plasma of type IV hyperlipoproteinemic patients by differential ultracentrifugation using a Beckman 70.1 Ti rotor (16hr, 40,000 rpm, 12°C) as previously described (Whitman et al., 1998).

2.2.2 CELL CULTURE

The human THP-1 macrophage-like cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA). For experiments, cells were cultured at 4.0x10^6 cells/35-mm plate (Falcon Scientific, BD Biosciences) in RPMI 1640 supplemented with 10% fetal bovine serum (Sigma), β-mercaptopethanol (5x10^-5 mol/L), 100 units/mL penicillin, and 100 µg/ml streptomycin and differentiated with 300 nmol/L
phorbol 12,13-dibutyrate (PDB, Sigma) for 1 week prior to use in experiments as described (Argmann et al., 2005, Beyea et al., 2007). PPARδ agonists GW0742 (Sigma) and GW501516 (Alexis Biochemicals, Plymouth, PA) were dissolved in dimethyl sulfoxide (DMSO, Sigma) and incubated with cells at the indicated concentrations. THP-1 macrophages were preincubated (24 hr) in the presence or absence of PPARδ agonists. Subsequently, cells were incubated with PPARδ agonists in the presence or absence of lipoproteins or various inhibitors as indicated. HepG2 cells were obtained from ATCC and grown as described previously (Evans et al., 1992). For experiments, HepG2 cells were plated in either 100-mm or six-well (35-mm) culture plates (Falcon, Mississauga, ON) and maintained in minimal essential medium (MEM) containing 10% fetal bovine serum (FBS), but switched to MEM containing 5% human lipoprotein-deficient serum (LPDS) for experimental incubations.

2.2.3 LUCIFERASE REPORTER ASSAYS

Luciferase reporter assays were performed as previously described (Mulvihill et al.). Briefly, HepG2 cells were transfected with 0.01µg/mL human PPARα,γ or δ.SG5 expression vectors and reporter gene plasmids, 0.5µg/mL of pTK-PPRE(x3)-Luc and 0.05µg/mL of the TK promoter-Renilla luciferase construct, (tk.pRL) (provided by Dr. John Capone, McMaster University, Hamilton ON). Cells were incubated for 24 hr with DMSO or the appropriate PPAR agonists: PPARα (10nmol/L, GW7647, Sigma); PPARγ (3µmol/L, rosiglitazone, Alexis Biochemicals, Cedarlane Laboratories, Burlington, ON), or PPARδ (GW0742 and GW501516) at a range of concentrations. Cell lysates were prepared and the Luciferase activity (relative light units (RLU)) was measured and normalized to Renilla activity, as previously described (Allister et al., 2005, Argmann et al., 2005).
2.2.4 CELLULAR LIPID MASS

THP-1 macrophages were preincubated in the presence of PPARδ agonists or equal volume of DMSO (not to exceed 0.5% of total medium) for 24 hr in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 300nmol/L PDB. Cells were incubated for a further 16 hr with fresh media containing 5% LPDS and compounds in the absence or presence of HTG-VLDL (50 μg of lipoprotein total cholesterol (TC)/mL medium). Cellular CE, TC, FC, TG, FFA (NEFA) and protein mass were determined using enzymatic colorimetric assays for NEFA, TC and FC (Wako Diagnostics, Richmond, VA) as well as TG (Boehringer Mannheim, Laval, QC) as previously described (Rowe et al., 2003). Cellular CE was determined as the difference between TC and FC (Rowe et al., 2003). Cells were lysed in 1mL of 0.1N NaOH, and aliquots were used to determine protein concentrations (Beyea et al., 2012).

2.2.5 ENZYME-LINKED IMMUNOSORBENT ASSAY

THP-1 macrophages were preincubated in the presence of PPARδ agonists or equal volume of DMSO (not to exceed 0.5% of total medium) for 24 hr in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 300nmol/L PDB. Cells were incubated for a further 16 hr with fresh media containing 5% LPDS and compounds in the absence or presence of hypertriglyceridemic (HTG)-VLDL (50 μg of lipoprotein total cholesterol (TC)/mL medium). Media was collected and analyzed for IL-1β secretion via enzyme-linked immunosorbent assay (ELISA) using the BD OptEIA human IL-1β ELISA kit II (BD Biosciences, Mississauga, ON) as per manufacturer’s protocol.

2.2.6 QUANTITATIVE REAL-TIME PCR GENE ABUNDANCE ANALYSIS

THP-1 cells were incubated for 24 hr in RPMI 1640 with 5% LPDS, 300nmol/L PDB, in the presence or absence of PPARδ agonists, and subsequently total RNA was isolated using TriZol reagent (Invitrogen, Burlington, ON) according to manufacturer’s instructions. In experiments examining VLDL-induced inflammatory cytokine expression,
cells were preincubated for 24 hr in RPMI 1640 with 10% FBS, 300nmol/L PDB, in the presence or absence of PPARδ agonists. Cells were then incubated with fresh 5%-LPDS media and compounds with or without the CPT-1α inhibitor etomoxir (Sigma, 50μmol/L for 0.5 hr, followed by a further 16 hr in the absence or presence of HTG-VLDL (50μg-TC/mL) prior to TriZol RNA extraction. Abundance of total RNA (2μg) was reverse transcribed using the Applied Biosystems High Capacity cDNA reverse transcription kit according to the manufacturer’s protocol. Subsequently, cDNA (10ng) was analyzed in triplicate by quantitative real time RT-PCR (qRT-PCR) on an ABI Prism (model 7900HT) Sequence Detection System (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions and as previously described (Beyea et al., 2007). Primer-probe sets for each gene were obtained from Applied Biosystems (Carlsbad, CA). Abundance of target genes was normalized to GAPDH abundance.

2.2.7 LPL ACTIVITY, TG SYNTHESIS, FA β-oxidation, AND FA UPTAKE

LPL activity of THP-1 cells (cell surface and medium) was determined following a 24 hr incubation in RPMI 1640 with 5% human LPDS and 300nmol/L PDB in the presence or absence of selected concentrations of PPARδ agonists, as the release of free fatty acids from intralipid (an exogenous lipid source) as previously described (Whitman et al., 1999). The synthesis of triacylglycerol was measured in THP-1 cells following a preincubation in 5% LPDS-containing medium for 19 hr in the presence or absence of selected concentrations of PPARδ agonists. For a subsequent 5 hr incubation, 0.08nCi/mL [1-14C]oleic acid (Amersham Biosciences) complexed with fatty acid-free bovine serum albumin in a molar ratio of 5.36:1 (Sigma) was added as described previously (Evans et al., 1993). Cellular lipid extracts were separated by thin layer chromatography (Evans et al., 1993). Fatty acid β-oxidation experiments were performed as described previously (Mulvihill et al.). Briefly, THP-1 cells were preincubated in the presence or absence of PPARδ agonists in 10% FBS-containing
medium for 24 hr, followed by the addition of 2.0µCi/mL [³H]-palmitate in 100µmol/L palmitate per well for 0.5 hr. The media was removed and 10% trichloroacetic acid was added. Unreacted FAs were extracted from the supernatant with n-hexane and the remaining counts determined by scintillation counting. Data was determined as nmol palmitate oxidized/min/mg cell protein and was corrected for differences in fatty acid uptake in the presence of PPARδ agonists. Fatty acid uptake experiments were performed as described (Lee et al., 2006). Briefly, THP-1 cells were preincubated in the presence or absence of PPARδ agonists in 5% LPDS-containing medium for 24 hr, followed by the addition of either [1-¹⁴C]oleic acid or [³H]-palmitate (both prepared as described above) for 1min. Ice cold stop solution (200µmol/L phloretin in phosphate buffered saline) was added directly to the culture medium. Cells were washed five times with ice cold stop solution. Cells were lysed in 1mL of 0.1N NaOH, and aliquots were used to determine protein concentrations and the amount of unprocessed radiolabelled fatty acid.

2.2.8 IMMUNOBLOT ANALYSIS AND DENSITOMETRY

Total cell lysates were fractionated into cytosolic and nuclear fractions as previously described (Azzout-Marniche et al., 2000). Proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted as described previously (Rowe et al., 2003). Cellular cytosolic fractions were probed using antibodies against human phospho (p)-FoxO1, pERK1/2, p-p38, pAKT, FoxO1, ERK1/2, p38, AKT, β-actin (Cell Signaling, Danvers, MA) and nuclear fractions were probed using antibodies against human total-FoxO1 and Lamin A/C (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Quantification analysis of the developed films was performed using an imaging densitometer (Bio-Rad Quantity One Software). Phospho-proteins from cytosolic fractions were normalized to their respective total proteins or β-Actin, whereas nuclear fractions were normalized to lamin A/C. Additionally, cytosolic and nuclear
fractions were immunoblotted for Lamin A/C and β-Actin, respectively, in order to demonstrate complete separation of these fractions.

2.2.9 STATISTICAL ANALYSIS

Data are expressed as means ± standard error of the mean (SEM). The Shapiro-Wilk normality test was used to test for parametric distributions in each data set. P values for observed differences between treatment and control groups were calculated by one-way ANOVA followed by Bonferroni post hoc test or paired student’s t-test where indicated. P values for observed pair-wise comparisons were calculated by one-way ANOVA followed by Tukey’s post hoc test. Significance thresholds were P values less than 0.05. Statistical analyses were performed with SigmaPlot 11.0 software (Systat, Inc, San Jose, CA).

2.3 RESULTS

2.3.1 PPARδ-SPECIFIC ACTIVATION ATTENUATES VLDL-INDUCED MACROPHAGE TRIACYLGLYCEROL ACCUMULATION

THP-1 cells treated with VLDL demonstrated a dose-dependent increase in TG mass achieving a marked 5-fold increase with VLDL at 50 µg/mL (Figure 2.1A-B). Pre-treatment with PPARδ agonists for 24 hours modestly but significantly reduced VLDL-induced TG mass by 25-30% (Figure 2.1A-B). VLDL significantly induced intracellular FFA mass, which was unchanged by pre-treatment with PPARδ agonists (Figure 2.1C). Cellular cholesteryl ester or free cholesterol concentrations were unaffected by VLDL or PPARδ agonists (Figure 2.1D), indicating that whole particle VLDL uptake was modest. A known PPARδ-specific target gene, adipocyte differentiation-related protein (ADRP) (Chawla et al., 2003), was significantly increased by both agonists (Figure 2.1E), indicating PPARδ activation.

High doses of PPAR agonists can activate PPAR isoforms non-selectively (Berger et al., 1999, Willson et al., 2000). Therefore, we determined the PPARδ-
Figure 2.1 PPARδ-specific activation attenuates VLDL-induced triacylglycerol mass accumulation.

THP-1 cells were pre-incubated with PPARδ agonists GW0742 and GW501516 for 24hr, followed by a 16hr incubation with or without VLDL (50μg-TC/mL). A,B TG mass (n=5-7). C, Free fatty acid (FFA) mass (n=3-4). D, Cholesteryl ester (CE) and free cholesterol (FC) mass (n=6). E, ADRP mRNA in THP-1 cells following preincubation with PPARδ agonists for 24hr, and following a 16hr incubation, with or without VLDL (n=4). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05). * indicates significant difference versus DMSO control; ANOVA with post hoc Bonferroni’s test (P<0.05).
specificity of the concentrations of agonists employed. PPARδ-deletion results in derepression of PPARδ target genes (Lee et al., 2006), and transrepression of inflammatory cytokine expression, creating an experimental confounder for the present studies (Lee et al., 2003a). We therefore assessed agonist-specificity by co-transfecting HepG2 cells with luciferase reporter constructs driven by PPAR response elements and each PPAR isoform (α, γ, δ). We determined dose-responses for each receptor in cells treated with PPARδ agonists (GW0742 and GW501516), and used agonists for PPARα (GW7647) and PPARγ (rosiglitazone) as positive controls. GW0742 at 25nmol/L and GW501516 at 100nmol/L were concentrations at which these ligands maximally activated PPARδ, without activation of either PPARα or PPARγ (Figure 2.2A-D). Furthermore, canonical PPARα and PPARγ target genes (ACOX and FABP4, respectively) were unaffected by either 25nmol/L GW0742 or 100nmol/L GW501516 (Figure 2.2E-F). Although unlikely, these agonists may have effects on non-PPAR targets. However, with respect to PPARs, these data demonstrate selectivity of the agonist concentrations used for PPARδ.

2.3.2 PPARδ AGONISTS REGULATE LPL ACTIVITY, FATTY ACID UPTAKE AND FATTY ACID β-OXIDATION

We examined whether PPARδ activation attenuated VLDL-induced TG mass by regulating lipoprotein hydrolysis, fatty acid uptake or fatty acid esterification. In contrast to rosiglitazone, LPL mRNA was unchanged in response to PPARδ agonists, further demonstrating PPARδ-specificity (Figure 2.3A and Figure 2.2G). The PPARδ-target gene, angiopoietin-like 4 (ANGPTL4) encodes a protein known to potently inhibit LPL activity (Sukonina et al., 2006). ANGPTL4 mRNA expression was markedly enhanced by both PPARδ agonists in the presence or absence of VLDL, which was associated with a 50% inhibition of LPL activity (Figure 2.3B,C). The PPARδ ligands significantly increased
Figure 2.2 GW0742 and GW501516 are PPARδ-specific agonists.

Human hepatoma (HepG2) cells were co-transfected with plasmids encoding a PPRE-luciferase construct, a Renilla luciferase construct (transfection control) and vectors encoding each individual PPAR isoform as indicated. Cells were incubated with (A) PPARα agonist GW7647, (B) PPARγ agonist rosiglitazone or PPARδ agonists (C) GW0742 or (D) GW501516 for 24hr. Cell lysates were isolated and luciferase relative light units (RLU) were measured (n=2-4). In separate experiments, THP-1 cells were incubated with PPAR agonists for 24hr. Total RNA was isolated and (E) ACOX, (F) FABP4 and (G) LPL mRNA abundance was measured by qRT-PCR (n=3-6). Data is presented as mean +/- SEM. * indicates significant difference versus DMSO control; ANOVA with post hoc Bonferroni test (P<0.05).
Figure 2.3 PPARδ activation regulates triglyceride metabolism.

A, LPL mRNA in THP-1 cells following preincubation with PPARδ agonists for 24hr. mRNA abundance of (B) ANGPTL4, (D) CD36 and (G) CPT-1α in THP-1 cells following preincubation with PPARδ agonists for 24hr, and following a 16hr incubation, with or without VLDL (n=4). C, LPL activity (n=4). Cell surface-bound LPL activity = Total activity (heparin) minus secreted activity (without heparin). E,F Fatty acid uptake (n=3). H, β-oxidation (n=3). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05). *indicates significant difference versus DMSO control. In C, # indicates significant difference versus cell bound DMSO control; ANOVA with post hoc Bonferroni’s test (P<0.05).
expression of the PPAR-target gene CD36 (Welch et al., 2003) irrespective of lipid load, which was correlated with a 25% increase in palmitate uptake, but not oleate uptake (Figure 2.3D-F). DGAT1 mRNA, DGAT2 mRNA, and TG synthesis were unaffected by PPARδ activation (Figure 2.4). PPARδ ligands significantly upregulated CPT-1α mRNA, with or without VLDL, which was associated with a 40% increase in fatty acid oxidation (Figure 2.3G,H). Collectively, these results indicate that although PPARδ activation modestly increases palmitate uptake, the attenuation of LPL-mediated VLDL TG-hydrolysis and the enhancement of fatty acid β-oxidation results in a net reduction of macrophage triglyceride content.

2.3.3 PPARδ AGONISTS INHIBIT VLDL- AND FREE FATTY ACID-INDUCED CYTOKINE EXPRESSION

Exposure of mouse macrophages to VLDL stimulates Mip-1α expression, an AP-1 mediated inflammatory response (Saraswathi and Hasty, 2006). Here, human VLDL significantly induced macrophage expression of IL-1β, MIP-1α, and ICAM-1 mRNA. Pretreatment with PPARδ ligands significantly inhibited the VLDL-induced expression of all three cytokines (Figure 2.5A-C), without affecting basal cytokine expression (Figure 2.6). Furthermore, media levels of VLDL-induced IL-1β were significantly decreased by both PPARδ agonists (Figure 2.7A). Canonical NFκB-target genes TNFα and IL-6 were unaffected by VLDL treatment (Figure 2.7B). Moreover, parthenolide, an inhibitor of NFκB signaling, had no effect on VLDL-stimulated expression of IL-1β, MIP-1α and ICAM-1, however parthenolide completely inhibited cytokine stimulation by LPS, a known NFκB activator (Figure 2.7C). Collectively, these data suggest that VLDL-induced macrophage inflammatory responses do not require NFκB activation.
Figure 2.4 Effect of PPARδ activation on FFA re-esterification mechanisms.

THP-1 cells were incubated with PPARδ-specific agonists for 24hr. Total RNA was isolated and (A) *DGAT1* and (B) *DGAT2* mRNA was measured by qRT-PCR (n=4). C, Following a 19hr incubation with PPARδ agonists at indicated concentrations, THP-1 cells were incubated for a further 5hr with PPARδ agonists and 1-[\textsuperscript{14}C]oleic acid to measure oleate incorporation into cellular triacylglycerol (n=3). Data is presented as mean +/- SEM.
A  

$DGAT1$  

\begin{align*}
\text{DMSO} & \quad 1 & \quad 25 & \quad 1 & \quad 100 \\
\text{GW0742} \quad \text{(nmol/L)} & \quad \text{GW501516} \quad \text{(nmol/L)}
\end{align*}

B  

$DGAT2$  

\begin{align*}
\text{DMSO} & \quad 1 & \quad 25 & \quad 1 & \quad 100 \\
\text{GW0742} \quad \text{(nmol/L)} & \quad \text{GW501516} \quad \text{(nmol/L)}
\end{align*}

C  

TG Synthesis  

\begin{align*}
\text{DMSO} & \quad \text{GW0742} \quad \text{(25nmol/L)} & \quad \text{GW501516} \quad \text{(100nmol/L)}
\end{align*}
Figure 2.5 PPARδ agonists attenuate VLDL-stimulated expression of AP-1 associated inflammatory cytokines.

THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 16hr incubation with or without VLDL. mRNA abundance for (A) IL-1β, (B) MIP-1α and (C) ICAM-1 was measured (n=4). D, THP-1 cells were incubated with PPARδ agonists for 24hr, followed by an incubation with Etomoxir (ETO 50μmol/L) for 0.5hr and a subsequent incubation with or without VLDL for 16hr. mRNA for IL-1β, MIP-1α and ICAM-1 mRNA was measured (n=3). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey's test (P<0.05).
Figure 2.6 PPARδ activation does not affect basal cytokine expression in THP-1 human macrophages

THP-1 cells were incubated with PPARδ-specific agonists at the indicated concentrations for 24hr. Total RNA was isolated and *IL-1β*, *MIP-1α* and *ICAM-1* mRNA was measured by qRT-PCR (n=4). Data is presented as mean +/- SEM (n=4).
Figure 2.7 The effect of PPARδ agonists on media IL-1β protein; the effect of VLDL on TNFα or IL-6 expression and the VLDL-induced inflammatory response in the presence of an inhibitor of NFκB. THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 16hr incubation with or without VLDL (50μg-TC/mL). A, Media was collected and analyzed for IL-1β protein levels by enzyme-linked immunosorbent assay. In separate experiments, THP-1 cells were incubated with or without VLDL (50μg-TC/mL) for 16hr. Total RNA was isolated and (B) TNFα and IL-6 mRNA were measured by qRT-PCR (n=4). C, THP-1 cells were incubated with IκB kinase inhibitor (Parthenolide 10μmol/L) for 0.5hr followed by 16hr incubation with or without VLDL or LPS at the indicated concentrations. Total RNA was isolated and IL-1β, MIP-1α and ICAM-1 mRNA was measured by qRT-PCR (n=3-4). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).
2.3.4 INHIBITION OF VLDL-INDUCED INFLAMMATION BY PPARδ ACTIVATION IS INDEPENDENT OF REDUCED CELLULAR TRIGLYCERIDE

We examined if inhibition of VLDL-induced inflammation by PPARδ agonists was a consequence of reduced TG accumulation. Complete inhibition of LPL with tetrahydrolipstatin (THL), blocked cellular TG and cytokine expression. However, inhibition of TG accumulation with low-dose THL, to the same extent as that achieved by PPARδ agonists (~25%), decreased ICAM-1 expression by 30% but did not affect MIP-1α or IL-1β (Figure 2.8). PPARδ activation normalized VLDL-induced cytokine expression, even when β-oxidation was inhibited by etomoxir (Figure 2.5D), a CPT-1α inhibitor (Galic et al., 2011). This data suggests that activated PPARδ-induced β-oxidation only partially accounts for reduced cytokine expression by PPARδ activation.

Our results are consistent with the concept that VLDL-derived FAs are the primary mediators of the inflammatory response (Anderson et al., 2012, Saraswathi and Hasty, 2006). Paradoxically, FAs also activate PPARδ (Chawla et al., 2003). To reconcile this, macrophages were treated with oleic acid, which resulted in a marked induction of TG mass and expression of IL-1β and MIP-1α (Figure 2.9A,B). These effects were significantly attenuated by pre-incubation of cells with GW501516 (Figure 2.9A,B), suggesting that the known ability of FAs to activate PPARδ (Chawla et al., 2003), is insufficient to prevent macrophage TG accumulation and cytokine expression.

2.3.5 VLDL-STIMULATED EXPRESSION OF INFLAMMATORY CYTOKINES IS DEPENDENT ON MAPK ACTIVATION AND REPRESSION OF AKT/FoxO1 SIGNALING

VLDL-induced Mip1α expression in mouse macrophages involves activation of ERK1/2 (Saraswathi and Hasty, 2006). In THP-1 cells, ERK1/2 phosphorylation increased significantly within 0.5hr of VLDL exposure, which returned to baseline by 1hr
Figure 2.8 Prevention of VLDL-induced TG accumulation and cytokine expression are independent effects of PPARδ activation.

THP-1 cells were incubated with lipolysis inhibitor (THL) at the indicated concentrations for 0.5hr followed by 16hr incubation with or without VLDL (50μg-TC/mL). A, TG mass (n=2). B, TG mass (n=4). THP-1 cells were incubated with THL at the indicated concentrations for 0.5hr followed by 16hr incubation with or without VLDL (50μg-TC/mL) or LPS (0.1ng/mL). Total RNA was isolated and (C) IL-1β, MIP-1α and ICAM-1 mRNA was measured by qRT-PCR (n=3). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).
Figure 2.9 Free fatty acids are the primary effectors of the VLDL-induced inflammatory response in human macrophages. THP-1 cells were pre-incubated with PPARδ agonist GW501516 for 24hr, followed by a 16hr incubation with or without oleic acid (OA, 200μmol/L). A, TG accumulation (n=4). B, Total RNA was isolated and IL-1β and MIP-1α mRNA was measured by qRT-PCR (n=4). C, In a separate set of experiments, THP-1 cells were pre-incubated with the PPARδ agonist at the indicated concentration for 24hr, followed by a 0.5hr incubation with or without 200μmol/L OA. Cytosolic fractions were isolated and immunoblotted for ERK1/2. Equal loading was confirmed by total ERK. Representative immunoblots for phosphorylated and total ERK1/2 with quantitation shown (n=4). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey's test (P<0.05).
Similarly, VLDL stimulated p38 phosphorylation, reaching peak phosphorylation by 0.5hr, and remained elevated for ~3hr (Figure 2.10B). The MEK1/2 inhibitor, U0126, abrogated VLDL-stimulated expression of all cytokines (Figure 2.10C). In contrast, the p38 inhibitor SB203580 stimulated cytokine expression under basal conditions, and further increased cytokine expression in VLDL-treated cells (Figure 2.10D). Inhibition of p38 resulted in a 5-fold induction in ERK1/2 phosphorylation (Figure 2.11A) suggesting that the MAPK<sup>erk</sup> signal stimulates cytokine expression, whereas MAPK<sup>p38</sup> represses the actions of MAPK<sup>erk</sup>.

The temporal disconnect between VLDL-induced MAPK<sup>erk</sup> activation/deactivation (1hr) and elevated cytokine expression (16hr), suggests that other macrophage inflammatory signaling pathways are stimulated by VLDL. Given that IL-1β is a target of nuclear FoxO1 in macrophages in the context of fatty acid-induced insulin resistance (Su et al., 2009), we examined the role of AKT/FoxO1 in VLDL-induced inflammation. Exposure of THP-1 cells to VLDL resulted in a time-dependent reduction of phospho-AKT levels for up to 6hr (Figure 2.12A). Reduced phospho-AKT was correlated with attenuated phospho-FoxO1 and increased nuclear-FoxO1 by 3hr (Figure 2.12B, C), demonstrating that VLDL inhibits AKT/FoxO1-signaling. As proof-of-concept, treatment of macrophages with AKT<sub>inhibitor</sub> IV mimicked VLDL-treatment, resulting in reduced phospho-AKT, reduced phospho-FoxO1 over 6hr (Figure 2.11B) and significant elevations in the expression of IL-1β as well as MIP-1α and ICAM-1 over 16hr (Figure 2.11C).
Figure 2.10 MAPK signaling in THP-1 human macrophages in response to VLDL.

THP-1 cells were incubated for indicated times with or without VLDL. Representative immunoblots of phosphorylated (A) ERK1/2 and (B) p38 from cytosolic fractions (n=4). 

C, THP-1 cells were incubated with MEK1/2 inhibitor (U0126 10μmol/L) or its inactive form (U0124 10μmol/L) for 0.5hr followed by 16hr incubation with or without VLDL. *IL-1β, MIP-1α and ICAM-1* mRNA was measured by qRT-PCR. 

D, THP-1 cells were incubated with p38 inhibitor (SB203580 10μmol/L) or its inactive isoform (SB202474 10μmol/L) for 0.5hr followed by a 16hr incubation with or without VLDL. mRNA determinations as in (C). Values are mean +/- SEM (n=4). A,B * indicates significant difference versus respective DMSO control; ANOVA with post hoc Bonferroni’s test (P<0.05). Representative bands are from the same immunoblot, cut from different regions. C,D Different letters are significantly different; ANOVA with post-hoc Tukey’s test (P<0.05).
**Figure 2.11 Effects of inhibitors on cell signalling cascades.** THP-1 cells were incubated with or without p38 inhibitor SB203580 (10μmol/L) for 0.5hr. Cytosolic fractions were isolated and immunoblotted for (A) pERK1/2 and p-p38. Equal loading was confirmed by total ERK and total p38, respectively (n=3). In a separate experiment, THP-1 cells were incubated for indicated times with or without AKT inhibitor (AKT\textsubscript{i} IV) (10μmol/L). Levels of (B) pAKT and pFoxO1 were determined by immunoblotting of cytosolic fractions. Quantitation was determined relative to total AKT and β-Actin, respectively (n=3). C, THP-1 cells incubated for 16hr with or without AKT activity inhibitor (AKT\textsubscript{i} IV 10μmol/L). mRNA for *IL-1β*, *MIP-1α* and *ICAM-1* mRNA was measured by qRT-PCR. Data is presented as mean +/- SEM (n=4). * indicates significant difference versus control; *t*-test (*P*<0.05). For A-B, relative intensities represent the mean ratio of phospho:total protein relative to the respective DMSO control of 3 independent experiments.
Figure 2.12 VLDL induces human macrophage inflammation via AKT/FoxO1 signaling.

THP-1 cells were incubated for indicated times with or without VLDL. Representative immunoblots of (A) phosphorylated-AKT and (B) phosphorylated-FoxO1 from cytosolic fractions. (C) nFoxO1 from nuclear fractions. Equal loading was confirmed by total AKT, β-Actin, and Lamin A/C respectively (n=4). The immunoblots for Lamin A/C in (B) and for β-Actin in (C) show no detectable bands demonstrating complete separation of cytosolic and nuclear fractions, respectively. Data is presented as mean +/- SEM (n=4). * indicates significant difference versus control; t-test (P<0.05). Representative bands are from the same immunoblot, cut from different regions.
2.3.6 VLDL-STIMULATED ACTIVATION OF MAPK SIGNALING AND REPRESSION OF AKT/FoxO1 SIGNALING ARE CORRECTED BY PPARδ ACTIVATION

To determine the mechanism whereby PPARδ activation attenuates VLDL-induced cytokine expression, we examined the effect of PPARδ agonists on macrophage MAPK and AKT/FoxO1 signaling. GW0742 and GW501516 significantly attenuated both VLDL-stimulated ERK1/2 and p38 activation (Figure 2.13A, B). Furthermore, both PPARδ agonists increased phospho-Akt and phospho-FoxO1 in control cells (Figure 2.13C), and reversed the reductions of phospho-Akt and phospho-FoxO1 in VLDL-treated cells (Figure 2.13D, E). Importantly, GW0742 and GW501516 prevented the VLDL-induced increase in nuclear FoxO1 (Figure 2.13F). Inhibition of β-oxidation by etomoxir had no effect on the ability of PPARδ activation to normalize VLDL-induced MAPK signaling (Figure 2.14A,B) or restore normal AKT/FoxO1 signaling (Figure 2.14C,D). Collectively, these data demonstrate that PPARδ activation inhibits VLDL-induced inflammatory cytokine expression by inhibiting MAPK signaling and restoring signaling through AKT/FoxO1. Furthermore, the modulation of both signaling pathways by PPARδ activation was independent of PPARδ agonist-induced β-oxidation.
Figure 2.13 PPARδ activation normalizes VLDL-stimulated inflammatory signaling.

THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 0.5hr incubation with or without VLDL. Representative immunoblots of phosphorylated (A) pERK1/2 and (B) p-p38 from cytosolic fractions (n=5-7). THP-1 cells were incubated for 6hr with or without PPARδ agonists. Levels of (A) pAKT and pFoxO1 were determined by immunoblotting cytosolic fractions. Equal loading was confirmed by total AKT and β-Actin, respectively (n=2). Relative intensities represent ratio of phospho:total protein relative to the respective DMSO control of the representative immunoblot. D-F, THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by 6hr incubation with or without VLDL. Representative immunoblots of phosphorylated (C) pAKT and (D) pFoxO1 from cytosolic fractions and (E) nFoxO1 from nuclear fractions. Equal loading was confirmed by total AKT, β-Actin, and Lamin A/C respectively (n=5-7). Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).
Figure 2.14 Inhibition of β-oxidation had no effect on the ability of PPARδ activation to correct VLDL-induced inflammatory signalling. THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 0.5hr incubation with the CPT-1α inhibitor etomoxir (ETO). For a subsequent 0.5hr, cells were incubated with or without VLDL. Representative immunoblots of phosphorylated (A) pERK1/2 and (B) p-p38 from cytosolic fractions (n=3). C,D, THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 0.5hr incubation with ETO. For a subsequent 6hr, cells were incubated with or without VLDL. Representative immunoblots of phosphorylated (C) pAKT and (D) pFoxO1 from cytosolic fractions (n=3). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).
2.4 DISCUSSION

Patients with insulin resistant syndromes such as type 2 diabetes and metabolic syndrome have significant elevations of plasma VLDL, which confers increased risk for atherosclerosis (Facchini et al., 2001, Reaven, 2005). Type 2 diabetes, metabolic syndrome and atherosclerosis are interwoven by the commonality of chronic low-grade inflammation (Dandona et al., 2004, Hotamisligil, 2006). However, the molecular processes that link elevated plasma VLDL, atherosclerosis and inflammation require further elucidation. In the present study, we demonstrate that human native VLDL induces both macrophage TG accumulation and expression of proinflammatory cytokines, in the absence of exogenous LPS. Furthermore, we demonstrate that PPARδ activation attenuates both of these pathogenic macrophage foam cell processes, and define the mechanisms involved. Although VLDL-derived fatty acids are the stimulus for cytokine expression, the ability of PPARδ agonists to dampen the inflammatory response is independent of agonist-induced LPL inhibition, stimulation of β-oxidation or reduction in cellular TG.

PPARδ is expressed in abundance in macrophages (Vosper et al., 2001), but its biological role in lipid homeostasis has been controversial (Chawla et al., 2003, Lee et al., 2006, Vosper et al., 2001). In this study, we demonstrate that VLDL-induced TG accumulation is significantly decreased by PPARδ activation. Hydrolysis of VLDL-TG by macrophage LPL is required for cellular FA uptake and TG resynthesis (Evans et al., 1993). PPARδ agonists increased ANGPTL4 expression, which was coupled to a reduction in LPL activity thereby limiting liberated FAs for macrophage uptake. These findings are consistent with recent studies demonstrating that ANGPTL4 is a PPARδ target gene, which is expressed in macrophages and irreversibly inactivates LPL by converting active LPL-dimers into inactive LPL-monomers (Adhikary et al., , Sukonina et
al., 2006). PPARδ activation increased expression of the FA transporter CD36, which resulted in a modest increase in FA uptake, albeit from a smaller FA pool. However, we confirm that PPARδ agonists upregulate CPT-1α expression (Lee et al., 2006), which enhances FA oxidation. Furthermore, we show for the first time, that PPARδ activation results in a net depletion of VLDL-induced TG accumulation. These results are consistent with the concept that one role for PPARδ activation in macrophages is to prevent lipotoxicity by limiting VLDL hydrolysis and enhancing FA catabolism (Chawla et al., 2003, Lee et al., 2006), and contradict the notion that PPARδ activation promotes lipid accumulation (Vosper et al., 2001). Furthermore, although VLDL-derived FAs activate PPARδ (Chawla et al., 2003), potent synthetic agonists of PPARδ are required in order to attenuate VLDL-stimulated macrophage foam cell formation, as well as inhibit the inflammatory response.

VLDL markedly stimulates expression of AP-1-inducible inflammatory cytokines, which occurs in the absence of NFκB signaling or exogenous LPS. VLDL has been demonstrated to induce Mip-1α in murine macrophages via ERK1/2 activation (Saraswathi and Hasty, 2006). We extend this response to human THP-1 macrophages and to include the induction of IL-1β and ICAM-1. In THP-1 macrophages, both ERK1/2 and p38 are activated in response to VLDL, and p38 phosphorylation remains elevated well beyond that of ERK1/2. Inhibition of p38 stimulated ERK1/2 phosphorylation and enhanced cytokine expression. Moreover, the combination of VLDL treatment and p38 inhibition results in additive stimulation of cytokine expression over either treatment alone, suggesting that relieving the p38-induced impediment on ERK1/2 signaling enhances cytokine expression. Although in some cells, p38 activation has no effect or amplifies ERK1/2 signaling, we and others have reported that in hepatoma cells, insulin-induced phosphorylation of p38 also acts as a negative regulator of insulin-stimulated
ERK1/2 activation (Allister et al., 2005, Keeton et al., 2002). The present study supports this paradigm, and demonstrates for the first time, that VLDL-stimulation of macrophage cytokine expression through MAPK_{erk} involves p38 acting as a negative regulator of ERK1/2 signaling.

VLDL-treated macrophages displayed attenuated AKT and FoxO1 phosphorylation which coincided with increased nuclear FoxO1 and increased cytokine expression. Although the mechanism by which VLDL attenuates AKT signaling leading to activation of FoxO1 has not been defined, it is known that FoxO1 is a direct transcriptional activator of \textit{Il-1}\beta in mouse macrophages (Su et al., 2009). Several reports indicate that lipid-induced macrophage insulin resistance is associated with impaired AKT/FoxO1 signaling, increased FoxO1 activity, and thus plays a critical role in macrophage inflammation and ER-stress-induced apoptosis (Han et al., 2006, Senokuchi et al., 2008, Su et al., 2009). Some studies have suggested that free fatty acids induce macrophage inflammation through activation of toll-like receptor (TLR) signaling (Nguyen et al., 2007, Shi et al., 2006). However, more recent reports have provided contrary evidence (Anderson et al., 2012, Erridge and Samani, 2009). The present study is consistent with the concept that VLDL-stimulated macrophage inflammatory cytokine expression results from macrophage insulin resistance, rather than elicitation of a TLR-NFκB response. This is evidenced by: (i) impaired AKT/FoxO1 signaling and enhanced MAPK signaling by VLDL treatment, (ii) canonical NFκB target genes \textit{TNFa} and \textit{IL-6} being unaffected by VLDL treatment, and (iii) the inability of parthenolide, (an inhibitor of NFκB signaling) to block VLDL-stimulated expression of \textit{IL-1}\beta, \textit{MIP-1}\alpha and \textit{ICAM-1}.

It is tempting to hypothesize that VLDL-induced inflammatory responses are initially derived from rapid ERK1/2 activation followed by later and sustained AKT
signaling. The ERK1/2 signal is rapidly down-regulated by activated p38, whereas the AKT signal is possibly mitigated by a self-limiting feedback loop (Fan et al., 2010). Furthermore, with time, it is possible that incoming FAs increase the saturated lipid content of the ER membrane, thereby inducing an ER-stress response (Borradaile et al., 2006), and subsequent amplification of nuclear FoxO1 (Ozcan et al., 2004). The exact relationship among time-dependent signaling events governing VLDL-stimulated inflammatory responses requires further study.

VLDL-induced expression of inflammatory cytokines was completely normalized by both PPARδ agonists, despite a lack of effect on intracellular FFA levels, and even under conditions of inhibited β-oxidation. This suggests that stimulation of β-oxidation by PPARδ activation is insufficient to explain the anti-inflammatory effects. Additionally, VLDL-stimulated phosphorylation of both ERK1/2 and p38 were normalized by PPARδ activation, suggesting regulation of a common upstream MAPK factor. This concept is consistent with a previous report that GW0742 inhibited angiotensin II-induced phosphorylation of ERK1/2 and p38 in mouse macrophages, via upregulation of RGS4 and RGS5 (Takata et al., 2008). Whether this mechanism applies to the present study remains to be determined.

Macrophages exposed to VLDL in the presence of PPARδ agonists restored levels of phospho-AKT, phospho-FoxO1 and nuclear FoxO1 to those observed in untreated cells, an effect independent of PPARδ agonist-induced enhanced β-oxidation. Although modulation of AKT activity by PPARδ activation has been observed in keratinocytes and endothelial cells (Di-Poi et al., 2002, Han et al., 2008), the mechanisms underlying this phenomenon remain unclear. Di-Poi et al. demonstrated that PPARδ ligand L-165041 induced expression of integrin-like kinase (ILK) and 3-phosphoinositide-dependent kinase-1 (PDK1), which led to phosphorylation of AKT and
FoxO1 (Di-Poi et al., 2002). In contrast, Han et al. reported that GW501516-treated endothelial progenitor cells displayed marked elevations in phospho-AKT, without increased ILK expression (Han et al., 2008). In our experiments in macrophages, PPARδ agonists increased phospho-AKT and phospho-FoxO1, without effecting ILK or PDK1 expression (Figure 2.15). This suggests that the anti-inflammatory effect of PPARδ activation is, in part, due to direct stimulation of AKT/FoxO1 phosphorylation, thereby preventing VLDL from dysregulating this signaling cascade.

In summary, VLDL-induced macrophage lipid accumulation and proinflammatory cytokine synthesis are attenuated by PPARδ activation, effects which involve ERK1/2- and AKT-dependent signaling mechanisms. These combined reductions of lipid accumulation and inflammatory cytokine expression by PPARδ ligands reveal a novel mechanism for preventing the deleterious consequences of macrophage foam cell formation.
Figure 2.15 Effects of PPARδ agonists on expression of ILK and PDK1.

THP-1 cells were incubated with PPARδ-specific agonists at the indicated concentrations for 24hr. Total RNA was isolated and ILK and PDK1 mRNA was measured by qRT-PCR (n=4). Data is presented as mean +/- SEM.
2.5 REFERENCES


Agonist Enhances Vasculogenesis by Regulating Endothelial Progenitor Cells through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-Kinase/Akt Pathway. Circulation 118, 1021-1033.


Chapter 3
Activation of PPARδ inhibits human macrophage foam cell formation induced by native and modified low-density lipoprotein

3.1 INTRODUCTION

During atherogenesis, excessive macrophage uptake of lipoproteins drives lipid accumulation and the synthesis and secretion of proinflammatory mediators within the arterial wall, events that potentiate lesion progression (Libby et al., 2011). An important risk factor for the development of atherosclerosis is the elevation of plasma lipoproteins, primarily due to their ability to permeate the vessel wall and initiate macrophage foam cell formation as well as maladaptive immune responses (Libby et al., 2011, Moore and Tabas, 2011). Specifically, increased plasma cholesteryl ester (CE)-rich low-density lipoprotein (LDL) is a major foam cell-inducing lipoprotein, and in turn, a significant contributor to accelerated atherogenesis (Libby et al., 2011, Moore and Tabas, 2011). High plasma LDL is also positively correlated with inflammation linked to atherogenesis in both humans and mice (Blake and Ridker, 2003, Getz and Reardon, 2006). Therefore, pharmacological inhibition of LDL-induced macrophage foam cell formation and the linked inflammatory response(s) represent an attractive therapeutic strategy.

Cholesterol homeostasis in macrophages is a dynamic process regulated by uptake, storage and efflux. The predominant LDL uptake pathway in macrophages of the arterial intima is via its modified form through the scavenger receptors cluster of differentiation (CD) 36 and scavenger receptor A I/II (SRAI/II) (Moore and Freeman, 2006). Subendothelial retention of LDL leads to the formation of oxLDL (Steinberg, 2009, Steinberg and Witztum, 2010), a high-affinity scavenger receptor ligand (Moore and Freeman, 2006). Binding of oxLDL to either of these scavenger receptors readily induces macrophage cholesterol accumulation (Argmann et al., 2003). Once internalized, lipoprotein derived CEs are hydrolyzed in the late endosomes to free cholesterol and fatty acids (Maxfield and Tabas, 2005), which are subsequently re-
esterified in the endoplasmic reticulum (ER) by acyl-CoA:cholesterol acyltransferase (ACAT) (Brown et al., 1980, Ikonen, 2008). In macrophages, ACAT1 is the only expressed isoform that generates CE for storage in cytoplasmic lipid droplets (Ikonen, 2008). Collectively, under these circumstances, it is important that cholesterol efflux maintains the rate of cholesterol uptake, to prevent accumulation of cholesterol-laden foam cells within the arterial intima (Libby et al., 2011).

In response to massive cholesterol accumulation, macrophage foam cells also synthesize and secrete proinflammatory mediators that potentiate lesion progression (Tabas, 2010). Although the mechanisms by which cholesterol induces inflammatory responses are not fully understood, one proposed stimulus has been the induction of the endoplasmic reticulum (ER)-stress pathway (Tabas, 2010). As a consequence of excessive lipoprotein-derived cholesterol uptake, free cholesterol (FC) builds up in the ER, causing ER-stress (Tabas, 2010). Subsequently, the C/EBP homologous protein (CHOP) is induced, which in turn stimulates Nfkβ signaling to upregulate the expression of tumor necrosis factor (TNF) α and interleukin (IL)-6 (Li et al., 2005). Therefore, excessive lipoprotein-derived cholesterol delivered to macrophages must be appropriately partitioned, either to storage in cytoplasmic lipid droplets or to cholesterol efflux pathways, in order to prevent the deleterious proinflammatory consequences of FC accrual in the ER (Rong et al., 2013, Tabas, 2010).

In addition to the ER-stress pathway, a growing body of evidence suggests that cell-surface receptor signaling also plays a role in the stimulation of macrophage inflammatory responses. Specifically, a series of studies support the concept that oxLDL stimulates proinflammatory cytokine expression through CD36 in concert with the pattern recognition toll-like receptors (TLR) (Moore and Tabas, 2011). The assembly of CD36-TLR complexes leads to the activation of nuclear factor kappa B (Nfkβ) signal transduction to simulate expression of proinflammatory effector molecules, such as Tnf
and interleukin \( \text{IL-6} \) (Stewart et al., 2010). Addition of lipopolysaccharide (LPS) to cultured macrophages significantly enhances oxLDL-induced inflammation (Wiesner et al., 2010). In macrophages isolated from CD36 deficient patients, oxLDL fails to stimulate cytokine expression (Janabi et al., 2000). In mice, genetic ablation of either CD36 or various TLRs is linked to protection from diet-induced atherosclerosis and aortic inflammation (Curtiss et al., 2012, Febbraio et al., 2000, Michelsen et al., 2004, Mullick et al., 2005).

Despite the overwhelming positive evidence for oxLDL-induced inflammatory responses, a series of studies have provided contrary evidence (Chung et al., 2000, Kannan et al., 2012, Qiu et al., 2007). LPS-induced expression of the proinflammatory cytokine IL-12 was significantly reduced in macrophages treated with oxLDL (Chung et al., 2000). A subsequent study showed that macrophages treated with oxLDL exhibited lower expression of a panel of proinflammatory cytokines that included TNF\( \alpha \) and IL-6 (Qiu et al., 2007). Most recently, oxLDL-treatment of monocytes failed to increase TNF\( \alpha \) and IL-6 expression, and protected these cells from LPS-induced proinflammatory responses (Kannan et al., 2012). Collectively, these studies suggest that our understanding of macrophage inflammatory responses in the context of lipoprotein uptake, is not well defined.

The peroxisome proliferator-activated receptors (PPARs) are important regulators of metabolic and inflammatory signaling (Harmon et al., 2011, Lee et al., 2003). There are three known isoforms (PPAR\( \alpha \), \( \gamma \) and \( \delta \)) which exhibit distinct patterns of tissue distribution and function (Harmon et al., 2011, Lee et al., 2003). In contrast to the predominant expression of PPAR\( \alpha \) and PPAR\( \gamma \) in a cell- or tissue-specific manner (Harmon et al., 2011), expression of PPAR\( \delta \) is ubiquitous. However, the expression of PPAR\( \delta \) is high in macrophages (Vosper et al., 2001) where its role in cholesterol homeostasis remains unclear. Conflicting reports have demonstrated that synthetic PPAR\( \delta \) agonists either stimulate cholesterol efflux and reverse cholesterol transport or
promote lipid accumulation (Oliver et al., 2001, Vosper et al., 2001, Wallace et al., 2005). One study suggested that the PPARδ agonist GW0742 had no effect on cholesterol accumulation in mouse peritoneal macrophages isolated from mice fed a high-fat, high cholesterol diet supplemented with the compound (Li et al., 2004). Consequently, the net effect of PPARδ activation on oxLDL-induced macrophage cholesterol accumulation has been difficult to define. With regard to inflammation, in adipocytes and cardiomyocytes, PPARδ agonists inhibit LPS-induced Nfκb-mediated inflammatory responses (Ding et al., 2006, Rodriguez-Calvo et al., 2008). However, the impact of PPARδ activation on the mechanisms underlying oxLDL-induced inflammatory responses, in the absence of LPS, has not been examined.

In the present study, we report that synthetic ligand activation of PPARδ in macrophages attenuates LDL- and oxLDL-induced CE accumulation as well as oxLDL-induced FC accumulation. This was at least in part due to promoting ABCA1-mediated cholesterol efflux to apoAI. OxLDL-treated macrophages displayed reduced expression of TNFα and IL-6 compared to untreated cells, which was not further affected by PPARδ activation. The oxLDL-mediated anti-inflammatory response was associated with increased expression of genes known to be regulated by the liver X receptor (LXR) as well as by PPARγ and PPARδ.
3.2 MATERIALS AND METHODS

3.2.1 LIPOPROTEINS

LDL and high-density lipoprotein$_3$ (HDL$_3$) were isolated from plasma of human subjects recruited from the Lipid Clinic at the London Health Sciences Centre, University Campus (London, Ontario, Canada). This study was approved by the University of Western Ontario Institutional Review Board (IRB reference #15685). Lipoproteins were separated by differential ultracentrifugation using a Beckman 70.1 Ti rotor (16 hr, 40,000 rpm, 12°C) as previously described (Whitman et al., 1997). LDL was oxidized (oxLDL) via the copper sulfate method and the extent of modification was confirmed by alterations in electrophoretic mobility (Whitman et al., 1997).

3.2.2 CELL CULTURE

Human THP-1 macrophages were obtained from American Type Culture Collection (Manassas, VA) and cultured as described previously (Beyea et al., 2007). PPARδ agonists GW0742 (Sigma) and GW501516 (Alexis Biochemicals, Plymouth, PA) were dissolved in dimethyl sulfoxide (DMSO, Sigma) and incubated with cells at the indicated concentrations. These concentrations have been determined to specifically activate PPARδ, in the absence of PPARα or PPARγ activation (Chapter 2). THP-1 macrophages were preincubated (24 hr) the presence or absence of PPARδ agonists. Subsequently, cells were incubated with PPARδ agonists in the presence or absence of lipoproteins as indicated. The ACAT inhibitors Dup-128 (DuPont Merck Pharmaceutical Co.) and CI-1011 (Parke-Davis Pharmaceutical Research) were dissolved in DMSO and applied to THP-1 macrophages 0.5 hr prior to lipoprotein additions. Experimental concentrations of DMSO did not exceed 0.5% of total medium.

3.2.3 CELLULAR LIPID MASS

THP-1 macrophages were preincubated in the presence of PPARδ agonists or equal volume of DMSO (not to exceed 0.5% of total medium) for 24 hr in RPMI 1640
supplemented with 10% fetal bovine serum (FBS) and 300nmol/L PDB. Cells were incubated for a further 16 hr with fresh media containing 5% LPDS and compounds in the absence or presence of native or oxidatively modified LDL (150 μg of lipoprotein total cholesterol (TC)/mL medium). Cellular TC, FC, TG, and protein mass were determined using enzymatic colorimetric assays for TC and FC (Wako Diagnostics, Richmond, VA) as well as TG (Boehringer Mannheim, Laval, QC) as previously described (Rowe et al., 2003). Cellular CE was determined as the difference between TC and FC (Rowe et al., 2003).

3.2.4 CHOLESTEROL ESTERIFICATION

The esterification of cholesterol was measured in THP-1 cells following a preincubation in 5% LPDS-containing medium for 19 hr in the presence or absence of the indicated concentrations of PPARδ agonists. For a subsequent 5 hr incubation, 0.08nCi/mL [1-14C]oleic acid (Amersham Biosciences) complexed with fatty acid-free bovine serum albumin in a molar ratio of 5.36:1 (Sigma) was added with or without LDL or oxLDL as described previously (Beyea et al., 2012). Cellular lipid extracts were separated by thin layer chromatography. Cells were lysed in 1mL of 0.1N NaOH, and aliquots were used to determine protein concentrations (Beyea et al., 2012).

3.2.5 CHOLESTEROL EFFLUX

THP-1 macrophages were incubated with acLDL (5 µg-TC/mL) in medium containing 0.2% FAF:BSA and [1α,2α (n)-3H]cholesterol (1 µCi/mL, Amersham Biosciences) for 24 hr. Monolayers were then washed with phosphate buffered saline (PBS) and incubated in fresh medium with GW0742 or GW1516 at the indicated concentrations for 24 hr. Subsequently, macrophages were incubated with fresh compound and medium with 0.2% FAF:BSA alone, apoAl (10 µg/mL, Sigma) or HDL₃ (100µg-TC/mL) for a further 16 hr. Cholesterol efflux was expressed as the percentage of [³H] counts in the media versus total [³H] cholesterol counts (media plus cell) and
normalized to cell protein determined from 0.1N NaOH lysates as described (Argmann et al., 2003).

3.2.6 QUANTITATIVE REAL-TIME PCR mRNA ABUNDANCE ANALYSIS

THP-1 cells were incubated for 24 hr in RPMI 1640 with 5% LPDS, 300nmol/L PDB, in the presence or absence of PPARδ agonists, and subsequently total RNA was isolated using TriZol reagent (Invitrogen, Burlington, ON) according to the manufacturer’s instructions. In experiments examining oxLDL-induced inflammatory cytokine expression, cells were preincubated for 24 hr in RPMI 1640 with 10% FBS, 300nmol/L PDB, in the presence or absence of PPARδ agonists. Cells were then incubated with fresh 5%-LPDS media and compounds for a further 16 hr in the absence or presence of oxLDL (150μg-TC/mL) prior to TriZol RNA extraction. Abundance of total RNA (2μg) was reverse transcribed using the Applied Biosystems High Capacity cDNA reverse transcription kit according to the manufacturer’s protocol. Subsequently, cDNA (10ng) was analyzed in triplicate by quantitative real time RT-PCR (qRT-PCR) on an ABI Prism (model 7900HT) Sequence Detection System (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions and as previously described (Chapter 2). Primer-probe sets for each gene (ABCA1, ABCG1, ACAT1, ACOX, ADFP, DHCR24, FABP4, FAS, IL-6, MYLIP, SREBP-1c, and TNFα) were obtained from Applied Biosystems (Carlsbad, CA). Abundance of target genes, calculated using the standard curve method, was normalized to GAPDH abundance.

3.2.7 IMMUNOBLOT ANALYSIS AND DENSITOMETRY

Total cell lysates were prepared as previously described (Chapter 2). Proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted as described (Rowe et al., 2003). Cellular cytosolic fractions were probed using antibodies against human ABCA1, ABCG1 (Novus Biologicals, Littleton, CO) and β-actin (Cell Signaling, Danvers, MA). Quantification analysis of the developed films was
performed using an imaging densitometer (Bio-Rad Quantity One Software). ABCA1 and ABCG1 from cytosolic fractions were normalized to β-Actin.

3.2.8 STATISTICAL ANALYSES

Data are expressed as means +/- standard error of the mean (SEM). The Shapiro-Wilk normality test was used to test for parametric distributions in each data set. $P$ values for observed differences between treatment and control groups were calculated by one-way ANOVA followed by Bonferroni post hoc test. $P$ values for observed pairwise comparisons were calculated by one-way ANOVA followed by Tukey’s post hoc test. Significance thresholds were $P$ values less than 0.05. Statistical analyses were performed with SigmaPlot 11.0 software (Systat, Inc, San Jose, CA).
3.3 RESULTS

3.3.1 PPARδ-SPECIFIC ACTIVATION ATTENUATES NATIVE AND OXIDIZED LDL-INDUCED MACROPHAGE CHOLESTERYL ESTER ACCUMULATION

THP-1 cells treated with native LDL (150 µg-TC/mL) displayed a modest but significant 1.6-fold increase in CE accumulation (Figure 3.1A). Pre-treatment with PPARδ agonists at concentrations known to be PPARδ-specific (Chapter 2) for 24 hours almost completely normalized LDL-induced CE mass (Figure 3.1A). Cellular free cholesterol (FC) concentrations were unaffected by LDL or PPARδ agonist treatment, whereas triglyceride (TG) mass trended towards a reduction in the presence of the PPARδ ligands (Figure 3.1B). In contrast to the modest induction of foam cell formation by native LDL, oxLDL (150 µg-TC/mL)-treated macrophages exhibited a marked 5-fold increase in CE mass, which was significantly attenuated (~40%) by 24 hour pre-treatment with PPARδ agonists (Figure 3.1C). The 1.8-fold increase in FC accumulation induced by oxLDL was reduced (~50%) in the presence of the PPARδ ligands (Figure 3.1D). Collectively, these results demonstrate that PPARδ activation attenuates CE-rich lipoprotein induced macrophage foam cell formation.

3.3.2 PPARδ AGONISTS ENHANCE CHOLESTEROL UPTAKE GENES AND ABCA1-MEDIATED CHOLESTEROL EFFLUX TO APOAI, HAVE NO EFFECT ON ABCG1-MEDIATED EFFLUX TO HDL₃ AND INHIBIT CHOLESTEROL ESTERIFICATION

We hypothesized that the observed attenuation of CE mass mediated by the PPARδ agonists may be due to reduced lipoprotein uptake. However, PPARδ activation enhanced both LDLR (Figure 3.2A) and CD36 mRNA abundance (Chapter 2, Figure 2.3D), which would be predicted to enhance native and oxidized LDL uptake, respectively. We next examined cholesterol esterification, and found that ACAT1 expression was unchanged in response to the PPARδ ligands (Figure 3.2B). However, both PPARδ agonists attenuated basal and lipoprotein-induced
Figure 3.1: PPARδ activation attenuates LDL-induced cholesteryl ester mass accumulation.

THP-1 cells were pre-incubated with PPARδ agonists at the indicated concentrations for 24h, followed by a 16h incubation with or without LDL. A, Total and free cholesterol mass were measured via a colorimetric assay. Cholesteryl ester (CE) is calculated as the difference between total and free cholesterol. Values are expressed as CE mass +/- SEM of duplicate determinations (n=6). B, Free cholesterol and triacylglycerol mass were measured via a colorimetric assay. Values are expressed as CE mass +/- SEM and FC mass +/- SEM of duplicate determinations (n=6). C, oxLDL-induced CE mass. D, oxLDL-induced FC and TG mass. Different letters are significantly different from one another. ANOVA with post hoc Tukey’s test (P<0.05).
Figure 3.2: Effect of PPARδ activation on uptake and FFA re-esterification into cholesteryl ester.

THP-1 cells were incubated with PPARδ-specific agonists at the indicated concentrations for 24h. mRNA was harvested and (A) LDLR and (B) ACAT1 abundance was measured by qRT-PCR. Values are expressed as a fold change of DMSO control cells normalized to GAPDH +/- SEM of duplicate determinations (n=2-4). In separate experiments, following a 19h incubation with PPARδ agonists at indicated concentrations, THP-1 cells were incubated for a further 5h with PPARδ agonists and (C) 1-[14C]oleic acid, (D) with or without LDL and (E) with or without oxLDL to measure oleate incorporation into cellular cholesteryl ester. Values are expressed as a fold change of DMSO control cells +/- SEM of duplicate determinations (n=3-4). Different letters are significantly different from one another. ANOVA with post hoc Tukey’s test (P<0.05).
cholesterol esterification, as evidenced by reduced incorporation of $^{14}$C-oleic acid into CE (Figure 3.2C-E).

Regarding cholesterol efflux, abundance of ABCA1 mRNA and protein was significantly increased in THP-1 cells treated with either PPARδ agonist (Figure 3.3A, B). Moreover, cells treated with GW0742 (25nmol/L) displayed a marked 2-fold increase in \( ABCG1 \) mRNA, and significantly increased ABCG1 protein, effects which were not observed with GW501516 (Figure 3.3C, D). Increased ABCA1 mRNA and protein was associated with a significant 1.8-fold increase in cholesterol efflux to apoAI (Figure 3.3E). Although there was a trend towards increased cholesterol efflux to HDL\(_3\), this did not achieve statistical significance (Figure 3.3C). Collectively these results suggest that PPARδ activation stimulates ABCA1- but not ABCG1-mediated cholesterol efflux, which likely contributes to a net reduction in macrophage CE content.

3.3.3 PPARδ ACTIVATION DOES NOT FURTHER AFFECT THE OXLDL-MEDIATED REDUCTION IN PROINFLAMMATORY CYTOKINE EXPRESSION

Exposure of macrophages to oxLDL has been shown to stimulate Nfκb-mediated proinflammatory responses (Janabi et al., 2000, Stewart et al., 2010), and macrophages loaded with FC are thought to stimulate expression the canonical Nfκb-target genes, \( TNFa \) and \( IL-6 \) (Li et al., 2005). Here, oxLDL-treated macrophages exhibited reduced expression of \( TNFa \) (-50%) and \( IL-6 \) (-30%) (Figure 3.4A, B). Pre-treatment with the PPARδ agonists had no further effect on expression of these cytokines (Figure 3.4A, B). We reasoned that the observed 1.8-fold increase in macrophage FC content in response to oxLDL (Figure 3.1D) was perhaps insufficient to stimulate ER-stress and induce an inflammatory response (Li et al., 2005). Treatment of macrophages with ACAT inhibitors Dup-128 or Cl-1011 in the presence of oxLDL resulted in a further 1.3- and 1.5-fold increase in macrophage FC content, respectively (Figure 3.4C). CE mass
Figure 3.3: PPARδ activation enhances ABCA1 and ABCG1 mRNA and protein, leading to increased cholesterol efflux.

THP-1 cells were incubated with PPARδ agonists for 24h. Total RNA was analyzed for (A) ABCA1 and (C) ABCG1 mRNA by qRT-PCR. Values are expressed as a fold change of DMSO control cells normalized to GAPDH +/- SEM of duplicate samples. ANOVA with post hoc Bonferroni correction, *P<0.05 versus control (n=4). B,E, ABCA1 and ABCG1 protein; representative immunoblots of 4 independent experiments shown. D, Cholesterol efflux from macrophages was measured following incubation with [3H]cholesterol and acetylated LDL (5μg of total cholesterol/mL, 24h) in 0.2% (w/v) fatty acid-free bovine serum albumin medium followed by 24h with vehicle or PPARδ agonists at the indicated concentrations, and a final 16h incubation with vehicle or PPARδ agonists in the presence of FAF:BSA alone or apoAI (10μg/mL) or HDL₃ (100μg/mL). Cholesterol efflux is expressed as the percentage of [3H]cholesterol in the medium relative to total [3H]cholesterol (medium plus cell) normalized to total cell protein and plotted as a ratio of apoAI with vehicle alone (mean +/- SEM, n=4). ANOVA with post hoc Tukey’s test, different letters are statistically different (P<0.05).
A

[Graph showing the fold change of ABCA1/GAPDH expression levels under different conditions: DMSO, GW0742 (1 and 25 nmol/L), and GW501516 (1 and 100 nmol/L).]

B

[Images showing Western blot analysis for ABCA1 and β-Actin under the same conditions as in (A).]

C

[Graph showing the fold change of ABCG1/GAPDH expression levels under the same conditions as in (A).]

D

[Images showing Western blot analysis for ABCG1 and β-Actin under the same conditions as in (A).]

E

[Bar graph showing cholesterol efflux per mg cell protein (ratio of ApoAI control) under the following conditions: DMSO, GW0742 (25 nmol/L), and GW501516 (100 nmol/L).]

Legend:

- DMSO
- GW0742 (25 nmol/L)
- GW501516 (100 nmol/L)

Significance:

- a
- b
- c
- d

Notes:

- FAF:BSA
- ApoAI
- HDL_3
Figure 3.4: PPARδ agonists and ACAT inhibitors do not further affect the oxLDL-mediated reduction in proinflammatory cytokine expression.

THP-1 cells were pre-incubated with PPARδ agonists at the indicated concentrations for 24h, followed by a 16h incubation with or without oxLDL (150µg-TC/mL) for 16h. Total RNA was analyzed for the proinflammatory cytokines (A) TNFα and (B) IL-6 by qRT-PCR and normalized to GAPDH. In a separate set of experiments, THP-1 cells were pre-incubated with or without ACAT inhibitors at the indicated concentration for 0.5h, followed by a 16h incubation with or without oxLDL (150µg-TC/mL) for 16h. C, Free cholesterol mass. D, Cholesteryl Ester mass. TNFα (E) and IL-6 (F) mRNA abundance normalized to GAPDH. Data is presented as mean +/- SEM of duplicate samples (n=2).
was significantly reduced by the presence of the ACAT inhibitors (Figure 3.4D). Despite the further induction of cellular FC by ACAT inhibition, the suppression of TNFα or IL-6 expression by oxLDL was unaffected (Figure 3.4E, F). These data suggest that oxLDL treatment or FC accumulation in macrophages does not stimulate the inflammatory response.

3.3.4 OXLDL-TREATED MACROPHAGES DISPLAY INCREASED EXPRESSION OF LXR, PPARγ AND PPARδ TARGET GENES

It has recently been reported that peritoneal macrophages isolated from high-fat, high cholesterol fed Ldlr−/− mice display significant enrichment of cholesterol, coupled to substantially reduced dehydrocholesterol reductase (DHCR) 24 expression (Spann et al., 2012). The DHCR24 transcript encodes the enzyme responsible for catalyzing the conversion of lanosterol to 24,25-dihydrolanosterol in the Kandutsch-Russel cholesterol biosynthetic pathway, as well as the conversion of desmosterol to cholesterol in the Bloch pathway (Spann et al., 2012). Accordingly, a significant accumulation of the potent LXR-ligand desmosterol was observed in cholesterol-rich peritoneal macrophages. As LXR activation is known to negatively regulate the inflammatory response, increased desmosterol was associated with a marked reduction in the expression of proinflammatory genes (Spann et al., 2012). We hypothesized that this phenomenon might reconcile the data observed in Figure 3.4 of the current study. THP-1 cells exposed to increasing concentrations of oxLDL exhibited a dose-dependent decrease in TNFα and IL-6 expression (Figure 3.5A, B). Reduced cytokine expression was associated with a significant decrease in DHCR24 mRNA abundance (Figure 3.5C). Moreover, expression of the LXR-target genes ABCA1, ABCG1 and MYLIP was substantially enhanced in oxLDL-treated macrophages (Figure 3.5D-F). Macrophages abundant in oxysterols, like desmosterol, are known to exhibit reduced processing of SREBP-1c, resulting in reduced expression of SREBP-1c target genes (Beyea et al.,
Here, SREBP-1c and FAS expression were significantly reduced in oxLDL-treated THP-1 macrophages (Figure 3.5G, H). Taken together these data support the notion that cholesterol-loaded macrophages down-regulate DHCR24 expression and activity, which results in an anti-inflammatory response mediated partially through LXR activation.

Given that PPARs are known to regulate anti-inflammatory responses (Harmon et al., 2011), and that oxLDL-treatment of macrophages can activate PPARγ transcriptional activity (Nagy et al., 1998), we examined whether there was any evidence of PPAR activation in oxLDL-loaded THP-1 cells. OxLDL had no effect on the PPARα-specific target gene ACOX (Figure 3.5I). In contrast, macrophage oxLDL-treatment significantly increased expression of the PPARγ- and PPARδ-specific target genes FABP4 and ADFP, respectively (Figure 3.5J, K). These results suggest that PPARγ and PPARδ activation may contribute to part of the oxLDL-mediated anti-inflammatory response.
Figure 3.5: oxLDL dose-dependently reduces proinflammatory cytokine expression which is associated with a dose-dependent increase in LXR, PPARγ and PPARδ target genes

THP-1 cells were incubated with oxLDL (25-150µg-TC/mL) for 16h. Total RNA was analyzed for the proinflammatory cytokines (A) TNFα and (B) IL-6, for the cholesterol biosynthesis regulatory gene (C) DHCR24, the LXR-target genes (D) ABCA1, (E) ABCG1 and (F) MYLIP, the SREBP-1c target genes (G) SREBP-1c and (H) FAS and the PPARα-, γ-, and δ-specific target genes (I) ACOX (J) FABP4 and (K) ADFP, respectively, by qRT-PCR and normalized to GAPDH. Data is presented as mean +/- SEM of duplicate samples. Asterisk (*) indicates P<0.05 versus control; ANOVA with post hoc Bonferroni test.
3.4 DISCUSSION

High circulating LDL significantly increases the risk for the development of atherosclerotic cardiovascular disease (Libby et al., 2011). A strong positive correlation exists between high plasma LDL, inflammation and atherosclerosis (Blake and Ridker, 2003, Getz and Reardon, 2006, Libby et al., 2011). However, the molecular processes of atherosclerosis-associated inflammation as a consequence of high plasma LDL require further elucidation. Here, we demonstrate that oxLDL induces both CE and FC accumulation in THP-1 human macrophages, which are significantly attenuated by PPARδ activation. Additionally, we show that in response to oxLDL, proinflammatory cytokine expression is decreased, rather than activated, and is not further affected by synthetic PPARδ agonists or ACAT inhibitors. The anti-inflammatory response observed in oxLDL-treated macrophages was associated with decreased \(DHCR24\) expression, and increased expression of LXR-, PPARγ- and PPARδ-target genes.

PPARδ is expressed in abundance in macrophages (Vosper et al., 2001), but its biological role in cholesterol homeostasis has been controversial (Li et al., 2004, Oliver et al., 2001, Vosper et al., 2001, Wallace et al., 2005). In this study, we demonstrate that oxLDL-induced CE and FC accumulation are significantly decreased by PPARδ activation. We confirm that PPARδ activation increases \(ABCA1\) mRNA and protein, which enhances cholesterol efflux to apoAI (Ogata et al., 2009, Oliver et al., 2001). Furthermore, our results imply that the PPARδ agonist-induced increase in macrophage \(ABCA1\) expression is greater than that induced by downregulation of \(DHCR24\) in response to oxLDL alone. With regard to ABCG1 activation, the effects of PPARδ have not been reported. Although GW0742 enhanced \(ABCG1\) mRNA and protein, functionally, this did not enhance cholesterol efflux to HDL₃. Nevertheless, both PPARδ agonists used in this study reduced LDL- and oxLDL-induced CE and FC accumulation. Deletion of \(Abca1\) but not \(Abcg1\) in mice, results in increased atherosclerotic plaque
development (Yvan-Charvet et al., 2007). Furthermore, Abcg1−/− mice crossed to an apolipoprotein E knockout background are protected from diet-induced atherosclerosis (Tarling et al., 2010). These studies suggest that ABCA1, rather than ABCG1, is a critical efflux transporter for the regulation of cholesterol homeostasis in hematopoietic cells of the arterial intima. The findings reported here, at least with respect to macrophages, support this concept.

Given that oxLDL-uptake is mediated, in part, by CD36, and that PPARδ activation is known to increase CD36 expression (Chapter 2, Figure 2.3D) it would be predicted the PPARδ ligands would promote oxLDL uptake. Our laboratory has previously demonstrated that macrophages treated with PPARγ activators, which also activate CD36 expression, increased oxLDL uptake, yet increased ABCA1-mediated cholesterol efflux, resulting in a net depletion of CE and FC (Argmann et al., 2003). The data reported here suggest that PPARδ activation may promote a similar mechanism of macrophage cholesterol homeostasis in response to oxLDL. Furthermore, the results in the current study contradict the notion that PPARδ activation has either no effect, or a stimulatory effect, on cholesterol accumulation (Li et al., 2004, Vosper et al., 2001).

Cholesterol esterification under basal and lipoprotein-stimulated conditions was attenuated by PPARδ activation. The apparent reduction in ACAT activity is likely a secondary effect of the PPARδ agonist’s ability to increase cholesterol efflux, thereby preventing cholesterol from reaching the ACAT-accessible pool. Pharmacological and genetic manipulations that increase cholesterol efflux pathways are known to reduce cholesterol esterification by virtue of shuttling cholesterol away from the ER esterification pool, and towards the plasma membrane for efflux (Beyea et al., 2012, Yamauchi et al., 2004). Although further studies would be required to determine the specific effects of PPARδ agonists on cholesterol trafficking in macrophages, our results support the
paradigm that increasing cholesterol efflux leads to a secondary reduction in cholesterol esterification (Francis and Perry, 1999, Wang et al., 2001).

Several studies have suggested that oxLDL stimulates macrophage inflammatory responses through elicitation of TLR-Nfκb signaling (Curtiss et al., 2012, Febbraio et al., 2000, Janabi et al., 2000, Michelsen et al., 2004, Mullick et al., 2005, Stewart et al., 2010). Additionally, ACAT inhibition leading to FC-loading of macrophages is thought to activate the ER-stress-Nκb cascade, resulting in the stimulation of TNFα and IL-6 expression (Li et al., 2005). However, recent reports have provided contrary evidence to both of these paradigms (Anderson et al., 2012, Kannan et al., 2012, Qiu et al., 2007). oxLDL not only reduces monocyte and macrophage basal expression of TNFα and IL-6, but it also inhibits LPS-stimulated expression of both these cytokines (Kannan et al., 2012, Qiu et al., 2007). Furthermore, lipotoxicity-induced inflammation can occur in the absence of ER-stress (Anderson et al., 2012). The findings reported here are in support of these latter studies. In our hands, oxLDL-treated macrophages displayed attenuated expression of TNFα and IL-6, which was unaffected by treatment with the PPARδ agonists. Furthermore, inhibition of ACAT activity to significantly increase FC accumulation, did not induce a pro-inflammatory phenotype in oxLDL-treated macrophages. Collectively, the present study is consistent with the concept that macrophages loaded with cholesterol are anti-inflammatory (Spann et al., 2012, Suzuki et al., 2012), rather than proinflammatory, and that PPARδ agonists are incapable of further suppression.

Cholesterol-loaded mouse peritoneal macrophages display significant accumulation of desmosterol, a known potent activator of LXR (Spann et al., 2012). It is well characterized that activation of LXR is anti-inflammatory, as liganded LXR recruits corepressor complexes to promoter regions of proinflammatory genes (Im and Osborne, 2011). This recruitment event results in protein-protein interactions between Nfκb and
the LXR-bound corepressors, which prevents Nfκb from stimulating transcription of proinflammatory cytokines (Im and Osborne, 2011). PPARγ activation exerts anti-inflammatory effects through a similar mechanism (Straus and Glass, 2007). Whether oxLDL-treatment increases corepressor occupancy of the TNFα and IL-6 promoters in THP-1 macrophages remains to be determined. Nevertheless, our studies support the concept that desmosterol accumulation within macrophages is associated with suppression of pro-inflammatory gene expression (Spann et al., 2012).

Given that oxLDL stimulated the expression of the PPARδ-specific target gene ADFP, it is tempting to hypothesize that PPARδ ligands accumulate in response to cholesterol loading. Fatty acids are known to activate PPARδ (Chawla et al., 2003). In cholesterol-loaded or desmosterol-treated mouse peritoneal macrophages, Spann et al. observed increases in cellular oleic acid in the picomolar range (Spann et al., 2012). In the micromolar range, oleic acid induces macrophage inflammatory responses (Chapter 2). However, picomolar concentrations of oleic acid may be sufficient to activate PPARδ but insufficient to stimulate the inflammatory response. The possibility that PPARδ activation plays a role in the oxLDL-mediated anti-inflammatory response of macrophages requires further study.

In summary, oxLDL-induced foam cell formation is attenuated by PPARδ activation, supporting the use of synthetic PPARδ agonists as a macrophage-targeted therapeutic strategy in the treatment of atherosclerosis. Furthermore, our studies suggest that macrophages of the arterial intima are not proinflammatory in response to cholesterol loading, per se. Rather we support the shift in paradigm that under conditions of high plasma LDL, immune cells of the arterial intima, such as dendritic cells (Becker et al., 2012), are the inflammatory effectors that secrete extrinsic factors to promote proinflammatory macrophage activation (Spann et al., 2012).
3.5 REFERENCES


4.1 INTRODUCTION

The principal cause of mortality in type 2 diabetic patients is atherosclerosis (Grundy et al., 2002, Libby et al., 2009), a chronic inflammatory disease that is the primary precursor underlying most cardiovascular events (Tabas et al., 2007). Although the molecular and pathophysiological links between type 2 diabetes and atherosclerosis are not fully understood, a crucial factor is likely insulin resistance (DeFronzo, 2010, Rewers et al., 2004). This is in part due to promotion of multiple independent risk factors associated with cardiovascular disease including obesity, hypertension and dyslipidemia (DeFronzo, 2010, Ginsberg, 2000). Atherogenic dyslipidemia associated with insulin resistance is characterized by increased plasma concentrations of triglyceride (TG)-rich very low-density lipoprotein (VLDL) and cholesteryl ester (CE)-rich LDL, both of which can permeate a compromised endothelium and initiate atherogenesis (Ginsberg, 2000, Tabas et al., 2010). Therapeutic strategies to reduce plasma LDL have proven effective in reducing cardiovascular events (Kearney et al., 2008). However, a significant unmet medical need persists in cardioprotective therapy, making VLDL-lowering strategies an attractive therapeutic target.

Subendothelial retention of atherogenic lipoproteins leads to a series of maladaptive immune responses, culminating in the development of macrophage foam cells (Tabas et al., 2010, Tabas et al., 2007). Macrophages of the arterial intima also play a critical role in the evolution of fatty streaks towards progression of complex lesions. In particular, M1 macrophages secrete inflammatory effector cytokines such as
interleukin (IL)-1β and tumor necrosis factor alpha (TNFα), driven predominantly by MAPK and NF-κB signaling (Moore and Tabas, 2011, Stollenwerk et al., 2005). However, insulin signaling, namely the Akt/forkhead box O1 (FoxO1) pathway, may also play an important role in atherogenic inflammation (Tabas et al., 2010). In vitro, Il-1β is a FoxO1 target gene in macrophages with fatty acid-induced insulin resistance (Su et al., 2009). Although not consistent across all experimental models, a growing body of evidence suggests that in vivo, arterial insulin resistance directly promotes atherosclerosis (Tabas et al., 2010). In fat-fed apolipoprotein E knockout mice (apoE−/−) mice, insulin receptor (IR) deletion (Insr−/−) in myeloid cells decreased lesion size (Baumgartl et al., 2006). In contrast, global loss of the major insulin signaling mediator Akt1 in apoE−/− mice resulted in accelerated coronary artery disease and aortic atherosclerosis, concomitant with significant aortic inflammation (Fernandez-Hernando et al., 2007). Hematopoietic deletion of the insulin receptor in LDL receptor knockout (Ldlr−/−) mice significantly increased atherosclerosis, an effect attributed to impaired macrophage Akt signaling (Han et al., 2006). Furthermore, increased areas of apoptotic macrophages and necrotic core have been visualized in atherosclerotic lesions from patients with type 2 diabetes (Burke et al., 2004). Collectively, these studies highlight that arterial insulin resistance and inflammation may amplify atherogenesis.

Peroxisome proliferator-activated receptors (PPARs) are a class of ligand-dependant transcription factors involved in regulation of metabolic and inflammatory signaling (Wahli and Michalik, 2012). Three isoforms exist (α,γ,δ) which exhibit overlapping but distinct patterns of tissue distribution and function (Evans et al., 2004). Although PPARδ has been considered the most enigmatic of the PPARs, this receptor has emerged as an important regulator of cellular lipid homeostasis and the inflammatory response (Barish et al., 2006). In cultured macrophages, PPARδ inhibits
both macrophage lipid accumulation and pro-inflammatory cytokine expression in response to human VLDL (Chapter 2). Furthermore, TG accumulation was decreased via inhibition of extracellular lipolytic activity through angiopoietin-like (ANGPTL) 4-mediated inhibition of lipoprotein lipase (LPL) and enhanced carnitine palmitoyltransferase (CPT) 1α-stimulated fatty acid β-oxidation, whereas attenuated cytokine expression was mediated through both inhibition of ERK1/2 and activation of Akt/FoxO1 signaling (Chapter 2). In vivo, Lee et al. demonstrated that macrophage deletion of Pparδ in Ldlr−/− mice paradoxically suppressed atherogenesis, attributed to the suppression of atherogenic inflammation by liberation of the inflammatory repressor protein BCL-6, as BCL-6 is normally sequestered by the PPARδ/RXR co-repressor complex (Lee et al., 2003). These studies elegantly highlighted that deletion of Pparδ mimicked the liganded state of the receptor, suggesting that ligand-activation may be atheroprotective. However, the studies that have examined the effects of synthetic PPARδ agonists using prevention protocols in mouse models of atherosclerosis have produced a spectrum of results (Barish et al., 2008, Graham et al., 2005, Li et al., 2004). In the first study, administration of the PPARδ agonist GW0742 to male Ldlr−/− mice on a high-fat, high cholesterol diet for 14 weeks had no effect on lesion size (Li et al., 2004). In a second study, 16 weeks of treatment with GW0742 reduced lesion development in female Ldlr−/− mice (Graham et al., 2005), however, the doses used yielded serum drug levels 2-fold higher than the reported EC50 values for murine PPARα and PPARγ (Barish et al., 2008), raising the possibility that the atheroprotective effects of GW0742 were not PPARδ-specific. In Ldlr−/− mice fed a high-fat diet, low doses of GW0742, prevented the development of angiotensin II-accelerated atherosclerosis (Takata et al., 2008). Barish et al. reported that a next generation PPARδ agonist (GW1516) at PPARδ-specific doses, prevented the development of atherosclerosis in apoE−/− mice fed a high-fat diet,
concomitant with reduced aortic inflammatory cytokine expression (Barish et al., 2008). Although on balance these studies indicate that PPARδ-specific agonists prevent the development of atherosclerosis and arterial inflammation, it is unknown whether PPARδ agonists are atheroprotective in an intervention model with pre-established insulin resistance. Furthermore, the impact of PPARδ activation on lesion pathology, as well as aortic inflammatory signaling cascades, insulin resistance and ER-stress has not been examined.

In the present study we use C57BL/6J Ldlr⁻/⁻ mice fed a high-fat, cholesterol containing (HFHC) diet, a model of diet-induced dyslipidemia and insulin resistance. We demonstrate that following an induction phase, intervention with the addition of the PPARδ-specific agonist GW1516 to the HFHC diet resulted in regression of metabolic dysregulation including reduced plasma lipids, glucose and insulin, and improved glucose and insulin tolerance. Intervention with GW1516 inhibited aortic MAPK and NF-κB signaling, attenuated aortic inflammation, improved indices of aortic insulin signaling, reduced aortic ER-stress, and collectively attenuated the progression of pre-established atherosclerosis.
4.2 MATERIALS AND METHODS

4.2.1 ANIMALS AND DIETS

Male \textit{Ldlr}^{-/-} mice on the C57BL/6 background were obtained from the Jackson Laboratory and housed in pairs in standard cages at 23\(^\circ\)C. The animals were cared for in accordance with the Canadian Guide for the Care and Use of Laboratory Animals, and all experimental procedures were approved by the Animal Care Committee at the University of Western Ontario. Mice 10-12 weeks of age were fed \textit{ad libitum}, a purified rodent chow diet (14\% of calories from fat, Harlan Teklad TD8604, Madison WI) for 12 weeks. Another group of mice were fed a high-fat cholesterol-containing western diet (HFHC - 42\% of calories from fat, 0.2\% cholesterol, Harlan Teklad TD09268) for 4 weeks, followed by segregation of half of these mice to intervention to the HFHC with 3mg/kg/day GW1516 (Enzo Life Sciences, Ann Arbor, MI) for an additional 8 weeks. In previously published reports, this dose administered by oral gavage rendered a plasma concentration of GW1516 that was more selective for PPAR\(\delta\) over PPAR\(\alpha\) or PPAR\(\gamma\) by >1,000-fold (Barish et al., 2008, Barroso et al., 2011, Narkar et al., 2008). Animals were fasted for 4h prior to analyses or sacrifice. For fasting/re-feeding studies, animals were either fasted for 16h prior to sacrifice or fasted for 16h followed by 2h of acute re-feeding of experimental diets prior to sacrifice (Lu et al., 2012). Blood samples were obtained and the heart and aorta were excised as previously described (Covey et al., 2003, Mulvihill et al., 2009, Mulvihill et al., 2010).

4.2.2 PLASMA LIPID, BLOOD GLUCOSE AND PLASMA INSULIN DETERMINATIONS

Plasma TG, total cholesterol (TC), non-esterified fatty acids (NEFA), and blood glucose were determined as previously described (Mulvihill et al., 2009). Plasma insulin concentrations were determined by ELISA (Alpco Diagnostics, Salem, NH) on EDTA-
plasma as per manufacturer’s instructions. Fast Performance Liquid Chromatography (FPLC) was performed on unfrozen EDTA-plasma using an AKTA purifier and Superose 6 column (Mulvihill et al., 2009).

4.2.3 GLUCOSE TOLERANCE AND INSULIN TOLERANCE

A glucose tolerance test (GTT) was performed following i.p. injection with 15% glucose in 0.9% NaCl (1 g/kg of body weight). Blood for glucose measurements (Ascensia Elite glucometer, Bayer Healthcare, Toronto, Canada) was taken up to 120 min post-injection. Insulin tolerance test (ITT) was conducted by i.p. injection with 0.6 IU/kg Novolin ge Toronto (Novo Nordisk, Cooksville, ON). Blood for glucose measurements was obtained up to 60 min post-injection. Insulin sensitivity and glucose utilization were calculated based on the area under the curve (AUC).

4.2.4 TISSUE HISTOLOGY AND IMMUNOHISTOCHEMISTRY

Histological and morphometric analyses were performed as described previously (Mulvihill et al., 2010). Briefly, at sacrifice, hearts were mounted in OCT and frozen. For quantitation of lesion area in the aortic sinus, oil red-O-stained sections were measured. Frozen serial sections (70-100 per heart, 10μm) of the aortic sinus, initiating at the origin of the aortic valves, were prepared using a Leica CM 3050S cryostat. Slides were stained with modified Verhoff’s and Masson’s trichrome at the Robarts Research Institute Molecular Pathology Core facility. Immunohistochemistry staining for macrophages by MOMA-2 (Accurate Chemical and Scientific Corporation #MCA519G, Westbury, NY) and smooth muscle α-actin (monoclonal anti-α-smooth muscle actin, Clone 1AH, Sigma) was performed. Briefly, slides were fixed in acetone and blocked in 2% bovine serum albumin. After incubation with primary antibody, a goat biotinylated secondary antibody was used. Slides were then incubated in peroxidase blocking reagent, followed by incubation with the ABC reagent (ABC Elite Standard Kit, Vector
Laboratories, Burlington, ON). Slides were then exposed to the DAB substrate (Peroxidase substrate kit, Vector Laboratories) followed by counterstain in hematoxylin and mounting in xylene. Photomicrographs were obtained using an Olympus BX50 microscope and a QImaging Retiga EXi FAST camera. In the aortic sinus, lesion area of four serial sections (100μm apart) were quantified using Axiovision computer software. Morphometric analysis of plaques in mice from each dietary group was also performed on serial sections. The relative area of the atherosclerotic plaque positive for MOMA-2, collagen or smooth muscle α-actin staining was determined as the area of positive staining divided by the area of the respective plaque. Quantitation was determined using Axiovision software. To ensure that a standard region was measured in each mouse, lesion analysis began at the origin of the aortic valves.

4.2.5 IMMUNOBLOTTING AND DENSITOMETRY

Total cell lysates were isolated from full-length aortae of mice as previously described (Beyea et al., 2007, Rowe et al., 2003). Proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted (Rowe et al., 2003). Lysates were probed using antibodies against mouse phospho and total Akt, FoxO1, ERK1/2, p38, IKKα, and IκBα, as well as GRP78, CHOP, SHP-1 and β-actin (Cell Signaling, Danvers, MA). Protein levels were determined by densitometry as described (Beyea et al., 2007, Rowe et al., 2003).

4.2.6 QUANTITATIVE REAL-TIME PCR GENE ABUNDANCE ANALYSIS

Total RNA was isolated from full-length aortae of mice via standard TRIzol® reagent (Life Technologies, Burlington, ON) as per manufacturer’s instructions. Specific mRNA abundances (Ccl3, Il1b, Icam1, Tnf, Il6, Ccl2, Arg1, iNos, Ptpn6, Trib3, Adfp, Angptl4, Cpt1a, Acox, Lpl, Rgs4, Rgs5, and Gapdh) were measured via quantitative real-time PCR (qRT-PCR) using an ABI Prism (7900HT) Sequence Detection System.
(Applied Biosystems, Foster City, CA) as previously described (Beyea et al., 2012, Mulvihill et al., 2009).

### 4.2.7 STATISTICAL ANALYSES

Data are expressed as means +/- SEM. One-way ANOVA followed by the Bonferroni test was used to determine significant differences between two groups. One-way ANOVA followed by pair-wise comparisons by the Tukey’s test was used to determine differences between three or more groups. For fasting/re-feeding experiments, two-way ANOVA followed by pair-wise comparisons by the Tukey's test was used to determine differences and interactions between diet groups and fasted/re-fed state. Significance thresholds were $P$ values less than 0.05 and indicated by different upper case or lower case letters as well as asterisks as indicated in the figure legends.
4.3 RESULTS

4.3.1 GW1516 IMPROVES HFHC-INDUCED METABOLIC DYSREGULATION IN LDLR⁻/⁻ MICE

Male C57BL/6 Ldlr⁻/⁻ mice were administered a Western diet with 0.2% cholesterol (HFHC diet) for 4 weeks. The metabolic effects of intervention with the PPARδ agonist GW1516 were evaluated following an additional 8 weeks (Figure 4.1A). Addition of GW1516 to the HFHC diet significantly attenuated HFHC-induced weight gain without affecting caloric intake (Figure 4.2A,B). GW1516 decreased fasting plasma cholesterol, TG and NEFAs compared to 4-week baseline levels, whereas the dyslipidemia of animals remaining on the HFHC diet alone continued to progress (Figure 4.1B). FPLC analyses demonstrated that reduced fasting plasma cholesterol in GW1516-treated mice, was due to a significant reduction in the VLDL-C fraction and a modest but not statistically significant reduction in LDL-C (Figure 4.1C). GW1516 increased HDL-C by 35% (Figure 4.1C). Furthermore, the GW1516-mediated reduction in plasma TG levels was due to a substantial 63% reduction in VLDL-TG (Figure 4.1D). GW1516 intervention decreased epididymal fat mass by 11% compared to 4-week baseline, and by 35% compared to mice remaining on the HFHC diet alone (Figure 4.2C) thus contributing to the attenuation in the rate of weight gain.

GW1516-intervention maintained blood glucose and significantly decreased plasma insulin compared to levels in HFHC-fed mice at 4-weeks. Relative to mice remaining on the HFHC diet, GW1516 intervention completely prevented the significant increase in fasting blood glucose and markedly attenuated the induction of fasting hyperinsulinemia (Figure 4.3A,B). In addition, GW1516 intervention improved whole body insulin sensitivity, as evidenced by improved glucose and insulin tolerance tests (Figure 4.3 C,D).
Figure 4.1: GW1516 regresses diet-induced dyslipidemia.

Ldlr<sup>-/-</sup> mice were fed standard chow, or a high-fat, high-cholesterol diet (HFHC) for 4 weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the HFHC-fed mice either remained on HFHC alone or HFHC supplemented with GW501516 (GW1516) (3mg/kg/day). A, Experimental timeline for all studies performed. B, Plasma cholesterol, triglyceride, and non-esterified fatty acid (NEFA) concentrations were measured at week 0, 4 and 12 (8-12/group). C and D, Plasma was subjected to FPLC analysis at week 12, and cholesterol and triglyceride were measured in the eluted fractions (n=3-5/group). Arrows indicate time of GW1516 intervention. Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05). * indicates significant difference versus HFHC at the end of the study; ANOVA with post hoc Bonferroni’s test (P<0.05).
Figure 4.2: GW1516-treatment attenuates rate of body weight gain and epididymal fat mass. Ldlr/- mice were fed a standard lab chow, or a high-fat, high-cholesterol diet (HFHC) for 4 weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the HFHC-fed mice either remained on HFHC alone or HFHC supplemented with GW501516 (GW1516) (3mg/kg/day). **A,** Body weight. Arrow indicates time of GW1516 intervention. **B,** Caloric intake expressed as kcal per gram body weight per day of study. **C,** Epididymal fat mass in grams. Data is presented as mean +/- SEM (n=8-12/group). Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test ($P<0.05$).
Figure 4.3: GW1516 improves diet-induced dysregulation of metabolic indices.

\textit{Ldlr}\textsuperscript{-/-} mice were fed standard chow, or a high-fat, high-cholesterol diet (HFHC) for 4 weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the HFHC-fed mice either remained on HFHC alone or HFHC supplemented with GW501516 (GW1516) (3mg/kg/day). \textbf{A}, Fasting blood glucose levels. \textbf{B}, Fasting plasma insulin concentrations. \textbf{C}, Intraperitoneal glucose tolerance test at 12 weeks. \textbf{Inset graph}, absolute area under the curve (glucose mmol/Lx120min). \textbf{D}, Intraperitoneal insulin tolerance test at 12 weeks. \textbf{Inset graph}, absolute AUC (glucose mmol/Lx60min). Data is presented as mean +/- SEM (n=8-12/group). Different letters indicate significant differences; $P<0.05$. 


4.3.2 GW1516 ATTENUATES AORTIC SINUS ATHEROSCLEROSIS AND AORTIC INFLAMMATION IN HFHC-FED LDLR−/− MICE

Examination of aortic sinus atherosclerosis revealed that oil red-O stained lesion area of HFHC-fed mice at 4 weeks progressed significantly (~6-fold) over the subsequent 8 weeks (Figure 4.4). In contrast, although lesion area continued to increase, the area was significantly attenuated in the GW1516-intervention cohort by ~33% compared to animals remaining on the HFHC diet alone (Figure 4.4). Dietary GW1516 influenced lesion composition. As a percent of total area, lesions of HFHC-fed animals for either 4- or 12-weeks displayed infiltration of MOMA-2-positive macrophages, which was significantly attenuated by intervention with GW1516 (Figure 4.4). No appreciable smooth muscle cell (SMC) infiltration or collagen deposition was observed in lesions of HFHC-fed mice at 4 weeks (Figure 4.4). However, smooth muscle α-actin occupied 40% of lesion area in HFHC-mice at 12 weeks, which was similar to that of GW1516-intervention mice. On the other hand, 12 weeks of the HFHC diet resulted in collagen deposition comprising 25% of lesion area, which was further increased (to 35%) in GW1516 intervention mice, despite no further effect on percent lesion SMC content (Figure 4.4). Lipid analyses of full-length aortae from HFHC-fed mice at 12 weeks revealed that aortic TG and TC mass increased 1.4-fold and 1.6-fold, compared to HFHC-mice at 4 weeks (Figure 4.5A,B). GW1516 supplementation decreased aortic TG by 60% compared to the 12-week HFHC-fed cohort, and by 40% compared to the 4-week HFHC-fed mice. GW1516 supplementation decreased aortic TC by 27% compared to HFHC-mice at 12 weeks, but values remained elevated (30%) compared to HFHC-mice at 4 weeks. Collectively, these analyses indicate that intervention to the HFHC diet with GW1516, results in the attenuation of lesion progression and the development of smaller, more stable atherosclerotic lesions.
**Figure 4.4: GW1516 attenuates HFHC-induced atherosclerosis.**

A, Representative examples are given for oil red-O and Hematoxylin, MOMA-2, SM α-actin and Trichrome stained aortic sinus sections. B, Quantitation of Oil-red-O, MOMA-2, collagen and SM α-actin stained areas expressed as lesion area or % of lesion area (n=6-9/group). SM α-actin and collagen were undetectable in 4-week baseline aortic sinus sections. Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey's test (P<0.05).
Figure 4.5: GW1516 attenuates lipid accumulation, M1 macrophage markers and induces a shift towards M2 macrophage markers in full length aortae.

A, Triglyceride (TG) and (B) cholesterol (TC) concentrations were determined in aortic extracts (n=5-7/group). C, mRNA abundance of the indicated proinflammatory M1 cytokines and (D) the anti-inflammatory M2 cytokine Arg1 and the Arg1/iNos ratio, determined in full length aortae dissected free of fat and connective tissue (n=4-6/group). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey's test (P<0.05).
To further assess disease progression, we examined a panel of cytokines known to modulate atherogenesis. In the full length aorta, following 4 weeks of HFHC feeding, only Ccl3 and Icam1 expression were increased compared to chow-fed controls, indicative of monocyte recruitment without overt inflammation (Figure 4.5C). However, expression of pro-inflammatory M1 cytokines, Ccl3, Il1b, Icam1, Tnf, Il6, and Ccl2 were markedly induced (2-to 25-fold) in the aortae of mice fed the HFHC diet for 12 weeks. In contrast, although all cytokines were elevated in GW1516-treated mice compared to HFHC-fed mice at baseline (4 weeks), cytokine expression was significantly lower (-25 to -85%, mean -60%) compared to HFHC-fed mice at 12 weeks (Figure 4.5C). Although lesion MOMA-2 stained macrophages decreased ~25% in GW1516-treated mice, the greater reduction in cytokine expression suggests that macrophages remaining in lesions of the intervention mice were less inflammatory. Furthermore, 12 week HFHC feeding significantly increased aortic expression of the M1 marker iNos and suppressed aortic expression of the anti-inflammatory M2 marker Arg1, resulting in a greatly exacerbated iNos/Arg1 ratio, compared to HFHC-fed mice at 4 weeks (Figure 4.5C,D). GW1516 intervention completely reversed this expression pattern. Together, these data suggest that although lesion macrophage content is lower (Figure 4.4), there is a shift from M1 to M2 cytokine expression in aortae from PPARδ-agonist treated mice.

We examined the cell signaling cascades known to regulate the macrophage inflammatory response (Moore and Tabas, 2011, Stollenwerk et al., 2005). Significant activation of MAP kinases ERK1/2 and p38 was observed in full-length aortae of HFHC-fed mice at 12 weeks, compared to chow-fed controls (Figure 4.6A). In addition, we observed a marked induction of NF-κB activation in HFHC-mice at 12 weeks, as demonstrated by increased phospho-IKK and phospho-IkBα (Figure 4.6B). In contrast, intervention with GW1516 abrogated HFHC-induced activation of both MAPK and NF-κB.
Figure 4.6: GW1516 corrects aberrant MAPK and NF-κB signaling in full-length aortae of HFHC-fed mice.

A, Immunoblots of MAPK signaling markers including pERK1/2 and p-p38 and (B) NF-κB signaling markers pIκK and IκBα in full length aortae dissected free of fat and connective tissue. Representative immunoblots of aortic lysates from two mice from each treatment group with quantitations of 4-6 mice/group are shown. Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (\( P<0.05 \)). Representative bands are from the same immunoblot, cut from different regions due to loading of multiple replicate lanes.
These results suggest that PPARδ activation diminishes aortic inflammation, in part, by attenuating diet-induced inflammatory signaling.

**4.3.3 GW1516-INTERVENTION CORRECTS DIET-INDUCED AORTIC INSULIN SIGNALING AND ER-STRESS, AND EXERTS PPARδ-SPECIFIC VESSEL WALL EFFECTS**

Genetic manipulations resulting in impaired insulin signaling in hematopoietic cells exacerbate atherosclerosis, due in part to increased aortic inflammation and ER-stress (Fernandez-Hernando et al., 2007, Han et al., 2006, Tabas et al., 2010). Given the pro-inflammatory phenotype of aortae isolated from insulin-resistant HFHC-fed mice, we hypothesized that this was mediated in part by impaired aortic insulin signaling. To test this, we examined aortic phospho-Akt and phospho-FoxO1 in fasted and acutely re-fed mice at the end of the 8-week intervention phase. Compared to chow-fed mice, Akt and FoxO1 phosphorylation was higher in the aortae excised from fasted HFHC-fed mice, and not further increased in response to re-feeding (Figure 4.7A). In contrast, GW1516-intervention restored the fasting-to-feeding dynamic regulation of Akt and FoxO1 phosphorylation to chow-fed controls (Figure 4.7A). The Src homology 2 domain-containing phosphatase (SHP)-1 is a protein tyrosine phosphatase (PTP) primarily expressed by hematopoietic cells, and is a known negative regulator of hepatic insulin signaling (Dubois et al., 2006). We observed that aortae excised from HFHC-fed mice at 12 weeks were significantly enriched for the SHP-1 transcript (Ptpn6) and SHP-1 protein, 5- and 30-fold, respectively, both of which were strongly attenuated by intervention with GW1516 (Figure 4.7B,C).

Coupled to dysregulated aortic insulin signaling was a significant increase in ER-stress markers GRP78 and CHOP (Figure 4.7D). The known CHOP-target gene and negative regulator of insulin signaling, Trib3 (Du et al., 2003), was elevated in aortae of
Figure 4.7: GW1516 corrects aberrant insulin signaling, the UPR and ER-stress in aortae of HFHC-fed mice.

Western blotting or qRT-PCR were performed on full length aortae dissected free of fat and connective tissue. A, Immunoblots of insulin signaling proteins phosphorylated (p) AKT and pFoxO1 in aortae excised from mice fasted for 16h (designated F) and fasted for 16h followed by a 2h re-feeding period (designated RF) (n=6-8/group). B, mRNA abundance of negative regulator of insulin signaling Ptpn6 (n=4-6/group). C, Immunoblots of SHP-1 (the protein product of Ptpn6) (n=4-6/group). D, ER-stress markers GRP78 and CHOP (n=4-6/group). E, mRNA abundance of negative regulator of insulin signaling Trib3 (n=4-6/group). Data is presented as mean +/- SEM. Representative immunoblots with quantitations shown. For A, different upper case letters indicate statistical significance among fasted animals, different lower case letters indicate statistical significance among re-fed animals, and asterisk (*) indicates statistical significance between fasted and re-fed within the same diet (P<0.05); two-way ANOVA with post-hoc Tukey’s test (P<0.05). For B-E different letters indicate significant differences; one-way ANOVA with post-hoc Tukey’s test (P<0.05). Representative bands are from the same immunoblot, cut from different regions due to loading of multiple replicate lanes.
HFHC-fed 12 week mice (Figure 4.7E). GW1516 intervention attenuated GRP78, CHOP and Trib3 to levels observed in 12-week chow-fed controls (Figure 4.7D,E).

To determine whether GW1516 exerted effects directly at the level of the aorta, we examined aortic expression of known PPARδ target genes. Expression of Adfp, Angptl4 and Cpt1a was significantly increased in aortae of GW1516-treated mice compared to HFHC-fed mice or chow-fed controls at 12 weeks (Figure 4.8A). Expression of the PPARα- and PPARγ-specific target genes (Acox and Lpl, respectively) were unaffected by GW1516-treatment (Figure 4.8B). Similar results were observed in liver (Chapter 5, Figure 5.1). These results suggest that GW1516 exerts a direct effect on the arterial wall, which likely contributes to the attenuation of inflammation, insulin resistance, ER-stress and diet-induced lesion progression. These results further indicate that with respect to PPARs, the aortic effects of GW1516 are PPARδ-specific.
Figure 4.8: GW1516 activates aortic PPARδ but not PPARα or PPARγ.

A, mRNA abundance of PPARδ-target genes Adfp, Angtp14 and Cpt1a and B, PPARα- and PPARγ-target genes Acox and Lpl, respectively in full length aortae dissected free of fat and connective tissue (n=4-6/group). Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).
4.4 DISCUSSION

Risk of atherosclerotic cardiovascular disease is elevated up to 4-fold in adults with type 2 diabetes (Fox et al., 2007, Fox et al., 2004). Despite this, therapeutic strategies to alleviate atherosclerosis associated with insulin resistant syndromes have remained sparse. Reports have speculated that PPARδ agonists may confer atheroprotection in settings of insulin resistance (Coll et al., 2010). The present study is the first to demonstrate that intervention with a synthetic PPARδ agonist in the context of diet-induced dyslipidemia and insulin resistance attenuates progression of early stage lesions to more complex lesions. Furthermore, we show that in HFHC-fed mice, the inflammatory response and insulin signaling within the aorta are impaired, which are completely reversed by PPARδ activation.

Atherogenic dyslipidemia in the setting of insulin resistance is characterized by elevated plasma VLDL and LDL, concomitant with reduced plasma HDL (Ginsberg, 2000, Grundy, 2004). Statins are the current standard of therapy and effectively lower plasma LDL concentrations, reducing the relative risk of cardiovascular disease by ~30% (Bays et al., 2011, Kearney et al., 2008). However, statins do not fully correct other features of atherosclerosis risk, namely elevated plasma VLDL, decreased HDL, insulin resistance, and body fat composition, resulting in a substantial unmet therapeutic need (Sattar et al., 2010). The present study demonstrates that intervention with a synthetic PPARδ agonist to a HFHC diet corrects previously established metabolic disturbances. Although plasma LDL was modestly reduced, our results suggest that PPARδ activation primarily targets plasma VLDL and HDL. This is consistent with recent human studies demonstrating that synthetic PPARδ agonists correct mixed dyslipidemia in patients with the metabolic syndrome (Bays et al., 2011, Ooi et al., 2011). The present study
contributes to the plausibility of PPARδ agonists as therapeutic agents for metabolic dysregulation associated with insulin resistance.

We recently demonstrated in cultured macrophages that PPARδ activation attenuates VLDL-induced triglyceride accumulation and pro-inflammatory cytokine expression (Chapter 2). We extend these in vitro findings, demonstrating that intervention with GW1516-treatment induces regression of aortic TG content associated with significant induction of the PPARδ-target genes Angptl4 and Cpt1a. These results suggest that GW1516 may stimulate aortic fatty acid β-oxidation and inhibit aortic lipoprotein lipase activity, thus contributing to reduced atherogenesis. We provide evidence that inflammatory cells within the aortae of HFHC-fed animals were polarized to the classically activated pro-inflammatory M1 phenotype (Goerdt et al., 1999, Mills et al., 2000). Furthermore, intervention with GW1516 resulted in polarization towards the anti-inflammatory M2 state (Gordon, 2003), consistent with reports demonstrating that alternative M2 activation of adipose tissue macrophages and hepatic Kupffer cells is, in part, mediated by PPARδ (Kang et al., 2008, Odegaard et al., 2008). M2 macrophages are thought to contribute to tissue remodelling and repair (Gordon, 2003), and are increased in lesions undergoing regression (Feig et al., 2011). Although GW1516 did not induce regression of early lesions, the M2 phenotype was associated with significant slowing of lesion progression. Longer-term studies would be required to assess whether PPARδ agonists can induce regression of more complex lesions. Nevertheless, the present study demonstrates the ability of PPARδ activation to alleviate aortic lipid accumulation and inflammation, thus contributing to attenuated lesion development.

That GW1516 increased lesion collagen deposition without altering lesion SMC content is possibly due to PPARδ activation having a direct effect on plaque SMCs, enhancing their capacity to synthesize and deposit extracellular matrix. This hypothesis
is consistent with a report that PPARδ activation in cultured vascular (v) SMCs inhibits IL-1β-induced matrix metalloproteinase (MMP)-2 and MMP-9 expression (Kim et al., 2010). Although reduced lipid deposition in VSMCs restores their capacity to synthesize extracellular matrix (Beyea et al., 2012, Frontini et al., 2009), the ability of PPARδ agonists to improve VSMC function in response to a lipid load requires further study.

The MAPK and NF-κB signaling pathways are critical regulators of inflammatory cytokine expression (Moore and Tabas, 2011, Stollenwerk et al., 2005). In the aortae of HFHC-fed animals, we observed marked activation of both of these cascades. Intervention with GW1516 almost completely normalized both MAPK and NF-κB activation. In cardiac myocytes, the PPARδ agonist GW0742 has been shown to attenuate lipopolysaccharide–induced NF-κB activation through increased IκB expression, thereby inhibiting nuclear translocation of NF-κB (Ding et al., 2006). We did not observe any appreciable changes in total aortic IκB protein. Thus, the mechanism by which PPARδ inhibits NF-κB activation in the context of aortic inflammation remains to be determined. With respect to MAPK activation, GW0742 inhibited angiotensin II-induced phosphorylation of ERK1/2 and p38 in mouse macrophages, via upregulation of Rgs4 and Rgs5 (Takata et al., 2008). Consistent with this report, we observed a significant upregulation of both Rgs4 and Rgs5 in aortae of GW1516-treated animals compared to aortae from HFHC-fed mice (Figure 4.9). Taken together, these results suggest that PPARδ activation in the aorta attenuates inflammatory signaling, leading to the attenuation of aortic inflammatory cytokine expression.

Impaired insulin signaling in the vasculature has recently emerged as a major contributor to lesion progression (Tabas et al., 2010). Ldlr<sup>−/−</sup> mice receiving Insr<sup>−/−</sup> bone marrow developed larger more complex lesions, attributed to enhanced ER-stress and apoptosis-induced necrotic core formation (Han et al., 2006). Insulin-resistant
Figure 4.9: GW1516 stimulates aortic expression of regulators of G-protein coupled receptor signaling *Rgs4* and *Rgs5*. *Ldlr*-/− mice were fed a standard lab chow, or a high-fat, high-cholesterol diet (HFHC) for 4 weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the HFHC-fed mice either remained on HFHC alone or HFHC supplemented with GW501516 (GW1516) (3mg/kg/day). Mice were fasted for 4h prior to sacrifice. Analyses were performed on samples of full length aortae dissected free of fat and connective tissue. The indicated cytokines were measured by qRT-PCR. Target genes were normalized to Gapdh. Expression relative to chow depicted for each cytokine as mean +/- SEM (n=4-6/group). Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).
macrophages with cholesterol-induced ER-stress display impaired Akt phosphorylation, increased nuclear FoxO1 activity and enhanced apoptosis (Senokuchi et al., 2008). In addition to macrophages, aberrant insulin signaling in vascular endothelial cells can also play a role in atherogenesis, as deletion of three Foxo isoforms in these cells resulted in atheroprotection, attributed in part to an anti-inflammatory effect (Tsuchiya et al., 2012). Although these proof-of-concept gene-deletion models highlight the significance of vascular insulin signaling in atherogenesis, these studies do not identify whether insulin signaling becomes dysregulated during lesion development (Bornfeldt and Tabas, 2011). Here we demonstrate that mice with diet-induced atherosclerosis exhibit impaired aortic insulin signaling, as evidenced by the loss of dynamic fasting-to-feeding regulation of both Akt and FoxO1 phosphorylation, coupled to a marked induction of negative regulators of insulin signaling, SHP-1 and Trib3 (Du et al., 2003, Dubois et al., 2006). Our data suggests that the loss of insulin regulation of both Akt and FoxO1 results in FoxO1 target genes such as Il1b (Su et al., 2009), to be chronically transcribed, rather than dynamically regulated during states of fasting and re-feeding. We propose that this mechanism contributes to the accumulation of pro-inflammatory mediators in the vessel wall, inducing a state of chronic low-grade inflammation. Moreover, this impairment of aortic insulin signaling is correlated with significant elevations in ER-stress markers CHOP and GRP78. We further demonstrate that activation of PPARδ restores dynamic insulin signaling responses within the aorta and attenuates ER-stress. It is important to note that the presence of arterial insulin resistance did not impair the ability of GW1516 to attenuate pre-established lesion progression. Thus, although difficult to quantify, it remains possible that improved insulin signaling within GW1516-treated aortae contributes to protection from lesion progression.
In this study, a major factor in the attenuation of lesion development by intervention with GW1516 is reduction of plasma lipids, particularly VLDL/IDL, thereby reducing the atherogenic stimulus. However, the data presented here clearly demonstrate that in the aorta, GW1516 stimulates PPARδ-specific target genes, which are known to improve macrophage lipid homeostasis and attenuate the inflammatory response. Although these effects likely contribute to the observed reduction in atherosclerosis, further studies are required to elucidate the extent to which improved metabolic parameters, as compared to direct vessel wall effects contribute to PPARδ-mediated atheroprotection. Nevertheless, the current study provides strong evidence that intervention to a HFHC diet with a PPARδ agonist delays the HFHC diet-induced progression of early lesions. It will be important to determine if intervention by PPARδ activation improves the pathology of more advanced lesions and whether extended treatment is able to achieve regression. We conclude that PPARδ activation remains a viable therapeutic target for atherosclerosis prevention and treatment.
4.5 REFERENCES


**Chapter 5**

**PPARδ-specific activation in liver attenuates triglyceride accumulation via enhanced fatty acid oxidation, reduced fatty acid synthesis and improved insulin sensitivity**

**5.1 INTRODUCTION**

The prevalence of the metabolic syndrome has reached an epidemic proportion which has significantly increased the incidence of type 2 diabetes and atherosclerotic cardiovascular disease (Eckel et al., 2010). It represents a constellation of metabolic abnormalities that include obesity, hypertension, glucose intolerance and a dyslipidemia characterized by low plasma high-density lipoprotein (HDL) and high plasma very low-density lipoprotein (VLDL) (Eckel et al., 2010). Insulin resistance can explain most, if not all of the metabolic syndrome and is defined as the inability of the hormone to maintain blood glucose homeostasis (Eckel et al., 2010, Haas and Biddinger, 2009). During insulin resistance hepatic lipogenesis persists which promotes hepatic steatosis, dyslipidemia and consequently cardiovascular disease risk (DeFronzo, 2010). Despite the prevalence of insulin resistant conditions and their significant morbidity and mortality, few therapeutic strategies exist that effectively correct these metabolic disorders.

Hepatic steatosis, defined as excessive lipid accumulation in the liver, is a major clinical manifestation of insulin resistance observed in greater than 40% of patients with type 2 diabetes (Farese et al., 2012, Williamson et al., 2011). Although a causal relationship between hepatic steatosis and insulin resistance has been difficult to define (Farese et al., 2012), inflammation and endoplasmic reticulum (ER)-stress have been implicated as contributing factors to dysregulated hepatic insulin signaling (Hummasti and Hotamisligil, 2010, Ozcan et al., 2004). As a consequence, hyperinsulinemia-mediated lipogenesis ensues which contributes to ectopic lipid deposition (Brown and

---

*a version of this chapter has been submitted*
Goldstein, 2008). At a molecular level, insulin binding to its cognate receptor leads to receptor-mediated tyrosine phosphorylation of IRS-1 and/or IRS-2, which in turn activates PI3-K to simulate the phosphorylation and activation of Akt (Kido et al., 2001). Normally, the downstream consequences of insulin-stimulated Akt activation include suppression of hepatic gluconeogenesis due to phosphorylation and inactivation of forkhead box (Fox) O1, and promotion of de novo lipogenesis due to phosphorylation and activation of the mammalian target of rapamycin complex (mTORC1) (Li et al., 2010). However, in the insulin resistant liver, Akt loses its ability to effectively inactivate FoxO1, but paradoxically maintains its ability to activate mTORC1 (Li et al., 2010). Consequently, mTORC1-driven transcription of the master regulator of lipogenesis, sterol regulatory element binding protein (SREBP)-1c, remains chronically active. In addition, insulin increases the amount of proteolytically processed active SREBP-1c through mechanisms that remain poorly understood (Yecies et al., 2011). Coupled to hyperinsulinemia, these actions of insulin during hepatic insulin resistance lead to continuous activation of genes required for fatty acid synthesis, thus contributing to excessive hepatic lipid accumulation.

In addition to unregulated lipogenesis, decreased fatty acid oxidation often contributes to exacerbation of lipid content in the insulin resistant liver (Assini et al., 2013, Mulvihill et al., 2009, Mulvihill et al., 2011). The adenosine monophosphate-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase that controls cellular and whole body energy metabolism (Dzamko and Steinberg, 2009, Fullerton et al., 2013). Specifically, hepatic AMPK is a pivotal regulator of fat oxidation and lipogenesis, primarily via direct phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) (Fullerton et al., 2013, Kemp et al., 2003). Biochemically, this reduces malonyl CoA levels in the liver which (1) depletes fatty acid synthase (FAS) of substrate in the lipogenic pathway and (2) results in the de-repression of CPT1α in the
fatty acid oxidation pathway (Carlson and Kim, 1973, Saggerson, 2008). Thus, activation of AMPK represents a potential mechanism for the attenuation of hepatic steatosis.

Peroxisome proliferator-activated receptors (PPARα, γ and δ) are a class of ligand-dependent transcription factors involved in regulation of glucose and lipid homeostasis (Evans et al., 2004). In contrast to PPARα and PPARγ, synthetic agonists for PPARδ have yet to reach the clinical arena, despite a number of studies having highlighted a potential role for this receptor in the treatment of metabolic disease (Reilly and Lee, 2008). In mice, genetic manipulations of Pparδ as well as prevention experiments involving administration of PPARδ agonists have revealed that activation of this receptor attenuates dyslipidemia and hyperglycemia, improves whole-body insulin sensitivity and prevents diet-induced obesity (Lee et al., 2006, Tanaka et al., 2003, Wang et al., 2003).

With respect to PPARδ and hepatic lipid metabolism in mice, there are seemingly conflicting and controversial reports. Supplementation of mice with the PPARδ agonist GW1516 attenuated diet-induced hepatic steatosis; however the 2-fold increase in hepatic Acox expression suggested a PPARα-dependent effect (Nagasawa et al., 2006). Tanaka et al. reported that increased expression of genes involved in hepatic fat oxidation resulted in reduced hepatic TG in high-fat fed mice treated with GW1516 (Tanaka et al., 2003). In db/db mice injected with adenoviral PPARδ (adPPARδ), liver TG content was reduced as a result of decreased SREBP-1c-mediated lipogenesis (Qin et al., 2008). Despite reports suggesting reduced hepatic steatosis, studies also demonstrated that PPARδ activation exerts either no effect (Barroso et al., 2011), or induction of liver TG accumulation (Lee et al., 2006, Liu et al., 2011). In db/db mice, GW1516-treatment resulted in accrual of hepatic TG as a result of direct transcriptional activation of ACCβ, and in turn, enhanced fatty acid synthesis (Lee et al., 2006). adPPARδ gene delivery to Ldlr−/− increased hepatic de novo lipogenesis and hepatic TG
(Liu et al., 2011). Of significance, none of these studies actually measured hepatic fatty acid oxidation.

That PPARδ activation increases hepatic steatosis is counterintuitive since PPARδ agonists are known to improve whole-body insulin sensitivity and lipid homeostasis, and stimulate Cpt1a-mediated fatty acid oxidation in a variety of cell types and tissues (Lee et al., 2006, Tanaka et al., 2003, Wang et al., 2003). Furthermore, in muscle, GW1516 stimulated fatty acid oxidation, in part, through increased AMPK activity (Kramer et al., 2007, Kramer et al., 2005). Additionally, in a model of hepatic steatosis, GW1516 prevented the diet induced inactivation of hepatic AMPK (Barroso et al., 2011). This suggests that AMPK activation by PPARδ agonists has the ability to regulate hepatic β-oxidation and/or fatty acid synthesis.

The objective of this study was to determine whether intervention to a high-fat, cholesterol containing diet (HFHC) with a selective PPARδ agonist can reverse hepatic steatosis. We demonstrate that GW1516 inhibited hepatic lipid deposition, a result of attenuated lipogenesis and increased fatty acid oxidation. Decreased fatty acid synthesis was due to GW1516-mediated correction of selective hepatic insulin resistance. We discovered that AMPK activation was required for the PPARδ-mediated attenuation of de novo lipogenesis, but was not required for PPARδ-mediated induction of fatty acid oxidation. The reduced liver TG content was coupled to attenuated hepatic inflammation and ER-stress.
5.2 MATERIALS AND METHODS

5.2.1 ANIMALS AND DIETS

Male Ldlr^-/- mice on the C57BL/6 background were obtained from the Jackson Laboratory and housed in pairs in standard cages at 23°C. The animals were cared for in accordance with the Canadian Guide for the Care and Use of Laboratory Animals, and all experimental procedures were approved by the Animal Care Committee at the University of Western Ontario. Mice 10-12 weeks of age (n=16) were fed ad libitum, a purified rodent chow diet (14% of calories from fat, Harlan Teklad TD8604, Madison WI) for 12 weeks. Another group of mice (10-12 weeks of age, n=48) were fed a high-fat cholesterol-containing western diet (HFHC - 42% of calories from fat, 0.2% cholesterol, Harlan Teklad TD09268) for 4 weeks. For the subsequent 8 weeks, half of these mice (n=24) remained on the HFHC diet, whereas the other half (n=24) were fed the HFHC diet supplemented with 3mg/kg/day GW1516 (Enzo Life Sciences, Ann Arbor, MI). In previously published reports, this dose administered by oral gavage produced plasma concentrations of GW1516 (106nmol/L) that was >1,000-fold more selective for PPARδ, compared to PPARα or PPARγ (Barish et al., 2008, Barroso et al., 2011, Narkar et al., 2008). Animals were fasted for 4h prior to analyses or sacrifice. For fasting/re-feeding studies, animals were either fasted for 16h prior to sacrifice or fasted for 16h followed by a 2h acute re-feeding period of the experimental diets prior to sacrifice (Lu et al., 2012). Blood samples were obtained as previously described (Mulvihill et al., 2009, Mulvihill et al., 2010).

5.2.2 ACTIVATION OF AMPK IN VIVO

Activation of AMPK in vivo was assessed following intraperitoneal injection of GW1516 or A-769662. Analysis of respiratory exchange ratio (RER) was performed using the Oxymax Columbus Instruments Comprehensive Lab Animal Monitoring System (CLAMS) (Columbus Instruments, Columbus, OH); mice were acclimatized to
the system for 24hr prior to data collection. Animals were fasted overnight (15:00-07:00) to synchronize RER to ~0.7, followed by a period of free access to food (experimental diets) and water at 07:00 for 2hrs to re-synchronize RER to ~1. At 09:00, chow was removed and mice were injected with vehicle (5% dimethyl sulfoxide in phosphate-buffered saline), 3mg/kg GW1516 or 30mg/kg A-769662 (SelleckBio, Houston, TX), a synthetic activator of AMPK (Cool et al., 2006). Metabolic measurements were collected until 15:30. Carbohydrate (4.58*VCO2-3.23*VO2) and fat (1.70*VO2 - 1.69*VCO2) utilization were calculated as previously described (Hawley et al., 2012). Analyses of in vivo phosphorylation of AMPK and ACC were performed in liver samples isolated at sacrifice by freeze-clamp method 90min after injection of the respective treatment and stored at -80°C until analysis as described (Hawley et al., 2012).

5.2.3 ENERGY EXPENDITURE

In the induction/intervention studies, analyses of energy expenditure (EE) and (RER) was performed using the Oxymax Columbus Instruments CLAMS; mice were acclimatized to the system for 24hr prior to a 24hr data collection period.

5.2.4 PRIMARY MOUSE HEPATOCYTE ISOLATION, LIPOGENESIS AND FATTY ACID OXIDATION

Primary mouse hepatocytes were isolated from WT or AMPKβ1-/- C57Bl/6J mice by the collagenase perfusion method as described (Dzamko et al., 2010). Experiments were performed the day following hepatocyte isolation. For mRNA expression analyses hepatocytes were incubated with either vehicle, GW1516 or A-769662 (at the indicated concentrations) for 6hrs prior to lysis in TRIzol® reagent. For lipogenesis and fatty acid oxidation experiments, cells were washed with PBS and incubated in serum-free Medium 199 for 3hrs. Lipogenesis was assessed by incubating cells with serum-free Medium 199 containing [1-14C]acetate (0.5 μCi/ml) (Amersham Biosciences) and 0.5 mM unlabeled sodium acetate. After a 4hr incubation, cells were washed twice with PBS
and harvested by scraping cells into PBS. Lipids were extracted using the Bligh and
Dyer method as described (Steinberg et al., 2006, Watt et al., 2006). For fatty acid
oxidation, cells were incubated for 4hrs with serum-free Medium 199 containing [1-
$^{14}$C]palmitic acid (0.5 μCi/ml) (Amersham Biosciences) and 0.5 mM unlabeled palmitate.
Fatty acid oxidation was determined by measuring labelled CO$_2$ and acid-soluble
metabolites as described (Chen et al., 2005).

5.2.5 PLASMA, BLOOD AND TISSUE ANALYSES

Plasma insulin concentrations were determined by ELISA (Alpco Diagnostics,
Salem, NH) in EDTA-plasma as per manufacturer’s instructions as described previously
(Mulvihill et al., 2011). Blood glucose was determined using an Ascensia Elite
glucometer (Bayer Healthcare, Toronto, Canada) (Mulvihill et al., 2011). Liver lipids were
extracted from 100mg of tissue using the method of Folch et al. and quantitated as
described previously (Assini et al., 2013, Folch et al., 1957). Fatty acid synthesis was
measured following intraperitoneal injection of [1-$^{14}$C]acetic acid as described (Mulvihill
et al., 2009). Hepatic fatty acid oxidation was determined in tissue homogenates of fresh
liver by conversion of [$^3$H]palmitate to $^3$H$_2$O (Mulvihill et al., 2009).

5.2.6 IMMUNOBLOTTING AND DENSITOMETRY

Total cell lysates were isolated from livers or primary mouse hepatocytes of mice
as previously described (Beyea et al., 2007, Rowe et al., 2003). Proteins were separated
by SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted
(Rowe et al., 2003). Lysates were probed using antibodies against mouse phospho and
total Akt, FoxO1, mTORC1, AMPK and ACC as well as GRP78, CHOP and β-actin (Cell
Signaling, Danvers, MA). Quantitation of protein was determined by densitometry as
described (Beyea et al., 2007, Rowe et al., 2003).
5.2.7 QUANTITATIVE REAL-TIME PCR GENE ABUNDANCE ANALYSIS

Total RNA was isolated from livers or primary mouse hepatocytes via TRIzol® reagent (Life Technologies, Burlington, ON) as per manufacturer’s instructions. Specific mRNA abundances (Pgc1a, Ppara, Acox, Cpt1a, Adfp, Srebp1c, Fasn, Pck1, Tnf, Icam1, Il1b, Ccl2, Ccl3, iNos, Arg1 and Gapdh) were measured via quantitative real-time PCR (qRT-PCR) using an ABI Prism (7900HT) Sequence Detection System (Applied Biosystems, Foster City, CA) as previously described (Beyea et al., 2012, Mulvihill et al., 2009). mRNA abundances were calculated using the standard curve method.

5.2.8 STATISTICAL ANALYSES

Data are expressed as means +/- SEM. One-way ANOVA followed by the Bonferroni test was used to determine significant differences between two groups. One-way ANOVA followed by pair-wise comparisons by the Tukey’s test was used to determine differences between three or more groups. For fasting/re-feeding experiments and experiments involving WT or AMPKβ1−/− primary mouse hepatocytes, two-way ANOVA followed by pair-wise comparisons by the Tukey’s test was used to determine statistically significant differences and interactions. Significance thresholds were P values less than 0.05 and marked by different upper case or lower case letters as well as asterisks as indicated in the figure legends.
5.3 RESULTS

5.3.1 GW1516-TREATMENT ATTENUATES HEPATIC TG ACCUMULATION, IN PART, BY STIMULATING FATTY ACID β-OXIDATION

To examine the role of PPARδ activation in hepatic lipid metabolism, male C57BL/6 Ldlr−/− mice were administered a HFHC diet for 4 weeks to induce hepatic steatosis. Subsequently, mice were fed the HFHC diet supplemented with either vehicle or GW1516 (3mg/kg/day) for an additional 8 weeks. In mice fed the HFHC diet, prominent hepatic steatosis developed at the end of the 4-weeks, as evidenced by significantly increased TC, CE and TG (Figure 5.1A). These lipids continued to increase over the subsequent 8 weeks on the HFHC diet. In contrast, the addition of GW1516 to HFHC diet for 8 weeks decreased hepatic lipids by 30-50% demonstrating a significant slowing of steatosis progression (Figure 5.1A).

We reasoned that GW1516 attenuates liver TG accumulation via increased fatty acid (FA) β-oxidation and/or reduced fatty acid synthesis. With respect to FA oxidation, Pgc1a expression was suppressed in livers of mice fed the HFHC-diet for 12 weeks (~20% compared to chow-fed mice), which was not further affected by GW1516-treatment (Figure 5.1B). Furthermore, at 12 weeks, the expression of Ppara and the PPARα-target gene Acox were unaffected by any diet (Figure 5.1C,D). In contrast, Cpt1a mRNA abundance was significantly enhanced (35%) in livers isolated from GW1516-treated animals, which was associated with a 50% increase in FA oxidation as compared to HFHC-fed animals (Figure 5.1E,F). We next examined the expression of the PPARδ-specific target gene Adfp to determine whether hepatic PPARδ was activated in response to GW1516-treatment. Indeed, expression of Adfp was significantly increased (2-fold) in liver from GW1516-treated animals (Figure 5.1G). Collectively, these results suggest that GW1516 attenuates liver TG accumulation partly due to increased hepatic
Figure 5.1: GW1516 attenuates diet-induced hepatic steatosis, in part, via increased fatty acid oxidation.

*Ldlr*−/− mice were fed a high-fat, cholesterol-containing diet (HFHC) for 4 weeks. For a subsequent 8 weeks, mice remained on HFHC alone or supplemented with GW50516 (GW1516) (3mg/kg/day) (n=12/group). A, Hepatic triglyceride (TG), total cholesterol (TC) and cholesteryl ester (CE) mass. Abundance of hepatic *Pgc1a* (B) *Ppara* (C) *Acox* (D) *Cpt1a* (E) and *Adfp* (G) was measured via qRT-PCR and normalized to *Gapdh*. F, Hepatic fatty acid β-oxidation was determined as conversion of [3H]palmitate to [3H]20. Energy expenditure (H) and respiratory exchange ratio (I) (RER=VO2/VCO2) were measured by indirect calorimetry (CLAMS system) during a 24hr period. Measurements were collected every 10 min. Mean of each parameter during the 24hr period shown. Data is presented as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test (*P*<0.05). Asterisk (*) indicates significant different between two groups; student’s paired t-test (*P*<0.05)
FA β-oxidation, which does not involve the activation of PGC1α or PPARα.

To further investigate the increase in hepatic FA oxidation by GW1516-treatment, we assessed energy balance in an animal metabolic monitoring system. Total energy expenditure (EE) was significantly higher (16%) in mice receiving GW1516 compared to mice remaining on the HFHC diet alone (Figure 5.1H). As there was no significant difference in caloric intake between the diet groups (Chapter 4, Figure 4.2B) increased energy expenditure likely contributed to the significant 30% attenuation of body weight gain observed in Chapter 4 (Figure 4.2A). Nevertheless, the respiratory exchange ratio (RER) profiles, which reflect the relative utilization of carbohydrate (RER~1) versus fat (RER~0.7), were similar between the HFHC-fed and GW1516-intervention groups (Figure 5.1I). Given the significant increase in total EE in GW1516-treated mice, the lack of difference in RER profiles suggests that both carbohydrate and fat utilization are increased by PPARδ activation.

5.3.2 AMPK ACTIVATION IS NOT REQUIRED FOR THE GW1516-MEDIATED INCREASE IN FAT OXIDATION

AMPK is a cellular energy sensor that regulates fat oxidation, in part, through phosphorylation of its downstream substrate ACC (O’Neill et al., 2012). Given that PPARδ activation stimulated hepatic FA oxidation in vivo, we hypothesized that AMPK activation may be involved. To evaluate the ability of GW1516 to directly stimulate acute hepatic AMPK activation in vivo, we employed a fasting, feeding, injection and re-fasting protocol (Hawley et al., 2012). In livers isolated 90min after the injection of GW1516, we observed a significant 2-fold increase in phosphorylation of AMPK and ACC (Figure 5.2A). Mice were also injected with the potent synthetic AMPK activator A-769662 (Cool et al., 2006), which increased AMPK and ACC phosphorylation ~2.5-fold (Figure 5.2A).
Figure 5.2: GW1516 increases AMPK and ACC phosphorylation, which is not required for fatty acid oxidation.

Eight to ten week-old Ldlr−/− mice fed a standard laboratory chow were fasted overnight, fed at 0700 for 2hrs and re-fastened at 0900. Intraperitoneal injection of vehicle, GW1516 (3mg/kg) or A-769662 (30mg/kg) (n=6/group) occurred at the beginning of the re-fasting period at 0900. A, Immunoblots of AMPK and ACC in freeze-clamped liver lysates 90-min post-injection. Representative immunoblots with quantitations shown. B-F, Primary hepatocytes isolated from WT and β1+/− mice. Cells were incubated for 1hr with or without GW1516 or A-769662 and lysates were immunoblotted for phosphorylated (p)AMPK and pACC (B). Representative immunoblots with quantitations are shown. C, Isolated hepatocytes were treated with 0.5mM palmitate (0.5μCi/mL [14C]palmitate) for 4hrs with or without GW1516 or A-769662 prior to determination of fatty acid oxidation. In isolated hepatocytes treated with or without GW1516 or A-769662 for 6hrs, mRNA abundances of Cpt1a (D), Adfp (E) and Acox (F) were measured by qRT-PCR and normalized to Gapdh. Data is presented as mean +/- SEM (n=3-4 from at least 3 independent experiments). In (A) asterisk (*) indicates significant difference between vehicle and treatment; student’s paired t-test (P<0.05). In (B) # and † indicate significant difference versus WT control; two-way ANOVA with post-hoc Bonferroni’s test (P<0.05). In (C-F) different upper case letters indicate statistical significance among treatments in WT hepatocytes, different lower case letters indicate statistical significance among treatments in β1+/− hepatocytes, and an asterisk (*) indicates statistical significance between WT and β1+/− within the same treatment group (P<0.05); two-way ANOVA with post-hoc Tukey’s test (P<0.05).
To investigate the requirement of AMPK in the GW1516-mediated stimulation of FA oxidation, we isolated primary mouse hepatocytes from wild type (WT) or AMPKβ1−/− mice (referred to as β1−/− mice). Deletion of the β1 subunit of AMPK results in 90% loss of hepatic AMPK activity (Dzamko et al., 2010). As depicted in Figure 5.2B, both GW1516 and A-769662 increased phosphorylation of AMPK and ACC in isolated WT primary mouse hepatocytes but not β1−/− hepatocytes. Furthermore, GW1516 and A-769662 stimulated a modest but significant 30% increase in FA oxidation in isolated WT hepatocytes (Figure 5.2C). The effect of A-769662 was lost in β1−/− hepatocytes, consistent with an AMPK-dependent effect (Hawley et al., 2012). However, in β1−/− hepatocytes GW1516 stimulated fat oxidation to the same extent as in WT cells (Figure 5.2C). To reconcile this, we examined Cpt1a expression in WT and β1−/− hepatocytes and found that GW1516-treatment significantly enhanced Cpt1a expression (~2-fold) irrespective of genotype (Figure 5.2D). A-769662 treatment had no effect on Cpt1a mRNA abundance in WT or β1−/− hepatocytes (Figure 5.2D). The PPARδ-specific target gene Adfp was increased 2-fold in isolated hepatocytes from either genotype, whereas the PPARα-specific target Acox was unaffected by genotype or treatment (Figure 5.2E,F). Taken together, these results provide evidence that the ability of GW1516 to increase FA oxidation does not require AMPK activation. Rather, GW1516 stimulates Cpt1a, an effect that does not require AMPK. Furthermore, the selected concentration of GW1516 does not activate PPARα.

To evaluate whether increased hepatic FA oxidation would be reflected in a more rapid switch to fat utilization, we examined RER profiles in the fasting, acute feeding, injection and re-fasting protocol outlined above. Consistent with a faster switch to post-prandial fat utilization, A-769662-injected mice exhibited more rapid depression of RER at 5 and 6 hours post-injection (Figure 5.3A). Accordingly, the calculated oxidation of carbohydrate was significantly decreased (~30%) during this period, whereas oxidation
Figure 5.3: GW1516 activates hepatic AMPK *in vivo*, yet stimulates carbohydrate utilization.

Eight to ten week-old *Ldlr−/−* mice fed a standard laboratory chow were fasted overnight, fed at 0700 for 2hrs and re-fasted at 0900. Intraperitoneal injection of vehicle, GW1516 (3mg/kg) or A-769662 (30mg/kg) (n=6/group) occurred at the beginning of the re-fasting period at 0900. **A**, Respiratory exchange ratio (RER) measured during a fasting, feeding, injection and re-fasting protocol with A-769662. **B-C**, Carbohydrate and fatty acid utilization, respectively, calculated from data shown in (A). **D**, Respiratory exchange ratio (RER) measured during a fasting, feeding, injection with GW1516 and re-fasting protocol. **E-F**, Carbohydrate and fatty acid utilization, respectively, calculated from data shown in (C). Data is presented as mean +/- SEM. * indicates significant difference versus vehicle; student's paired t-test (*P*<0.05).
of fat was markedly increased by 2.5-fold (Figure 5.3B,C). On the other hand, injection of GW1516 resulted in a slower depression of RER (Figure 5.3D), which is consistent with enhanced post-prandial carbohydrate utilization (Figure 5.3E). In contrast to the mutual inhibition of substrate utilization observed in A-769662-injected mice, GW1516-injection did not suppress post-prandial fat utilization (Figure 5.3F). Collectively, these data suggest that the ability of PPARδ activation by GW1516 to increase total body glucose oxidation is greater than its ability to increase liver FA oxidation.

5.3.3 GW1516-TREATMENT ATTENUATES DE NOVO LIPOGENESIS, IN PART, VIA ACTIVATION OF AMPK AS WELL AS CORRECTION OF SELECTIVE HEPATIC INSULIN RESISTANCE

In addition to regulating FA oxidation, AMPK is a critical regulator of de novo lipogenesis (Dzamko et al., 2010). We thus hypothesized that PPARδ activation inhibits FA synthesis via activation of AMPK. When incubated with WT hepatocytes, GW1516 significantly inhibited de novo lipogenesis by ~30% (Figure 5.4A). This effect was strongly attenuated in β1⁻¹ hepatocytes, in which the suppression was only 11% and not statistically significant (Figure 5.4A). Consistent with an AMPK-specific effect, the 80% reduction in lipogenesis by A-769662 in WT hepatocytes was lost in β1⁻¹ hepatocytes (Figure 5.4A). Both compounds increased expression of Insig1 (Figure 5.4B), a known negative regulator of SREBP-1c (Qin et al., 2008). The induction of Insig1 by GW1516 and A-769662 may have contributed to the residual 10% reduction in lipogenesis observed in β1⁻¹ hepatocytes. Nevertheless, in primary mouse hepatocytes GW1516 inhibits de novo lipogenesis, in part, through activation of AMPK.

During selective hepatic insulin resistance, hyperinsulinemia drives mTORC1 activation, resulting in enhanced SREBP-1c-mediated lipogenesis (Brown and Goldstein, 2008). Thus, another possible mechanism for reduced hepatic steatosis in GW1516-treated mice is correction of the mTORC1 branch of insulin signaling.
Figure 5.4: GW1516 inhibits hepatic fatty acid synthesis as a consequence of AMPK activation and correction of selective hepatic insulin resistance.

**A.** Primary mouse hepatocytes isolated from WT and β1−/− mice were incubated with 0.5mM sodium acetate (0.5μCi/mL 14C-acetate) for 4hrs with or without GW1516 or A-769662 prior to determination of lipogenesis (n=3-4 from at least 3 independent experiments). In isolated hepatocytes treated with or without GW1516 or A-769662 for 6hrs abundance of *Insig1* (B) was measured by qRT-PCR and normalized to *Gapdh*. **C.** Plasma insulin at the end of the induction and intervention phases in *Ldlr*−/− mice fasted overnight (designated F) and fasted overnight followed by a 2hr re-feeding period (designated RF). **D.** Immunoblots of insulin signaling proteins phosphorylated (p) AKT and pmTOR in liver lysates from F and RF mice. Representative immunoblots with quantitations shown. mRNA abundance of *Srebf1c* (E) and *Fasn* (F) in liver lysates isolated from animals fasted for 4hrs (n=6-8/group). **G.** Synthesis of fatty acid in liver obtained 60 min post injection (i.p.) with [14C]acetic acid (n=6-8/group). Data is presented as mean +/- SEM. In **(A)** different upper case letters indicate statistical significance among WT treatments, different lower case letters indicate statistical significance among β1−/− treatments, and asterisk (*) indicates statistical significance between WT and β1−/− within the same treatment group (P<0.05); two-way ANOVA with post-hoc Tukey’s test (P<0.05). In **(C,D)** different upper case letters indicate statistical significance among fasted animals, different lower case letters indicate statistical significance among re-fed animals, and asterisk (*) indicates statistical significance between fasted and re-fed within the same diet (P<0.05); two-way ANOVA with post-hoc Tukey’s test (P<0.05). In **(E-G)** different letters indicate significant differences; one-way ANOVA with post-hoc Tukey’s test (P<0.05).
In contrast to chow-fed animals, HFHC-feeding resulted in continued progression of fasting hyperinsulinemia (Figure 5.4C). Fasting hyperinsulinemia in the HFHC-fed animals was strongly attenuated by intervention with GW1516 to the HFHC diet (Figure 5.4C). Fasting hyperinsulinemia in the HFHC-fed animals was associated with increased phosphorylation of hepatic Akt and mTORC1 compared to chow-fed animals (Figure 5.4D). In contrast, GW1516-intervention restored fasting phospho-Akt (partially) and phospho-mTORC1 (completely) to levels observed in chow-fed controls (Figure 5.4D). In all three diet groups, re-feeding elicited enhanced phosphorylation of Akt and mTORC1 (Figure 5.4D). This is consistent with increased sensitivity in the lipogenic mTORC1 branch of the insulin signaling cascade in HFHC-fed mice and its normalization following GW1516 treatment (Brown and Goldstein, 2008).

Compared to chow-fed controls, the fasting hyperinsulinemia and increased phospho-mTORC1 observed in HFHC-fed mice at 12 weeks was associated with increased expression of Srebf1c and Fasn (Figure 5.4E,F), as well as markedly enhanced fasting FA synthesis (Figure 5.4G). In contrast, the GW1516-intervention cohort exhibited significant attenuation of Srebf1c and Fasn expression (Figure 5.4E,F), which was coupled to a complete inhibition of the HFHC-induced progression of FA synthesis from 4- to 12-weeks of feeding (Figure 5.4G). Together with results in primary mouse hepatocytes, these data suggest that PPARδ activation inhibits hepatic lipogenesis through activation of AMPK as well as correction of selective hepatic insulin resistance, both of which contribute to the attenuation of ectopic liver TG accrual.

5.3.4 PPARδ ACTIVATION RESTORES DYNAMIC REGULATION OF HEPATIC FoxO1 WHICH SLOWS THE DEVELOPMENT OF OF HYPERGLYCEMIA

Given that PPARδ plays a role in hepatic insulin sensitivity (Lee et al., 2006), we hypothesized that this was perhaps a result of correcting the bifurcation in the insulin signaling cascade induced by the HFHC diet. At 12 weeks, livers isolated from HFHC-
fed mice lost the ability to suppress \textit{Pck1} expression and stimulate FoxO1 phosphorylation in the fasting-to-feeding transition (Figure 5.5A,B). This is consistent with previous hyperinsulinemic euglycemic clamp studies in which the liver of \textit{Ldlr}--/-- mice fed a high fat diet were insulin resistant (Mulvihill et al., 2011). In contrast, animals receiving the GW1516-intervention retained the ability to dynamically regulate fasting/re-feeding \textit{Pck1} expression and FoxO1 phosphorylation, similar to that observed in chow-fed mice (Figure 5.5A,B). We examined fasting blood glucose levels and found a significant 1.5-fold increase in fasting hyperglycemia in mice fed the HFHC for 12 weeks, which was partially attenuated by GW1516-intervention (Figure 5.5C). These data suggest that PPARδ activation corrects the gluconeogenic branch of insulin signaling during selective hepatic insulin resistance, which prevents exacerbation of diet-induced dysglycemia.

5.3.5 GW1516 INHIBITS HEPATIC INFLAMMATION AND INDUCTION OF ER STRESS

Inflammation is a prominent feature of hepatic insulin resistance and steatosis (Hummasti and Hotamisligil, 2010). Given that GW1516-intervention attenuated hepatic steatosis and corrected selective hepatic insulin resistance, we postulated that this would be associated with reduced hepatic inflammation. As shown in Figure 5.6A, expression of the proinflammatory M1 cytokines \textit{Tnf}, \textit{Icam1}, \textit{Il1b}, \textit{Ccl2}, \textit{Ccl3} and \textit{iNos} were markedly induced (2-to 15-fold) in livers of mice fed the HFHC diet at 12 weeks. In contrast, these cytokines were significantly attenuated (-50% to -65%) in livers excised from the GW1516-intervention group (Figure 5.6A). Furthermore, HFHC-feeding strongly suppressed hepatic expression of the M2 anti-inflammatory marker \textit{Arg1}, resulting in greatly exacerbated \textit{iNos/Arg1} ratio compared to chow-fed control mice (Figure 5.6B). GW1516 intervention completely prevented this expression pattern (Figure 5.6B). Together these data suggest that PPARδ activation promotes an anti-inflammatory
Figure 5.5: GW1516 corrects the gluconeogenic branch of insulin signalling during selective hepatic insulin resistance which improves fasting hyperglycemia.  
A, mRNA abundance of *Pck1* in liver lysates isolated from fasted (F) and re-fed (RF) animals (n=6-8/group). B, Immunoblots of insulin signaling protein pFoxO1 in liver lysates from F and RF mice (n=6-8/group). Representative immunoblots with quantitations shown. C, Blood glucose levels in F and RF mice (n=6-8/group). Data is presented as mean +/- SEM. Different upper case letters indicate statistical significance among fasted animals, different lower case letters indicate statistical significance among re-fed animals, and asterisk (*) indicates statistical significance between fasted and re-fed within the same diet (P<0.05); two-way ANOVA with post-hoc Tukey’s test (P<0.05).
**Figure 5.6: GW1516 attenuates hepatic inflammation and ER-stress.**

*Ldlr*−/− mice were fed a high-fat, cholesterol-containing diet (HFHC) for 4 weeks. For a subsequent 8 weeks, mice remained on HFHC alone or supplemented with GW50516 (GW1516) (3mg/kg/day) (n=12/group). **A,B** Hepatic abundance of cytokines was determined at 12 weeks by qRT-PCR, and expression was normalized to *Gapdh* +/- SEM (n=8-12/group). **C**, Immunoblots of GRP78 and CHOP in liver lysates at 12 weeks. Representative immunoblots with quantitations shown. Data is presented as mean +/- SEM (8-12/group). Different letters indicate significant differences; one-way ANOVA with post-hoc Tukey’s test (P<0.05).
M2 cytokine milieu in the liver.

Inflammation is commonly interwoven with ER-stress in the development of hepatic insulin resistance (Hummasti and Hotamisligil, 2010, Van Beek et al., 2012). Accordingly, HFHC-feeding significantly increased hepatic GRP78 (Figure 5.6C), a marker of the unfolded protein response (UPR), which is the precursor to the ER-stress response (Kaplowitz et al., 2007). GW1516-intervention completely normalized the diet-induced increase in GRP78 (Figure 5.6C). However, CHOP, the effector of the ER-stress response was unaffected by any diet (Figure 5.6C) suggesting that although the UPR has been initiated, the ER-stress response has not. Nevertheless, PPARδ activation attenuates this diet-induced hepatic pathology.
5.4 DISCUSSION

In the current study, we evaluated the ability of intervention to a HFHC diet with a PPARδ agonist to attenuate the progression of hepatic steatosis. We show that GW1516-intervention inhibits the progression of diet-induced liver TG accumulation. Mechanistically, attenuation of hepatic steatosis was a result of reduced FA synthesis and increased FA oxidation. The loss of hepatic AMPK activity did not mitigate the ability of PPARδ activation to induce FA oxidation, whereas loss of AMPK partially prevented PPARδ agonist-mediated inhibition of lipogenesis. Selective hepatic insulin resistance was corrected by PPARδ activation, which was associated with reduced hepatic inflammation and ER-stress.

The role of PPARδ activation in liver TG metabolism has been controversial (Lee et al., 2006, Liu et al., 2011, Nagasawa et al., 2006, Qin et al., 2008). One study showed that GW1516 prevented diet-induced suppression of hepatic AMPK activation, which was associated with increased expression of genes involved in FA oxidation and increased plasma β-hydroxybutyrate. In spite of these observations, GW1516 had no effect on hepatic TG content (Barroso et al., 2011). Another study showed that injection of adPPARδ into Ldlr−/− mice significantly increased AMPK phosphorylation in the liver, which was thought to contribute to glucose lowering (Liu et al., 2011). The impact of increased hepatic AMPK activation on lipid metabolism was not explored (Liu et al., 2011). Here we provide direct evidence that PPARδ activation increases AMPK and ACC phosphorylation in vivo as well as in primary mouse hepatocytes. The GW1516-mediated increase in phospho-ACC was AMPK dependent as this effect was lost in β1−/− hepatocytes. With regard to lipid metabolism, we demonstrate that PPARδ activation in vivo stimulates hepatic FA oxidation through PPARδ-specific activation of Cpt1a. We recapitulated these results in primary mouse hepatocytes, and identified that AMPK
activation is not a requirement for GW1516 to stimulate FA oxidation, as enhanced Cpt1a expression and FA oxidation persisted in β1<sup>−</sup> hepatocytes.

Carbohydrate oxidation and fat oxidation are thought to be mutually inhibitory (Randle, 1998). Thus, an agent that induces liver fat oxidation would be predicted to stimulate a faster switch in post-prandial substrate utilization from carbohydrate to fat (Hawley et al., 2012). In the current study we show that in an acute setting, GW1516-injection increased carbohydrate oxidation, yet fat oxidation during this period was not suppressed. Furthermore, in a setting of prolonged PPARδ activation, we demonstrate that intervention to the HFHC diet with GW1516 increases total EE, yet has no further effect on average RER through a 24hr period. Previous work has generated the hypothesis that PPARδ activation stimulates carbohydrate and fat utilization simultaneously (Kramer et al., 2007, Lee et al., 2006). The findings reported here are consistent with this hypothesis, and contribute direct evidence for simultaneous oxidation of both fuel sources in response to a synthetic PPARδ ligand. The increased oxidation of fat likely contributes to reduced liver TG accumulation.

Studies which have examined the role PPARδ activation in hepatic de novo lipogenesis have yielded both positive and negative results (Lee et al., 2006, Liu et al., 2011, Qin et al., 2008). On one hand, both adPPARδ injection and GW1516-treatment have been shown to increase hepatic expression of genes involved in lipogenesis, and consequently increase liver TG accumulation (Lee et al., 2006, Liu et al., 2011). On the other hand, delivery of adPPARδ or the synthetic PPARδ agonist GW0742 have demonstrated reduced SREBP-1c processing, reduced lipogenic gene expression and prevention of hepatic steatosis (Qin et al., 2008). The data presented here are consistent with, and extend this latter concept, as we provide evidence that intervention to a HFHC diet with GW1516 in mice, corrects selective hepatic insulin resistance, reduces lipogenic gene expression and prevents any further increase in fasting fatty acid
synthesis. Furthermore, GW1516 reduced *de novo* lipogenesis in WT primary mouse hepatocytes, but not in β1⁻/⁻ hepatocytes, which demonstrated that a component of the inhibition of FA synthesis was AMPK-dependent. Given that two different mechanisms may contribute to the observed reduction in lipogenesis by GW1516-treatment, the relative contributions of these pathways requires further study.

During selective hepatic insulin resistance, Akt loses its ability to phosphorylate and inactivate FoxO1, while maintaining its ability to phosphorylate and activate mTORC1 (Li et al., 2010). Coupled to hyperinsulinemia, this bifurcation in the insulin signaling cascade contributes to hepatic steatosis, dyslipidemia and hyperglycemia (Brown and Goldstein, 2008). In the present study, we provide evidence that hepatic insulin signaling does in fact bifurcate in a model of diet-induced insulin resistance. Importantly, we demonstrate that PPARδ activation attenuates the progression of the selective hepatic insulin resistant phenotype, as dynamic regulation of fasting-to-feeding phospho-FoxO1 and Pck1 expression was restored in the GW1516-intervention cohort. These data elaborate on the body of evidence that supports a role for PPARδ activation in protection from metabolic disease (Lee et al., 2006, Tanaka et al., 2003, Wang et al., 2003), and further support the use of PPARδ agonists in management of insulin resistance.

Liver inflammation has been linked to hepatic steatosis and insulin resistance (Gregor and Hotamisligil, 2011, Hummasti and Hotamisligil, 2010). Vascular chronic low-grade inflammation is in part mediated by aortic lipid accumulation and insulin resistance (Chapter 2, Chapter 4, (Liang et al., 2007, Tabas et al., 2010)). Given the selective insulin resistant phenotype and TG acquisition in livers of HFHC-fed animals and correction by GW1516-intervention, it is tempting to hypothesize that similar mechanisms govern induction and attenuation of vascular and hepatic inflammation. Moreover, Kupffer cell-specific deletion of Pparδ resulted in increased proinflammatory
cytokine expression and reduced anti-inflammatory cytokine expression, which was coupled to increased liver TG accumulation and hepatic dysfunction (Odegaard et al., 2008). Therefore, our results are consistent with an anti-inflammatory role for PPARδ activation in the liver. The relative impact of reduced inflammation versus correction of insulin sensitivity to the attenuation of hepatic steatosis cannot be discerned from the present experiments and requires further elucidation.

In summary, the data reported here provide physiological and molecular evidence that intervention with PPARδ-specific activation in the liver alleviates diet-induced hepatic steatosis, insulin resistance, inflammation and ER-stress. We conclude that PPARδ agonists may serve as therapeutic options for the treatment of patients with hepatic steatosis.
5.5 REFERENCES


6.1 SUMMARY OF FINDINGS

Cardiovascular disease due to accelerated atherosclerosis is the primary cause of death in patients with dyslipidemia, insulin resistance and type 2 diabetes. Central to atherogenesis is the development of lipid-laden macrophage foam cells, which occurs in response to retention of apoB-containing lipoproteins within the arterial intima (Moore and Tabas, 2011). In addition to the accrual of lipid, macrophage foam cells synthesize and secrete proinflammatory effector molecules that potentiate lesion development (Libby et al., 2011). Therefore, a macrophage-targeted treatment that inhibits foam cell formation and the associated inflammatory responses would be desirable. In this thesis, two synthetic agonists for PPARδ were examined in vitro, one of which was extended to in vivo experiments. These studies were undertaken to: (1) identify the molecular mechanisms involved in macrophage foam cell-associated inflammatory responses, and (2) define the mechanism of action and therapeutic potential of PPARδ activation in the regulation of lipid metabolism, inflammatory signaling and protection from atherosclerosis in states of metabolic disturbance such as insulin resistance and dyslipidemia.

Elevated plasma TG-rich VLDL is an independent risk factor for the development of CVD, and can readily stimulate the development of macrophage foam cells (Evans et al., 1993, Whitman et al., 1999a, Whitman et al., 1999b). Paradoxically, VLDL-derived fatty acids also activate macrophage PPARδ resulting in up-regulation of genes involved in fatty acid and TG metabolism (Chawla et al., 2003). Thus, from an evolutionary standpoint, PPARδ serves as a fatty acid sensor in cells of the vasculature to prevent arterial lipid accumulation under normolipidemic conditions. The experiments described in Chapter 2 tested the hypothesis that synthetic ligand activation of PPARδ would
attenuate VLDL-induced macrophage foam cell formation in the context of hypertriglyceridemia. These in vitro studies confirmed that VLDL and synthetic PPARδ agonists each individually activated similar transcriptional programs (Chawla et al., 2003). However, the VLDL-stimulated PPARδ-target gene expression was insufficient to prevent the 5-fold increase in VLDL-induced macrophage TG deposition. In contrast, macrophages incubated with VLDL in the presence of the potent synthetic PPARδ agonists GW0742 and GW1516 resulted in the attenuation of VLDL-induced TG accumulation. Mechanistically, the PPARδ ligands reduced TG accumulation, at least in part, by increasing expression of ANGPTL4, CD36 and CPT1α above VLDL-treatment alone, which resulted in: (1) reduced lipolysis, (2) enhanced FA uptake, albeit from a smaller FA pool, and (3) increased FA oxidation, respectively. Collectively, the net effect of synthetic ligand activation of PPARδ was to reduce intracellular TG accumulation (Figure 6.1). It is important to note that the concentrations of the PPARδ agonists used in these studies were specific for activating PPARδ, in the absence of activating PPARα or PPARγ.

In addition to increasing lipid accumulation, previous work has suggested that VLDL or VLDL-derived FAs can also stimulate or potentiate macrophage inflammatory responses (Saraswathi and Hasty, 2006, Stollenwerk et al., 2005, Su et al., 2009). The second hypothesis tested in Chapter 2 was that PPARδ agonists could attenuate VLDL-induced macrophage inflammatory responses. In VLDL-treated macrophages, expression of the proinflammatory mediators IL-1β, MIP-1α and ICAM-1 was significantly enhanced, which was associated with increased MAPK activation as well as dysregulation of the insulin signaling cascade as evidenced by reduced phosphorylation of Akt and FoxO1 (Figure 6.1). In contrast, incubation with the PPARδ agonists almost completely inhibited VLDL-induced cytokine expression and MAPK activation, and restored the dysregulation of the insulin signaling cascade. These studies also revealed
Figure 6.1: PPARδ activation inhibits macrophage foam cell formation and the inflammatory response.

PPARδ activation attenuates VLDL-induced triglyceride (TG) accumulation by activating a transcriptional program resulting in enhanced CPT-1α-mediated fatty acid β-oxidation and ANGPTL4-mediated inhibition of lipoprotein lipase (LPL) activity. Furthermore, macrophage treatment with synthetic PPARδ ligands inhibits proinflammatory cytokine expression, by inhibiting VLDL-stimulated ERK1/2 activation and reversing VLDL-mediated inhibition of Akt/FoxO1 phosphorylation.
that the PPARδ-mediated inhibition of the inflammatory response was not a consequence of increased FA oxidation, as both of the PPARδ agonists normalized VLDL-induced cytokine expression, MAPK activation and dysregulated insulin signaling even in the presence of etomoxir, a potent inhibitor of CPT1α (Galic et al., 2011).

Although hypertriglyceridemia is an independent risk factor for the development of CVD, the canonical foam cell-inducing lipoprotein is CE-rich LDL in both its native and modified forms. The studies in Chapter 3 addressed the ability of PPARδ activation to attenuate native and modified LDL-induced macrophage foam cell formation and the associated inflammatory response(s). Cellular CE accumulation in response to native and oxLDL was significantly attenuated by both GW0742 and GW1516. With regard to oxLDL, both PPARδ agonists increased CD36 mRNA abundance (Chapter 2), which would be predicted to enhance particle uptake (Moore and Freeman, 2006). However, PPARδ activation also increased ABCA1-mediated cholesterol efflux to apoAI, likely owing to increased ABCA1 mRNA and protein, which contributed to a net inhibition of CE-rich lipoprotein-induced macrophage foam cell formation.

Previous studies examining oxLDL-induced inflammatory responses have yielded both positive and negative results (Curtiss et al., 2012, Febbraio et al., 2000, Janabi et al., 2000, Kannan et al., 2012, Michelsen et al., 2004, Mullick et al., 2005, Qiu et al., 2007). The studies in Chapter 3 contribute to the notion that cholesterol-loaded macrophages exhibit a dampened inflammatory phenotype, as evidence by reduced expression of TNFα and IL-6, which was not further affected by synthetic ligand activation of PPARδ. The anti-inflammatory effect of oxLDL was coupled to reduced DHCR24 expression, which is known to result in the accumulation of desmosterol, a known activator of LXR. Accumulation of desmosterol within cholesterol-loaded mouse peritoneal macrophages has recently been shown to have potent anti-inflammatory effects (Spann et al., 2012). Thus, the studies conducted in Chapter 3 agree with the
concept that cholesterol-loaded macrophages do not exhibit a proinflammatory phenotype, suggesting that other immune cells of the arterial intima are responsible for the atherosclerosis-associated inflammation observed \textit{in vivo}.

The studies in Chapter 4 were undertaken to determine whether the ability of the PPARδ agonists to attenuate macrophage foam cell formation translated into reduced foam cell formation \textit{in vivo}, and in turn, protection from diet-induced atherosclerosis. These studies tested the hypothesis that PPARδ activation attenuates the progression of diet-induced atherosclerosis and aortic inflammation in \textit{Ldlr}\textsuperscript{-/-} mice. Previous studies involving prevention protocols, in which the PPARδ agonist is administered at the same time as the atherogenic stimulus (a high-fat diet), have reported a preventative effect of PPARδ activation on atherogenesis (Barish et al., 2008, Graham et al., 2005). The studies in Chapter 4 involved an intervention approach, whereby \textit{Ldlr}\textsuperscript{-/-} mice were fed the HFHC diet for 4 weeks to induce dyslipidemia and insulin resistance, which predisposes the animals to atherosclerosis development. Subsequently, HFHC-fed animals either remained on the atherogenic diet, or were supplemented with GW1516 for a subsequent 8 weeks. A subset of animals was fed standard laboratory chow for the 12-week period. The continued progression of dyslipidemia and hyperinsulinemia in HFHC-fed mice contributed to extensive lipid deposition within atherosclerotic plaques. In concert with increased lipid accumulation, HFHC-fed animals had significant enrichment of lesion macrophage, smooth muscle cell and collagen content. In contrast to the continued progression of dyslipidemia, insulin resistance and plaque development in HFHC-fed mice, GW1516-intervention induced regression of elevated plasma lipid and plasma insulin levels, which contributed to slowed progression of plaque lipid deposition. GW1516-intervention also reduced macrophage infiltration, yet had no effect on lesion smooth muscle cell content. Despite this, collagen deposition was increased in lesions of
GW1516-treated animals, suggesting the development of smaller, more stable atherosclerotic lesions.

Examination of cytokine expression in full-length aortae revealed that HFHC-feeding stimulated a proinflammatory phenotype in the aorta, as the M1 cytokines, \( \text{Ccl3}, \ \text{Il1b}, \ \text{Icam1}, \ \text{Tnf}, \ \text{Il6}, \ \text{iNos} \) and \( \text{Ccl2} \) were all markedly elevated. Additionally, the M2 anti-inflammatory mediator \( \text{Arg1} \) was substantially lower and the \( \text{iNos}/\text{Arg1} \) ratio was greatly exacerbated in aortae excised from HFHC-fed animals as compared to those isolated from chow-fed animals. In contrast, GW1516-intervention attenuated the progression of aortic inflammation, as M1 cytokines were reduced, \( \text{Arg1} \) expression was restored and the \( \text{iNos}/\text{Arg1} \) ratio was reverted back to levels in chow-fed mice.

To further build on the translation of findings from Chapters 2 and 3 into the \textit{in vivo} setting, aortic analyses of the signaling cascades known to regulate cytokine expression were performed. HFHC-feeding significantly increased aortic MAPK activation. Furthermore, Nfkbp activation was also enhanced, which was correlated with the increased expression of aortic \( \text{Tnf}, \ \text{Il6} \) and \( \text{Ccl2} \). Both MAPK and Nfkbp activation were attenuated by intervention with GW1516. To assess aortic insulin signaling, aortae excised from fasted and re-fed mice were examined for phosphorylated Akt and FoxO1. In contrast to the dynamic fasting-to-feeding regulation of pAkt and pFoxO1 observed in aortae isolated from chow-fed animals, this effect was lost in aortae from HFHC-fed mice. GW1516-intervention corrected aortic insulin signaling, which likely contributed to reduced aortic inflammation.

In addition to exerting atheroprotective effects, the studies in Chapter 4 identified that PPAR\( \delta \) activation also corrects dyslipidemia and peripheral insulin resistance. Coupled to the fact that hepatic steatosis is a major clinical manifestation of insulin resistance that contributes to dyslipidemia (Farese et al., 2012), the studies in Chapter 5 were undertaken to determine whether PPAR\( \delta \) activation inhibits diet-induced liver lipid
accumulation. To assess this, the same induction/intervention protocol used in Chapter 4 was employed. The Chapter 5 studies demonstrated that the further 2-fold increase hepatic TG accrual in animals remaining on the HFHC diet was significantly attenuated by intervention with GW1516. The PPARδ agonist reduced cellular TG, in part, through increased FA oxidation, which was unrelated to activation of PGC1α, PPARα or PPARγ. This was evidenced by GW1516 having no effect on hepatic Pgc1a, Ppara, Acox or Fabp4 expression. Furthermore, the studies conducted in Chapter 5 identified that the stimulation of FA oxidation by a synthetic PPARδ agonist does not require the activation of AMPK. β-oxidation persisted in PPARδ agonist-treated primary mouse hepatocytes isolated from AMPKβ1−/− mice.

Compared to chow-fed controls, the HFHC-fed animals were hyperinsulinemic, which was coupled to increased hepatic phosphorylation of the insulin signaling mediators Akt and mTORC1. Accordingly, Sreb1c and Fasn expression were significantly upregulated. Functionally, increased phospho-mTORC1, Sreb1c and Fasn expression was associated with significantly enhanced fasting FA synthesis. All of these parameters were markedly attenuated by intervention with GW1516 to the HFHC diet. These experiments demonstrated that part of the mechanism by which PPARδ activation attenuates hepatic steatosis is through correction of the lipogenic branch of the insulin signaling bifurcation.

The studies in Chapter 5 also revealed that another mechanism by which PPARδ activation reduces FA synthesis is through increased AMPK activity. Treatment of isolated WT primary mouse hepatocytes with GW1516 resulted in a 30% reduction in basal de novo lipogenesis. This effect was lost in β1−/− hepatocytes. Consistent with an AMPK effect, the synthetic AMPK activator A-769662 reduced rates of lipid synthesis in hepatocytes isolated from WT mice. However, A-769662 was ineffective at inhibiting lipogenesis in β1−/− hepatocytes.
In addition to stimulating the development of hepatic steatosis and hyperinsulinemia, HFHC-feeding also induced a state of fasting hyperglycemia. The hyperglycemia observed in HFHC-fed animals was at least partially a result of the inability of insulin to elicit further phosphorylation of FoxO1 during re-feeding. Reduced dynamic regulation of FoxO1 activity was associated with a loss of fasting-to-feeding suppression of Pck1 expression, as hepatic Pck1 in the 12-week HFHC cohort was similar between fasted and re-fed animals. Importantly, GW1516-intervention to the HFHC diet prevented the progression of resistance in the gluconeogenic FoxO1 branch of the insulin signaling cascade, which likely contributed to the attenuated progression of dysglycemia.

Previous work has suggested that inflammation in the liver is linked to hepatic steatosis and insulin resistance (Gregor and Hotamisligil, 2011, Hummasti and Hotamisligil, 2010). The Chapter 5 studies confirmed a proinflammatory state of the liver during insulin resistance, and showed that intervention to the HFHC-diet with a PPARδ agonist was able to completely prevent progression of this inflammatory phenotype. Moreover, HFHC-feeding induced the UPR, which is the precursor to ER-stress often linked to inflammation and progression of insulin resistance (Gregor and Hotamisligil, 2011, Hummasti and Hotamisligil, 2010). Importantly, UPR induction was completely normalized by GW1516-intervention.

6.2 CONCLUSIONS AND FUTURE DIRECTIONS

6.2.1 CHAPTER 2 CONCLUSIONS

The studies in Chapter 2 demonstrated that although VLDL-derived FAs activate PPARδ, potent synthetic agonists for this receptor are required to attenuate VLDL-induced macrophage lipid accumulation and the associated inflammatory responses. Moreover, these studies revealed that the anti-inflammatory and lipid lowering
capabilities of PPARδ are discrete. That PPARδ activation was associated with reduced LPL activity and increased β-oxidation would suggest that the normalization of the VLDL-induced inflammatory response by the PPARδ agonists was a result of reduced TG accumulation. However, inhibition of TG accumulation with low-dose tetrahydrolipstatin to the same extent as that achieved by PPARδ activation failed to normalize VLDL-induced cytokine expression. Furthermore, GW0742 and GW1516 completely inhibited VLDL-induced cytokine expression, even when β-oxidation was inhibited by etomoxir. Whether PPARδ activation can attenuate VLDL-induced inflammatory responses in ANGPTL4−/−, CPT1α−/− or ANGPTL4/CPT1α double knockout macrophages would be the more definitive experiment to confirm the findings here. However, the data presented in Chapter 2 strongly suggest that the anti-inflammatory and lipid lowering properties of PPARδ activation are distinct.

A growing body of evidence indicates that lipid-induced macrophage inflammation is a consequence of increased MAPK signaling as well as impaired signaling through the Akt/FoxO1 pathway (Han et al., 2006, Saraswathi and Hasty, 2006, Senokuchi et al., 2008, Su et al., 2009). It is also thought that VLDL-derived FAs can stimulate macrophage inflammation through TLR-Nfkβ signaling (Nguyen et al., 2007, Shi et al., 2006). However, this hypothesis has more recently been challenged (Anderson et al., 2012, Erridge and Samani, 2009). The studies conducted in Chapter 2, performed in the complete absence of LPS, contribute to the paradigm that VLDL-derived FAs themselves stimulate macrophage inflammatory responses are a consequence of macrophage insulin resistance, rather than activation of the TLR-Nfkβ pathway. This is supported by: (1) reduced pAkt and pFoxO1, increased nuclear FoxO1 and enhanced MAPK signaling by VLDL treatment, (2) canonical Nfkβ target genes TNFα and IL-6 being unaffected by VLDL treatment, and (3) the inability of parthenolide (an inhibitor of Nfkβ signaling) to block VLDL-stimulated expression of IL-1β, MIP-1α,
and ICAM-1. Importantly, we found that PPARδ activation blocks VLDL-induced MAPK activation as well as the VLDL-mediated inhibition of the insulin signaling cascade.

6.2.2 CHAPTER 2 FUTURE DIRECTIONS

Going forward, it will be important to identify the mechanism(s) by which VLDL induces MAPK activation and the mechanism(s) by which PPARδ activation normalizes VLDL-induced MAPK signaling. It has been suggested that PPARδ activation stimulates the expression of Rgs4 and Rgs5 in mouse macrophages, which reduces angiotensin II-induced phosphorylation of ERK1/2 and p38 (Takata et al., 2008). It remains unknown whether this mechanism applies to prevention of VLDL-induced MAPK activation and downstream inflammation. If this were the mechanism, it would imply that VLDL-induced inflammation through the MAPK pathway involves activation of G-protein coupled receptor signaling, which may uncover novel candidates in the inhibition of macrophage inflammation and atherogenesis. We propose to examine RGS4 and RGS5 expression in macrophages treated with PPARδ agonists. Concurrently, we propose studies in which the ability of GW0742 and GW1516 to inhibit VLDL-induced MAPK activation will be compared in PPARδ agonist treated control, RGS4, RGS5 and combined RGS4/RGS5 knockdown macrophages. We hypothesize that the ability of PPARδ activation to attenuate VLDL-induced MAPK activation and cytokine expression will be strongly attenuated in the absence of RGS4 and/or RGS5.

Another important avenue of investigation will be to identify how VLDL-treatment dysregulates insulin signaling, and the mechanism(s) by which the PPARδ agonists restore this VLDL-induced dysregulation. One possibility is that VLDL induces negative regulators of one or more steps of the cascade. For example, the suppressor of cytokine signaling (SOCS)-3 negatively regulates insulin signaling by targeting IRS-1 and IRS-2 for proteosomal degradation, thereby diminishing signaling to PI3-K and to Akt (Emanuelli et al., 2000, Rui et al., 2002). Another example is the c-Jun N-terminal kinase
(JNK), which phosphorylates the insulin receptor on serine residues, and in doing so, inhibits the intrinsic autophosphorylation of insulin receptor tyrosine residues. In turn, JNK-mediated serine-phosphorylation of the insulin receptor dampens the propagation of the insulin signal through the IRS-proteins, PI3-K and Akt (Ozcan et al., 2004). The hypotheses that SOCS-3 and/or JNK play a role in the impairment of insulin signaling during VLDL-induced macrophage inflammation can be tested using knockdown experiments for SOCS-3 and inhibitor studies for JNK.

Regarding the mechanism by which PPARδ activation restores VLDL-mediated impairment of insulin signaling, both PPARδ agonists used in the Chapter 2 studies stimulated enhanced Akt and FoxO1 phosphorylation in the absence of VLDL. We concluded from these experiments that PPARδ activation primes the insulin signaling cascade to prevent its downregulation by VLDL-treatment. It has been suggested that PPARδ activation can directly activate Akt activity through the induction of integrin-like kinase (ILK) and 3-phosphoinositide-dependent kinase 1 expression (PDK1) (Di-Poi et al., 2002). These transcripts encode kinases that are known to directly phosphorylate Akt and, in turn, FoxO1. However, we and others have observed PPARδ activation-induced enhancement of Akt and FoxO1 phosphorylation, without increased ILK or PDK1 expression (Chapter 2, (Han et al., 2008)). Another series of candidates may be phosphatases that are known to downregulate the insulin signaling. One such example is the phosphatase and tensin homolog (PTEN), which catalyses the dephosphorylation of the 3′ phosphate of PIP₃, resulting in the biphosphate product PIP₂. This dephosphorylation event inhibits PI3-K activity, thereby mitigating signaling to Akt (Nicholson and Anderson, 2002). In keratinocytes, PPARδ plays a role in the downregulation of PTEN, thus relieving the impediment on the PI3-K to Akt signal (Di-Poi et al., 2002). Whether this mechanism applies to the GW0742 and GW1516-mediated reversal of VLDL-induced insulin resistance in macrophages is unknown. If this
were the case, one would hypothesize that macrophages treated with PPARδ agonists would exhibited reduced PTEN expression. Additionally, one would hypothesize that VLDL and PPARδ agonist treatment of macrophages transfected with constitutively active PTEN, would attenuate the ability of PPARδ activation to reverse VLDL-induced downregulation of Akt and FoxO1 phosphorylation, resulting in sustained proinflammatory cytokine expression. If the converse were true, this would identify that activation of insulin signaling by the PPARδ agonists occurs downstream of PI3-K. This latter scenario would warrant experiments involving treatment of macrophages expressing dominant-negative Akt or phosphorylation-resistant FoxO1, with or without PPARδ agonists.

6.2.3 CHAPTER 3 CONCLUSIONS

The studies in Chapter 3 showed that PPARδ activation attenuates both native and oxLDL-induced macrophage foam cell formation. Although the PPARδ agonists increased LDLR and CD36 expression (Chapter 2), these compounds also increased cholesterol efflux. We concluded from these studies that PPARδ agonists, similar to PPARγ ligands (Argmann et al., 2003), induce a transcriptional program that increases cholesterol uptake and concomitantly increases cholesterol efflux, which collectively leads to a net depletion of cellular CE and FC. Induction of cholesterol efflux to apoAI was significantly increased, whereas efflux to HDL₃ was not. The fact that macrophage foam cell formation was reduced despite no apparent increase in ABCG1 activity agrees with the paradigm that ABCA1 is a more critical efflux transporter in the regulation of cholesterol homeostasis in hematopoetic cells of the arterial intima (Tarling et al., 2010, Yvan-Charvet et al., 2007).

With regard to CE-rich lipoprotein-induced inflammatory responses, we observed decreased cytokine expression in macrophages treated with oxLDL compared to vehicle controls. Reduced cytokine expression was not further affected by the PPARδ agonists.
One interpretation of these data is that the PPARδ agonists require the induction of cytokine expression in order to exert their inhibitory effects. In Chapter 2, we observed no change in basal cytokine mRNA abundance when macrophages were treated with GW0742 or GW1516, yet a complete inhibition of cytokine expression by these compounds in the presence of the VLDL-stimulus. A study that supports this hypothesis demonstrated that in adipocytes, GW1516 had no effect on basal IL-6 mRNA and protein but completely inhibited LPS-induced IL-6 synthesis and secretion (Rodriguez-Calvo et al., 2008). Another line of evidence that supports this interpretation is that GW0742 had no effect on the inhibitors of Nfkb (IkBα and IkBβ) in cardiomyocytes unless an LPS-stimulus was present (Ding et al., 2006).

Previous studies have suggested that oxLDL-treated macrophages or FC-loaded macrophages exhibit a proinflammatory phenotype, characterized by increased TLR and/or Nfkb signaling (Curtiss et al., 2012, Febbraio et al., 2000, Janabi et al., 2000, Li et al., 2005, Michelsen et al., 2004, Mullick et al., 2011, Stewart et al., 2010). However, other studies have provided contrary evidence (Kannan et al., 2012, Qiu et al., 2007, Spann et al., 2012). In our hands, oxLDL treatment reduced cytokine expression, and inhibition of ACAT activity to significantly increase FC accumulation failed to reverse the anti-inflammatory phenotype of oxLDL-treated macrophages. These results suggest that oxLDL treatment or FC accumulation in macrophages is not a stimulus for the inflammatory response. Furthermore, oxLDL-mediated reduction in cytokine expression was coupled to markers of (1) oxysterol accumulation (reduced SREBP-1c and FAS expression), (2) LXR activation (increased ABCA1, ABCG1 and MYLIP), (3) PPARγ activation (FABP4), and (4) PPARδ activation (ADFP). The activation of LXR, PPARγ or PPARδ is known to be anti-inflammatory (Im and Osborne, 2011, Straus and Glass, 2007). Therefore, oxLDL-mediated activation of all three of these nuclear receptors may elicit a combination of effects that contributes to reduced cytokine expression.
6.2.4 CHAPTER 3 FUTURE DIRECTIONS

The association between oxLDL treatment, increased expression of LXR-target genes and reduced inflammatory cytokine expression is most likely linked to desmosterol accumulation as a consequence of reduced DHCR24 expression. However, it will be critical to determine whether desmosterol does in fact accumulate in THP-1 macrophages exposed to oxLDL. We propose to conduct experiments in which oxLDL-treated macrophages with or without the PPARδ agonists are examined for intracellular desmosterol concentrations by liquid chromatography tandem mass spectrometry (Honda et al., 2009, Honda et al., 2008). We hypothesize that oxLDL-treatment will stimulate an increase in desmosterol accumulation, which will not be further enhanced by the PPARδ agonists. The latter portion of this hypothesis is driven by the fact that the PPARδ agonists did not further suppress TNFα and IL-6 expression beyond oxLDL-treatment alone.

Although enhanced intracellular desmosterol is the most likely driving factor behind the oxLDL-mediated anti-inflammatory response, other mechanisms are certainly possible. In fact, Spann et al. reported that in mouse peritoneal macrophages elicited from LXR-double knockout mice, the anti-inflammatory phenotype was attenuated, but not eliminated, compared to macrophages elicited from LXR-wild type mice (Spann et al., 2012). Thus, LXR-independent anti-inflammatory mechanisms must also play a role in this context. In the Chapter 3 studies, oxLDL stimulated the expression of the PPARδ-specific target gene ADFP, implying that oxLDL may induce the accumulation of PPARδ ligands. Fatty acids are known to activate PPARδ (Chawla et al., 2003). Spann et al. observed increases in oleic acid accumulation in cholesterol-loaded and desmosterol-treated mouse peritoneal macrophages which were in the picomolar range (Spann et al., 2012). The studies in Chapter 2 revealed that in the micromolar range, oleic acid
induces macrophage inflammatory responses. However, picomolar concentrations of oleic acid may be sufficient to activate PPARδ but insufficient to stimulate the inflammatory response.

The hypothesis that oxLDL-mediated anti-inflammatory responses are partially the result of PPARδ activation can be tested by examining cytokine expression in macrophages treated with oxLDL in the presence or absence of PPARδ antagonists (GSK0660 or GSK3787). It is important to note that genetic ablation of PPARδ would not be an appropriate model system for these experiments, as PPARδ deletion mimics the liganded state of the receptor. This is due to genetic ablation of PPARδ resulting in the transrepression of inflammatory cytokine expression and derepression of PPARδ target genes (Lee et al., 2003, Lee et al., 2006a). Hence, this would create an experimental confounder for the proposed studies. Continuing with the proposed PPARδ inhibitor experiments, one would hypothesize that antagonizing PPARδ would result in partial reversal of the oxLDL-mediated reduction of TNFα and IL-6. If this hypothesis is correct, another series of experiments could perhaps determine whether oleic acid or other fatty acid ligands for PPARδ accumulate in oxLDL-treated macrophages. Subsequently, experiments may also include, but are not limited to, determining the expression of cytokines under the following conditions: (1) oxLDL in the presence of both PPARδ and LXR antagonists, (2) exogenous addition of the determined fatty acid PPARδ ligand, (3) in the presence or absence of PPARδ antagonist(s). The proposed experiments would determine the relative contribution of LXR and PPARδ activation to the oxLDL-mediated anti-inflammatory response in macrophages, and possibly identify a novel mechanism responsible for the reduced proinflammatory responses observed in oxLDL-treated macrophages.

Given that TNFα and IL-6 expression is regulated, at least in part, by Nfkb signaling (Ding et al., 2006, Li et al., 2005, Rodriguez-Calvo et al., 2008), one would be
inclined to hypothesize reduced phosphorylation of the Nfkb signaling mediators IKK and IκB in oxLDL-treated macrophages. However, the anti-inflammatory effects of LXR occur as a result of ligand-induced small ubiquitin-like modifier (SUMO)-dependent modification of the receptor. The SUMOylation of LXR results in the recruitment of co-repressor complexes to promoter regions of proinflammatory genes, which inhibit Nfkb from binding to its response elements within these targets (Im and Osborne, 2011). Hence, it is unlikely that oxLDL-treated macrophages would display reduced phospho-IKK and IκB. On the other hand, PPARδ inhibits Nfkb signaling through increased expression of the IκB proteins, suggesting that oxLDL-treated macrophages may exhibit higher IκBα and IκBβ than untreated controls. In oxLDL-treated macrophages with or without LXR and PPARδ antagonists, we propose to examine nuclear co-repressor occupancy of the TNFα and IL-6 promoters via chromatin immunoprecipitation (Ghisletti et al., 2007), as well as phospho- (as a control) and total-IKK, IκBα and IκBβ via immunoblotting. These experiments would expand on the mechanism by which oxLDL-mediates reduced TNFα and IL-6 expression.

6.2.5 CHAPTER 4 CONCLUSIONS

The studies in Chapter 4 revealed that, intervention with a synthetic PPARδ agonist to a diet-induced setting of pre-established dyslipidemia and insulin resistance attenuates the progression of early stage lesions to more complex lesions. A significant contributor to this effect was likely the reduction in plasma lipids, thus reducing the atherogenic stimulus. However, aortae excised from GW1516-treated mice exhibited significantly increased expression of the PPARδ-target genes Adrp, Angptl4 and Cpt1a, which we showed in Chapter 2 are important regulators of VLDL-induced macrophage foam cell formation. Coupled to the fact that aortic TG in mice receiving the GW1516-intervention regressed from the 4-week baseline levels, these data suggest that this
compound has direct vessel wall effects that contribute to the PPARδ-mediated reduction in lesion lipid deposition.

In HFHC-fed animals, the markedly increased aortic expression of Ccl3, Il1b, Icam1, Tnf, Il6, iNos and Ccl2 coupled to substantially lower Arg1 and a greatly exacerbated iNos/Arg1 ratio strongly suggests the polarization of these aortae towards the M1 proinflammatory phenotype. That GW1516-intervention attenuated the progression of this M1 polarization demonstrates that PPARδ activation exerts anti-inflammatory effects in the aorta, which likely contribute to protection from lesion progression. Furthermore, GW1516 prevented the induction of aortic MAPK, which was associated with increased Rgs4 and Rgs5 expression. Additionally, the PPARδ agonist inhibited HFHC diet-induced aortic Nfkb activation, through mechanisms that remain to be elucidated.

The studies in Chapter 4 also revealed that dynamic fasting-to-feeding regulation of aortic pAkt and pFoxO1 is lost in a diet-induced model of atherosclerosis. These data suggest that nuclear FoxO1 activity is chronically active in the aorta, which likely contributes to the sustained accumulation of FoxO1 target genes such as Il1b (Su et al., 2009), Icam1 and Ccl3 (Chapter 2). This hypothesis is supported by the paradigm that atherogenesis is a longitudinal process associated with chronic low-grade inflammation (Glass and Witztum, 2001, Libby et al., 2011). Importantly, we found that GW1516-intervention to the HFHC diet completely reversed the fasting-to-feeding regulation of aortic pAkt and pFoxO1 back to levels in chow-fed controls. These data suggest that part of the ability of PPARδ activation to protect mice from lesion progression is mediated by restoration of normal aortic insulin signaling.

6.2.6 CHAPTER 4 FUTURE DIRECTIONS

A caveat to the conclusions from the findings in Chapter 4 is the leap from drug-treatment to causal relationship. In other words, the ability of GW1516 to lower plasma
lipids is unequivocally a major contributor to protection from lesion progression. However, the data also provide compelling evidence that GW1516 exerts lipid lowering, anti-inflammatory and insulin-sensitizing at the level of the aorta. The relative contribution of lipid lowering and direct vessel wall effects cannot be deciphered from the experiments performed. Furthermore the lesions after 4-weeks of induction were early lesions, which were prevented from further development. Moving forward it will be important to determine if PPARδ activation improves the pathology of more advanced lesions, and whether extended treatment is able to achieve regression.

Given that the use of Pparδ−/− mice results in the experimental confounder discussed above, alternative strategies will need to be employed to reconcile the issue of lipid lowering versus direct vessel wall effects. To address this issue, and to determine if extended treatment is able to achieve regression, one potential experiment would be to induce lesion development with HFHC feeding for 12-weeks prior to a 12-week intervention with GW1516. Additionally, the introduction of HFHC-fed mice transferred to chow with or without GW1516 would provide unique insight into the contribution of PPARδ activation within the aorta to improved lesion pathology. The justification for this statement arises from ongoing experiments in our laboratory, in which 12-weeks of HFHC feeding prior to the introduction of chow for the remaining 12-weeks, completely normalizes all metabolic parameters back to levels observed in 24-week chow-fed mice. Thus, examining lesion pathology in GW1516-intervention during chow feeding would eliminate the variable of drastic lipid lowering contributing to inhibition of plaque progression or stimulation of plaque regression. The reversa mouse (Cre-induced deletion of hepatic Mttp) provides a similar platform to test the impact of a drug on atherosclerosis development independent of lipid lowering (Feig et al., 2011), but is unfortunately commercially unavailable.
Another strategy to help reconcile lipid lowering versus direct vessel wall effects is the utilization of laser-capture microdissection (LCM). Analysis of gene expression from LCM samples would allow us to determine the contribution of a particular cell-type to the changes we observed in full-length aorta. Specifically, LCM of MOMA-2 positive macrophages would provide a tool for the macrophage-specific measurement of Adrp, Angptl4 and Cpt1a expression. Additionally, the measurement of cytokines in MOMA-2 positive macrophages isolated by LCM would provide a more definitive conclusion of lesion macrophage polarization in all diet groups. Answering these questions would provide a PPARδ-specific mechanism in macrophages for reduced foam cell formation and inhibition of inflammatory cytokine expression, particularly in the condition of HFHC transferred to chow plus GW1516.

GW1516 increased lesion collagen deposition without altering lesion SMC content. This observation is possibly due to a direct effect of PPARδ activation on plaque SMCs, enhancing their capacity to synthesize and deposit extracellular matrix. This hypothesis is supported by a report that PPARδ activation in vascular smooth muscle cells (VSMCs) inhibits IL-1β-induced matrix metalloproteinase (MMP)-2 and MMP-9 expression (Kim et al., 2010). Although reduced lipid deposition in VSMCs restores their capacity to synthesize extracellular matrix (Beyea et al., 2012, Frontini et al., 2009), the ability of PPARδ agonists to improve VSMC function in response to a lipid load is unknown. In addition, LCM of smooth muscle cells from aortic lesions would allow us to determine whether GW1516-treatment enhanced collagen and elastin expression specifically in VSMCs, thus contributing to enhanced matrix deposition.

An interesting and novel finding in the Chapter 4 studies was the increased aortic expression of Ptpn6 and Trib3, which are known negative regulators of hepatic insulin signaling (Du et al., 2003, Dubois et al., 2006). While it has recently been demonstrated that silencing Trib3 using siRNA suppresses atherosclerosis in diabetic mice (Wang et
al., 2012), the role of \textit{Ptpn6} in atherogenesis has not been reported. Experiments using siRNA against \textit{Ptpn6} in a setting of HFHC diet-induced atherosclerosis would identify the contribution of induced \textit{Ptpn6}, and its protein product SHP-1, to atherogenesis. Moreover, the ability of GW1516 to inhibit lesion progression in a setting of already improved (vascular) insulin signaling (such as \textit{Trib3} and/or \textit{Ptpn6} knockdown) would help determine the impact of improved aortic insulin signaling on atherosclerosis. Alternatively, examining the ability of GW1516 to inhibit plaque progression in the setting of bone marrow transplantation from \textit{Insr}^{-/-} mice to \textit{Ldlr}^{-/-} recipients would also provide valuable information regarding the contribution of improved vascular insulin sensitivity by PPARδ activation to the atheroprotective effect. If in this scenario GW1516 can still inhibit atherogenesis, it will be important to determine the mechanism by which PPARδ activation reverses insulin resistance, as discussed in Chapter 2 future directions (Section 6.2.2).

6.2.7 CHAPTER 5 CONCLUSIONS

In Chapter 5 we demonstrated that intervention to a HFHC diet with a synthetic PPARδ agonist attenuates the progression of hepatic steatosis, as evidenced by a complete halting of liver TG accumulation from 4-week baseline levels. The addition of GW1516 to the HFHC diet did not affect hepatic expression of \textit{Pgc1a}, \textit{Ppara}, \textit{Acox} or \textit{Fabp4}, which led us to conclude that GW1516 did not activate PGC1α, PPARα or PPARγ. However, GW1516-treatment enhanced the hepatic expression of \textit{Adfp} and \textit{Cpt1a} in the liver, which was coupled to increased FA oxidation. These data strongly suggest that GW1516 increases CPT1α-mediated β-oxidation in the liver, and that with respect to PPARs, this effect is PPARδ specific.

The studies in Chapter 5 also revealed that AMPK is not required for PPARδ-mediated stimulation of liver fat oxidation, as the increase in β-oxidation observed in isolated WT primary mouse hepatocytes persisted in AMPKβ1Δ/Δ hepatocytes.
Irrespective of AMPKβ1 genotype, GW1516-treatment significantly increased Cpt1a expression, further demonstrating that PPARδ activates CPT1α-mediated FA oxidation independent of AMPK.

As alluded to above, GW1516-intervention inhibited hepatic fatty acid synthesis, which is partially attributable to AMPK activation. We also found that intervention to a HFHC diet with GW1516 in mice, corrected selective hepatic insulin resistance, which reduced lipogenic gene expression and prevented any further increase in fasting FA synthesis. Our findings are supported by a number of studies reporting that PPARδ plays a role in improving whole-body insulin sensitivity, which reduces metabolic disturbance (Lee et al., 2006b, Tanaka et al., 2003, Wang et al., 2003). However, we extended this concept in Chapter 5, as we provided evidence that improved insulin signaling specifically in the liver contributes to reduced hepatic steatosis.

A previous study demonstrated that transplantation of bone marrow from Pparδ−/− mice into WT mice polarized hepatic Kupffer cells to the proinflammatory M1 phenotype, which resulted in increased liver TG accumulation and hepatic dysfunction (Odegaard et al., 2008). Given that deletion of PPARδ mimics the liganded state of the receptor as discussed in Section 6.2.4, the study by Odegaard and colleagues would imply that PPARδ activation in hepatic Kupffer cells is proinflammatory. Although the studies performed in Chapter 5 cannot distinguish between the effects of PPARδ activation in hepatocytes versus Kupffer cells, the results suggest an anti-inflammatory rather than a proinflammatory effect. This is consistent with the notion that activation of PPARδ in hepatocytes protects from inflammatory responses induced by non-lipid stimuli such as cytokines or LPS (Serrano-Marco et al., 2011). Even so, it remains to be determined whether the inhibition of hepatic inflammation by GW1516 contributed to correction of hepatic insulin signaling, FA synthesis and hepatic steatosis, or was a secondary effect of reduced liver TG accumulation.
6.2.8 CHAPTER 5 FUTURE DIRECTIONS

Moving forward it will be important to determine the mechanism by which PPARδ activation corrects insulin signaling. The discussion in Chapter 2 highlighted the fact that GW1516 activated Akt and FoxO1 phosphorylation in macrophages. Here, the situation is vastly different. If GW1516 activated hepatic insulin signaling, mTORC1 phosphorylation and Srebf1c expression would have been increased compared to HFHC-fed mice. Furthermore, fatty acid synthesis would have been increased, or perhaps unchanged due to activation of AMPK mitigating the increase in insulin-stimulated lipogenesis, but certainly not decreased. The simplest explanation for the correction of hepatic insulin signaling is improved peripheral insulin sensitivity, which would result in enhanced peripheral glucose uptake and a reduction in hyperinsulinemia. This hypothesis is supported by: (1) the known ability of PPARδ activation to enhance glucose uptake in skeletal muscle (Kramer et al., 2005), (2) the fact that GW1516 treated mice exhibit increased insulin stimulated glucose disposal under hyperinsulinemic-euglycemic clamps (Lee et al., 2006b) and (3) that PPARδ activation in pancreatic islet cells increases glucose stimulated insulin secretion (Iglesias et al., 2012). Taken together, these studies suggest that the PPARδ-mediated correction of peripheral insulin resistance may contribute to reduced fasting hyperinsulinemia, and therefore the lower drive on hepatic insulin receptor signaling to stimulate the mTORC1-SREBP1c lipogenic axis. Hence, examining the contribution of corrected selective hepatic insulin resistance to reduced liver TG accumulation in GW1516-treated animals is not particularly straightforward.

Considering AMPK activation by GW1516 is required for the inhibition of lipogenesis, but is not required for the induction of FA oxidation, AMPKβ1−/− mice provide an appropriate platform to test the relative contribution of these parameters in the
GW1516-mediated inhibition of liver TG accumulation. Furthermore, AMPKβ1<sup>-/-</sup> mice are protected from diet-induced hepatic insulin resistance (Dzamko et al., 2010). Therefore, AMPKβ1<sup>-/-</sup> mice also represent a model which can be used to decipher the relative contribution of corrected insulin signaling and AMPK activation to reduced lipogenesis by PPARδ activation. We propose to examine the ability of GW1516 intervention to a HFHC diet to attenuate hepatic steatosis in AMPKβ1<sup>-/-</sup> mice. We hypothesize that the ability of GW1516 to inhibit liver TG accumulation will be partially attenuated in AMPKβ1<sup>-/-</sup> mice. Furthermore, the addition of a group of mice treated with adenoviral Cpt1a siRNA in the presence or absence of GW1516 would inhibit PPARδ activation induced FA oxidation. The proposed experiments would provide unique insight into the mechanism of GW1516-mediated inhibition of hepatic steatosis.

In the fasting, acute feeding, injection and re-fasting protocol we found that GW1516 acutely stimulated carbohydrate oxidation, while not suppressing fat oxidation. Furthermore, in the intervention study, a setting of prolonged PPARδ activation, GW1516 increased total EE yet had no further effect on average RER through a 24hr period. Taken together, these results suggest that PPARδ activation can simultaneously stimulate carbohydrate and fat oxidation. The mechanism by which this occurs has been postulated to involve increased glucose flux through the pentose phosphate pathway coupled to increased hepatic fatty acid synthesis (Lee et al., 2006b). The consequence of these processes being upregulated in response to a PPARδ agonist is that the former can consume up to 20% of hepatic glucose, while providing reducing power to stimulate fatty acid synthesis (Lee et al., 2006b); hence increased simultaneous carbohydrate and fat utilization. Although we did not measure activity of the pentose-phosphate pathway in livers of GW1516-treated animals, we did observe a significant reduction in the rate of hepatic fatty acid synthesis, thus challenging the theory of Lee and colleagues with respect to the liver. However, preliminary experiments in our lab have revealed that in
muscle, GW1516 does not inhibit HFHC feeding-induced fatty acid synthesis despite the resolution of hyperinsulinemia. Importantly GW1516-treatment significantly increases muscle FA oxidation (~2-fold). Together, these data suggest that PPARδ activation may stimulate the pentose-phosphate shunt and fatty acid synthesis in muscle, where the oxidative machinery to utilize the newly synthesized FAs is upregulated. This would create futile cycling of FA synthesis and oxidation which: (1) increases carbohydrate consumption as a consequence of increased pentose-phosphate activity to provide reducing power for FA synthesis, and (2) simultaneously increases fat oxidation to deplete the newly synthesized FAs. However, this is highly speculative and substantial experimentation would be required to test this hypothesis. Nevertheless, identifying the mechanism by which PPARδ activation stimulates simultaneous utilization of carbohydrate and fat is exciting and warrants further study.

6.3 OVERALL THESIS CONCLUSION

A substantial body of preclinical evidence supports the hypothesis that PPARδ activation represents a favourable therapeutic strategy for the treatment and prevention of dyslipidemia, insulin resistant syndromes and atherosclerosis. Despite this wealth of knowledge, a significant gap between preclinical and clinical studies has stalled the development of PPARδ agonists. The studies described in this thesis have contributed to the narrowing of this gap by elaborating on how PPARδ activation confers protection from metabolic insult in macrophages, in the aorta and in the liver (Figure 6.2). Specifically, Chapters 2-5 of this thesis provided molecular and physiological evidence that PPARδ activation favourably regulates lipid metabolism and inflammatory signaling, which results in the protection from atherosclerosis and hepatic steatosis in states of metabolic disturbance such as dyslipidemia, insulin resistance and type 2 diabetes.
Figure 6.2: Thesis Summary.

PPARδ activation in macrophages attenuates TG and CE accumulation in response to lipoproteins, corrects impaired insulin signaling and inhibits the inflammatory response (Chapters 2 and 3). The ability of PPARδ activation to inhibit foam cell formation, likely contributes to attenuation of diet-induced aortic insulin resistance and atherosclerosis in vivo (Chapter 4). In the liver, PPARδ activation attenuates hepatic steatosis via increased FA oxidation and inhibition of de novo lipogenesis, which is associated with the correction of hyperlipidemia, hyperglycemia and hyperinsulinemia (Chapter 4 and 5).
6.4 REFERENCES


Beta/Delta Agonist Gw501516 Inhibits IL-6-Induced Signal Transducer and Activator of Transcription 3 (Stat3) Activation and Insulin Resistance in Human Liver Cells. Diabetologia 55, 743-751.


Appendix 7.1

Order Completed

Thank you very much for your order.

This is a License Agreement between Lazar Bojc ("You") and Wolters Kluwer Health ("Wolters Kluwer Health"). The license consists of your order details, the terms and conditions provided by Wolters Kluwer Health, and the payment terms and conditions.

Get the printable license.

License Number 3126641196658
License date Apr 12, 2013
Licensed content publisher Wolters Kluwer Health
Licensed content publication Current Opinion in Lipidology
Licensed content title Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player
Licensed content author Lazar Bojc and Murray Huff
Licensed content date Jan 1, 2013
Volume number 24
Issue Number 2
Type of Use Dissertation/Thesis
Requestor type Individual
Author of this Wolters Kluwer article Yes
Title of your thesis / dissertation Regulation of Lipid Homeostasis, Inflammatory Signalling and Atherosclerosis by the Peroxisome Proliferator-Activated Receptor Delta
Expected completion date Jun 2013
Estimated size (pages) 300
Total 0.00 USD

Copyright © 2013 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. Comments? We would like to hear from you. E-mail us at customerservice@copyright.com
Appendix 7.2

Order Completed

Thank you very much for your order.

This is a License Agreement between Lazar Bojic ("You") and Wolters Kluwer Health ("Wolters Kluwer Health"). The license consists of your order details, the terms and conditions provided by Wolters Kluwer Health, and the payment terms and conditions.

Get the printable license.

License Number: 3126650169257
License date: Apr 12, 2013
Licensed content publisher: Wolters Kluwer Health
Licensed content publication: ATVB
Licensed content title: Activation of Peroxisome Proliferator-Activated Receptor δ Inhibits Human Macrophage Foam Cell Formation and the Inflammatory Response Induced by Very Low-Density Lipoprotein
Licensed content author: Lazar A. Bojic, Cynthia G. Sawyez, Dawn E. Telford, Jane Y. Edwards, Robert A. Hegele, Murray W. Huff
Licensed content date: Dec 1, 2012
Volume number: 32
Issue Number: 12
Type of Use: Dissertation/Thesis
Requestor type: Individual
Author of this Wolters Kluwer article: Yes
Title of your thesis / dissertation: Regulation of Lipid Homeostasis, Inflammatory Signalling and Atherosclerosis by the Peroxisome Proliferator-Activated Receptor Delta
Expected completion date: Jun 2013
Estimated size(pages): 300
Total: 0.00 USD
Appendix 7.3

Subject: eSirius Notification - New Animal Use Protocol is APPROVED2012-028::1

Western

AUP Number: 2012-028
PI Name: Huff, Murray W
AUP Title: Regulation Of Lipids And Lipoproteins In Mouse Models Of Atherosclerosis.
Approval Date: 09/13/2012

Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use Protocol (AUP) entitled
"Regulation Of Lipids And Lipoproteins In Mouse Models Of Atherosclerosis." has been APPROVED by the Animal Use
Subcommittee of the University Council on Animal Care. This approval, although valid for four years, is subject to
annual Protocol Renewal.2012-028::1

This AUP number must be indicated when ordering animals for this project.
Animals for other projects may not be ordered under this AUP number.
Purchases of animals other than through this system must be cleared through the ACVS office. Health certificates will be
required.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety, radiation
safety, general laboratory safety) comply with institutional safety standards and have received all necessary approvals.
Please consult directly with your institutional safety officers.

Submitted by: Copeman, Laura
on behalf of the Animal Use Subcommittee
University Council on Animal Care

https://iwc.uwo.ca/iwc_static/layout/shell.html?lang=en&2-4.01_224943

19/09/2012
Curriculum Vitae

NAME: Lazar Alexander Bojic
PLACE OF BIRTH: Toronto, Ontario, Canada
DATE OF BIRTH: 16 June 1985

Education and Training

2007 – 2013 University of Western Ontario
London, Ontario Canada
Ph.D. Candidate, Department of Biochemistry
Supervisor: Dr. Murray Huff

2003 – 2007 University of Western Ontario
London, Ontario Canada
Bachelor of Medical Science (Honours)
Department of Medical Sciences

Honours and Awards

2012 Best PhD Oral Presentation
Department of Medicine Research Day

2011-2012 Ontario Graduate Scholarship
Ontario Graduate Scholarship Program

2011 Best PhD Poster Presentation
Gordon Research Conference on Atherosclerosis

2011 Best PhD Oral Presentation
Department of Medicine Research Day

2010-2011 Ontario Graduate Scholarship in Science and Technology
Ontario Graduate Scholarship Program

2010 Best PhD Poster Presentation
Margaret P. Moffat Research Day

2009-2011 CIHR Strategic Training Fellowship in Vascular Imaging
Canadian Institutes of Health Research

2009 Best PhD Oral Presentation
Canadian Lipoprotein Conference

2009 Best PhD Oral Presentation
Department of Medicine Research Day
2009 ATVB Conference Young Investigator Award
Conference on Arteriosclerosis, Thrombosis and Vascular Biology

2008 CIHR National Training Program on Lipids, Lipoproteins and
Atherosclerosis
Canadian Institutes of Health Research

2007 Scholarship for Medical Research
Schulich School of Medicine & Dentistry

2007-2012 Graduate Research Scholarship (5 year)
University of Western Ontario

2006, 2007 Dean’s Honour List
University of Western Ontario

Related Work Experience

2012 Supervision of Undergraduate Honours Student
Department of Biochemistry
University of Western Ontario

2011-2012 Supervision of Undergraduate Honours Student
Department of Biochemistry
University of Western Ontario

2010-2011 Supervision of Undergraduate Honours Student
Department of Biochemistry
University of Western Ontario

2009-2010 Supervision of Undergraduate Honours Student
Department of Biochemistry
University of Western Ontario

2008-2012 Teaching Assistant
Medical Science 4930F – Biochemistry Module
University of Western Ontario

Peer Reviewed Publications

Bojic LA, Telford DE, Fullerton MD, Ford RJ, Sutherland BG, Edwards JY, Sawyez CG,
Gros R, Steinberg GR and Huff MW. PPARδ-specific activation in liver attenuates
triglyceride accumulation via enhanced fatty acid oxidation, reduced fatty acid synthesis
and improved insulin sensitivity in Ldlr⁻/⁻ mice. (Submitted).

Bojic LA, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Huff MW. PPARdelta
agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance and
atherosclerosis in Ldlr⁻/⁻ mice. (Under revision).


**Published Refereed Abstracts**


Bojic LA, Sawyez CG, Telford DE, Edwards JY, Hegele RA, Muff MW. Inhibition of very low-density lipoprotein-induced macrophage inflammation by the peroxisome proliferator-activated receptor delta. Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Chicago, IL, April 2011.


